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ABSTRACT 
Introduction and background 
Recruitment to cancer clinical trials needs to be improved, as does patient understanding 
about clinical trials, to enable patients to make an informed choice about whether or not to 
take part.  The main reason that clinically eligible patients do not take part in clinical trials 
is because they refuse; poor understanding of the research has been associated with 
patient refusal. Audiovisual patient information (AVPI) has been shown to improve 
knowledge/understanding in various areas of practice but there is limited information 
about its effect in the cancer clinical trial setting, particularly in relation to recruitment 
rates. Understanding the research is necessary for informed consent, and it was 
hypothesised that if patient understanding about clinical trials was increased with AVPI, 
then this could result in a reduction in the number of patients refusing clinical trials, and 
therefore provide an ethical approach to improving recruitment. This study aimed to test 
the impact of an audiovisual patient information intervention on recruitment to randomised 
cancer clinical trials (refusal rates), patient understanding of the information given, and 
levels of anxiety. Reasons for patients’ decisions about trial participation were also 
assessed.  
 
Method 
An AVPI intervention was developed that aimed to address the common misconceptions 
associated with randomisation and clinical equipoise, as well as improve patient 
understanding generally of randomised cancer trials, and of other core clinical trial 
informational requirements, such as voluntariness. Patients were randomised to receive 
either AVPI in addition to the standard trial-specific written information, or the written 
information alone. A new questionnaire was developed to assess patient understanding 
(also referred to as knowledge) in the randomised trial setting and, following testing with 
patients and research nurses, this was shown to be reliable and valid.  Patients completed 
self-report questionnaires to assess their understanding (new knowledge questionnaire) 
  
and anxiety (Spielberger State-Trait Anxiety Inventory), at baseline and after they had 
made their decision about clinical trial entry, when their perceptions of the intervention, as 
well as factors contributing to their decision were also determined (this tool incorporated 
Jenkins and Fallowfield’s (2005) questionnaire which assessed reasons for accepting and 
declining randomised cancer trials).  
 
Results 
A total of 173 patients with breast cancer (65%), colorectal cancer (32%) and lung cancer 
(3%) were entered into the main study. The median age was 60 (range 37-92 years). 
There was no difference in clinical trial recruitment rates between the two groups: 72.1% 
in the AVPI group and 75.9% in the standard information group. The estimated odds ratio 
for refusal (intervention/no intervention) was 1.19 (95% ci 0.55-2.58, p=0.661). Knowledge 
scores increased more in the intervention group compared to the standard group (U= 
2029, p=0.0072). The change in anxiety score between the arms was also statistically 
significant (p=0.011) with anxiety improving in the intervention arm more than in the no-
intervention arm.  The estimated difference in the median anxiety change score between 
the groups is –4.6 (95% ci –7.0 to –2.0). 
 
Clinical trial entry was not influenced by tumour type, stage of cancer, age, educational 
qualifications or previous research experience, however, there was a modest association 
with deprivation status (p=0.046) where more affluent patients were the least likely to 
consent to a trial. Educational qualifications and stage of cancer were independently 
associated with knowledge: patients who were better educated had higher levels of 
knowledge about randomised trials, and patients who had limited stage of cancer had 
higher baseline knowledge than patients with advanced cancer. Acceptability of the 
intervention was high with 93% of those who watched it finding it useful, and 42% stating 
that it made them want to take part in the clinical trial.  Personal benefit and altruism were 
  
key motivating factors for clinical trial participation, with reasons for refusal being less 
clear.   
 
Discussion and conclusions 
Although the potential for AVPI to increase clinical trial recruitment rates was highlighted 
in the literature, in this study, AVPI was not shown to have any effect on refusal rates to 
randomised cancer trials.  However, by improving patient understanding prior to decision 
making, AVPI was shown to be a useful addition to the consent process for randomised 
cancer trials.  AVPI addresses the fundamental ethical challenges of informed consent by 
improving patient understanding, and supports the ethical framework integral to Faden 
and Beauchamp’s (1986) theory of informed consent.  The new knowledge questionnaire 
was shown to be a sensitive and effective instrument for measuring understanding of 
randomised clinical trials in the cancer setting, although it would benefit from further 
testing.  The AVPI appears to reduce anxiety at the decision making time point and has 
been shown to be an acceptable medium for patients. This study confirms existing 
findings from studies assessing factors affecting decision making, with personal benefit 
and altruism being key motivating factors, and reasons for refusal being less clear.  The 
need for further qualitative work in this area is highlighted to gain a deeper understanding 
of what is important to patients, in terms of why they refuse clinical trial participation. 
 
Implications for practice and further research 
Several implications for practice have been identified, including using AVPI as part of the 
standard information package for patients considering randomised cancer trials, and 
focussing on patient and staff education in this area. The knowledge questionnaire could 
be introduced to routine practice as a tool to determine patient understanding prior to 
decision making, allowing clinicians the opportunity to correct any misconceptions prior to 
consent.  Further research focussing on AVPI specific to individual trials would be helpful, 
to determine if a more customised approach would be of benefit in terms of clinical trial 
  
recruitment. The importance of studying other aspects of the consent process such as the 
interaction between the clinician and the patient, in addition to more detailed exploration of 
the factors affecting patients’ decisions were highlighted.   
 
  
PROLOGUE 
For most of my nursing career, I have been involved with patients participating in clinical 
trials of new cancer treatments, both as an individual cancer nurse striving to make the 
experience as good as possible for each patient and their families/significant others, and 
also as a manager responsible for a team of research nurses aiming to deliver the best 
standard of care and support for patients participating in cancer clinical trials. As well as a 
strong clinical interest derived from experience, my research interests have also 
developed in this area and my Masters dissertation was focussed on patients’ motivations 
for taking part in trials,  with subsequent work in related areas since. 
 
Clinical research is a challenging area of nursing practice, balancing the needs of the 
individual patient with the need to increase recruitment to cancer trials, in order to further 
research and improve treatments for future patients with cancer.  Despite advances in 
cancer treatments and a variety of different approaches to research around the consent 
and information-giving processes, it was apparent that patients still appeared to be 
making their decision about whether or not to participate in a clinical trial without fully 
understanding what was being asked of them.  
 
In the current political climate with increasing pressure to recruit more patients to cancer 
clinical trials and the additional resources and infrastructure now in place for this purpose, 
it is important to look at ethical ways of increasing recruitment as well as improving the 
consent process itself.  I had read a lot about different ways of improving the consent 
process and about the effectiveness of audiovisual information in increasing knowledge 
and understanding in a variety of health care settings.  However, there was limited 
reported work testing the effect of audiovisual approaches on actual consent rates.  After 
discussion within the clinical and research teams in the cancer centre, it was agreed that 
this would be worthy of further investigation, and led to the development of this study. 
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CHAPTER ONE:  INTRODUCTION AND BACKGROUND TO THE STUDY 
 
1.1 Introduction 
1.1.1 Introduction to the thesis 
This thesis reports on a study designed to test the impact of an audiovisual patient 
information intervention on recruitment to randomised cancer clinical trials.  It was 
hypothesised that by increasing patient understanding of the information given, clinical 
trial refusal rates would be reduced, and that any increase in understanding would not be 
associated with an increase in anxiety. 
 
Clinical trials are the only safe and effective way to improve treatment of cancer.  
However, small numbers of patients are recruited to cancer clinical trials every year for 
several reasons, including issues around the patient (e.g. treatment preference, 
uncertainty, knowledge and understanding), the clinician (e.g. communicative behaviour, 
attitudes, difficulty with the consent procedure), the trial itself (e.g. study design, 
complexity) and system/organisation factors (e.g. organisation infrastructure, additional 
time required for consent requirements).  Aspects of informed consent are apparent in all 
four domains.  Few trials have been undertaken of interventions designed to improve trial 
recruitment, and those that have been carried out are small in scale and difficult to 
generalise. Further research is much needed to determine effective interventions to 
increase clinical trial recruitment (McDaid et al. 2006). 
 
A study of the recruitment literature demonstrated that patient refusal is the main reason 
that clinically eligible patients are not recruited to clinical trials. However, it is not always 
clear why patients refuse. Although a proportion of clinical trials report their refusal rates, 
the reasons why patients refuse are often not reported.  Where reasons have been 
reported, they are as cited above: for example, a patient’s difficulties in understanding trial 
information such as randomisation, and factors associated with the clinician, such as 
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perceptions of trust. Meanwhile, the results of studies that have focussed solely on the 
issue of why patients refuse clinical trials are very similar to those reported in the general 
recruitment literature. As with recruitment in general, patient refusal often appears to be 
associated with issues centred around the consent process. 
 
Patient refusal was chosen as the primary endpoint for this study because reducing 
refusal was considered to be a potentially effective way of increasing recruitment. This is 
because of the relatively large impact it has on clinical trial recruitment rates, and also 
because some of the factors associated with refusal appear to be amenable to change, for 
example correcting misconceptions and improving patient understanding as was the focus 
in this study.  Patient understanding was identified in the recruitment and patient refusal 
literature as being influential on refusal rates. Poor understanding was mainly due to 
misinterpretation and misconception of clinical trial information, particularly in relation to 
the concept of randomisation.   In view of the fact that a number of issues integral to the 
consent process are implicated in patient refusal, and the key role of understanding as the 
target of the intervention, and also as the fundamental underpinning of informed consent 
as identified from the literature, informed consent became a major focus for this study.   
 
The informed consent process was reviewed in the literature, from both a theoretical and 
empirical perspective, in order to determine the aspects that are important and amenable 
to change, prior to developing the intervention.  This resulted in the identification of patient 
understanding as integral to all dimensions of informed consent: what the patient needs to 
know (information); how that information is conveyed to optimise understanding 
(disclosure); the extent to which the patient understands the information conveyed 
(understanding); and the extent to which the patient’s consent meets the criteria for 
decision making in this context – competence and voluntariness [understanding is key to 
both competence and voluntariness] (decision making).  This provided further justification 
for focussing on patient understanding both in terms of the main study endpoint as a 
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potential way of reducing clinical trial refusal rates, and also in terms of patient 
understanding in its own right as a key component of informed consent. 
 
The theoretical underpinning for the study is taken mainly from the work of Faden and 
Beauchamp (1986), and to a lesser extent, Manson and O’Neill (2007). Patient 
understanding is considered the basis for autonomous action (Faden and Beauchamp 
1986), which is fundamental in the consent situation. Understanding that you are being 
asked to decide about taking part in a trial, and understanding what is communicated 
about the trial, are the key parts of understanding that are important in informed consent. 
Other factors essential for autonomous action are competence and voluntariness, which 
are also linked to patient understanding.  Evaluation of informed consent is challenging in 
the absence of an accepted definition, and as a result there has been a fragmented 
approach to measurement.  Evaluation has included assessment of satisfaction with the 
process, assessment of competence/capacity to consent, and assessment of patient 
knowledge and understanding. Because of the importance of understanding in terms of 
both consent and recruitment, this study focussed on evaluating informed consent in 
terms of patient understanding.  Due to the lack of suitable tools identified in the literature, 
relevant to the randomised cancer trial setting, a new questionnaire was developed, and is 
discussed in detail in Chapter 7. 
 
The rationale for including anxiety as a secondary outcome measure was the need to 
ensure that any intervention designed to increase patient understanding did not have a 
detrimental effect on anxiety. Consistent with previous literature associated with patient 
information interventions, the aim was for the intervention not to increase anxiety, with the 
hope that, by providing the patient with information they could understand, anxiety might 
even be reduced.  
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There is a small volume of literature suggesting that patients who have more knowledge, 
and better understanding, of clinical trial information are more likely to enrol; however, the 
evidence is not conclusive and this study aimed to add to the literature in this area, 
specific to the randomised cancer trial setting.  
 
Various approaches to improving knowledge and understanding in cancer (and other 
specialist areas) have been studied.  These include the use of audiovisual methods.  
Audiovisual patient information (AVPI) has been shown to increase knowledge, influence 
behaviour and assist patients with decision making.  However, limited information is 
available on the effect of these methods in the cancer clinical trial setting, in terms of both 
consent and recruitment.  AVPI was chosen as the intervention for this study because of: 
(i) the evidence outwith the clinical trial setting - its effectiveness in increasing knowledge 
without increasing anxiety, improving the decision making process, and in some cases 
influencing the decision itself; (ii) the small body of evidence on its effectiveness in the 
clinical trial setting; and (iii) its effectiveness as a tool for cancer patient education. The 
literature appears to suggest that AVPI has the potential to improve knowledge and 
understanding of clinical trials (without increasing anxiety), and to increase clinical trial 
recruitment by reducing refusal rates. As confirmed in the literature, patient understanding 
of the concept of randomisation poses particular challenges, so the decision was taken to 
focus on this issue, in the wider context of clinical trials. Other important features designed 
to improve understanding (again identified in the literature), such as tailoring, and aspects 
of information presentation, were incorporated. In order to meet the informational 
requirements in an audiovisual format, a video/DVD/CD-ROM had to be developed for this 
purpose: this process is described in detail in Chapter 6.  
 
The final area of interest in this study was the basis for the patient’s decision to participate 
(or not) in clinical trials. Patients’ reasons for consent or refusal were not part of the main 
focus of the study; however, because the literature is limited in this area, there was the 
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opportunity to add to this knowledge, specifically in the case of randomised cancer trials. 
The aim of this part of the study was to better understand the factors affecting patients’ 
decisions.  It was intended that this would also help to determine future areas for 
research, taking into account the results of the other aspects of this study. This is 
obviously a very brief summary of the justification for the study, and a more detailed 
discussion is provided in Chapters 2, 3 and 4.  
 
The structure of the thesis is as follows. The remainder of this chapter will focus on the 
clinical and political context within which the study was undertaken.  Chapters 2, 3 and 4 
comprise the literature review, and discuss the wealth of relevant literature concerning 
recruitment to clinical trials, informed consent, and audiovisual patient information.  
Chapter 5 focuses on the methodology employed in the main randomised study, with 
Chapter 6 describing the development of the intervention.  The development and testing 
of a new questionnaire to assess understanding of randomised clinical trials is discussed 
in Chapter 7.  Full results are reported in Chapter 8, which is followed by discussion, 
conclusions and recommendations for practice and research in Chapter 9. Some of the 
chapters incorporate material from papers, based on the study, which have already been 
published; these are shown in full in Appendix 1.1. For simplicity, this study will be 
referred to as the AVPI study. 
 
1.1.2 Background to the study 
Prior to reviewing the literature, this chapter will now describe the context within which the 
research was undertaken.  Background information will be given on the clinical setting, as 
well as the political context in relation to cancer care, clinical trial recruitment and informed 
consent.  
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1.2 Clinical setting  
1.2.1 Overview of The Beatson West of Scotland Cancer Centre  
The study was carried out at The Beatson West of Scotland Cancer Centre (BWoSCC).  
The BWoSCC is the lead centre for the delivery of non-surgical cancer care for the West 
of Scotland (WoS).  It serves a population of 2.6 million and has clinical links with 16 
hospitals in four surrounding health board areas.  It is Scotland’s largest cancer centre, 
and the second-largest in the United Kingdom.  Each year, over 8,000 new patients are 
seen, and more than 15,000 courses of chemotherapy and 6,500 courses of radiotherapy 
are administered.  All radiotherapy treatments and the majority of chemotherapy 
treatments in the WoS, are given in the centre.   
 
1.2.2. Clinical trials at The Beatson West of Scotland Cancer Centre 
Chemotherapy is administered routinely according to standard chemotherapy protocols at 
the BWoSCC for all cancers, in addition to being administered as part of a clinical trial.  
This includes the populations under study - breast, lung and colorectal cancer. Other 
standard and clinical trial treatments given at the BWoSCC for these cancers are 
radiotherapy and hormone therapy.   
 
Over the past 10-20 years the BWoSCC has been developing its research profile, and has 
become well established as a centre of excellence for cancer clinical trials.  Over 1000 
patients are entered into clinical trials every year at the centre, and there are 
approximately 80 clinical trials running at any one time.   These include all types of clinical 
trials, with a particular focus on early stage testing (phase I), which is the first time a drug 
or treatment is given to people. This follows on from laboratory and animal testing of a 
new drug or treatment.  In cancer care, phase I trials are carried out on people with cancer 
rather than on healthy volunteers, as would be the case for medicines applicable to other 
illnesses.  This is due to the potentially toxic nature of cancer treatments, and because it 
is necessary to determine metabolic effects of the disease and treatments.  Although 
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there is a substantial focus on phase I trials at the cancer centre, there is an equally 
substantial commitment to randomised phase III clinical trials, where a new treatment is 
compared with the standard current one.   This accounts for the largest number of clinical 
trials running at the cancer centre, as well as the largest numbers of patients taking part in 
trials.  It is from this group of trials that the study population was taken.  The pathway for a 
patient being considered for a clinical trial at The Beatson West of Scotland Cancer 
Centre is shown in Appendix 1.2 
 
The cancer centre has seven in-patient wards, a radiotherapy department, and a large 
out-patient and day case unit, in addition to the Clinical Research Unit, which specialises 
in early phase clinical trials. Patients undergoing treatment as part of a randomised clinical 
trial are usually seen in the out-patient department and day case area.  Some will receive 
their treatment in one of the in-patient wards. 
 
1.2.3 West of Scotland context 
Local WoS hospitals give routine chemotherapy for colorectal, lung and breast cancer, 
including treatment within clinical trials according to specific protocols.  The clinical trials 
aspect is coordinated by a Scotland-wide clinical trials network called the Scottish Cancer 
Research Network (SCRN). The SCRN is divided into 3 smaller networks, to link with the 
three regional cancer groups in Scotland.  The WoS arm of the SCRN is based at the 
BWoSCC.  Although other hospitals in the WoS could have contributed to the study 
sample, for practical reasons all of the patients in this study were seen at the BWoSCC, 
and received their treatment there too.  One of the eligibility criteria was that the patient 
had to be receiving treatment at the cancer centre. 
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1.3 Political context 
1.3.1 Cancer care 
Over the last 10 years cancer has become one of the national health priorities in the 
United Kingdom (UK), bringing an increase in financial investment.   
 
In England, the NHS Cancer Plan (Department of Health 2000) set out the action needed 
over a ten-year timeframe to improve cancer prevention and screening services, cut 
cancer patient waiting times, enhance treatment and palliative care services, and boost 
cancer research.  Since then, substantial progress has been made, and a follow-up 
document, the Cancer Reform Strategy was published in December 2007 (Department of 
Health 2007a). 
 
The Scottish Cancer Strategy, Cancer in Scotland: Action for Change, was published in 
July 2001, by the Scottish Executive (now the Scottish Government) setting out a clear 
direction for the improvement of cancer services in Scotland (Scottish Executive 2001a).  
It identifies a wide range of measures necessary to prevent, detect and improve treatment 
and care for people with cancer.  Substantial financial support was ring-fenced to support 
these measures.  A follow-up document, Cancer in Scotland: Sustaining Change, was 
published in May 2004 reporting on progress since 2001 and the next steps to ensure 
continuing improvement in cancer services (Scottish Executive 2004).  One of the 
cornerstones for taking forward the strategy was the establishment of three Regional 
Cancer Advisory Groups (RCAGs) in Scotland.  Cancer Managed Clinical Networks 
(MCNs) were also established and incorporated into the new structures, the majority of 
them being regional (national for rare cancers).  Further guidance on the structure and 
function of RCAGs was provided by the Scottish Executive in the NHS HDL (2001)71, 
which included the requirement to establish MCNs for all cancers (Scottish Executive 
2001b). The MCNs in each region are brought together within the RCAG, which functions 
as an overarching supra-regional body. Clinical trials are important in all of the cancer 
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MCNs.  The Scottish Cancer Group, coordinated by the Scottish Government, was 
established to oversee the implementation of the Scottish Cancer Strategy via the 
RCAGs.  The Scottish Cancer Group continues to require RCAGs to monitor progress and 
provide six monthly progress reports. 
 
 
1.3.2 Recruitment to clinical trials 
As a result of the high political profile of cancer care, and the publication of national 
cancer plans which included cancer research, there has been an increasing interest in 
clinical trials, particularly in relation to the challenges of increasing the numbers of patients 
recruited.  This is an international issue, discussed in Chapter 2. Since the publication of 
the cancer plans, there have been several UK ministerial announcements pledging 
millions of pounds to further develop the infrastructure and integration of cancer research.  
Following this, funding was made available, and monitoring plans put in place to ensure 
that targets were met.    
 
In Scotland, the Scottish Cancer Research Network (SCRN) (reporting into the WoS 
RCAG), was the result of the substantial investment from the Scottish Executive.  It was 
designed to provide patients with access to clinical trials in their local hospital, and to help 
meet the government’s target: 10% of cancer patients being recruited to clinical trials.  
Indeed, the initial objective of the SCRN was to double accrual to trials within a three-year 
period, from a baseline of less than 3% in 2001.  This target was achieved within the 
timeframe as a result of the additional infrastructure of dedicated research nurses and 
data managers.  Now, with the networks established, the focus has shifted to sustaining 
recruitment to clinical trials.   
 
A similar initiative – the National Cancer Research Network - had been established in 
England in April 2001 by the Department of Health, again with the aim of increasing 
recruitment to cancer clinical trials.  It had similar targets to the Scottish initiative, and also 
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achieved doubling of recruitment within a three year period. The revised Manual of Cancer 
Services (Department of Health 2007b) is an integral part of the NHS Cancer Plan and 
modernisation of cancer services in England. Research is a fundamental part of this, with 
Cancer Research Network Measures having recently been included in the Manual (March 
2007), which has the aim of improving the quality and standards of cancer research and 
integrating research networks with the generic cancer structures. 
 
In addition to the SCRN and the NCRN, an overarching clinical trial initiative was launched 
in April 2001, known as the NCRI, the National Cancer Research Initiative. Its main aim 
was to bring together the major funders of research to allow a more strategic approach to 
identifying and supporting cancer research. NCRI is a partnership between the 
Government, charity and industry, and promotes co-operation in cancer research among 
the 20 member organisations for the benefit of patients, the public and the scientific 
community.  Among the member organisations involved are: Department of Health 
(England); Scottish Government; Northern Ireland Research and Development Office; 
Wales Office of Research and Development; Association of the British Pharmaceutical 
Industry (ABPI); Medical Research Council (MRC); Cancer Research UK; Macmillan 
Cancer Support and Marie Curie Cancer Care. The NCRI has a central role in the 
integration of research and care to provide accessible, high quality patient-centred cancer 
services. It consists broadly of two research Networks: the National Translational Cancer 
Research Network (NTRAC), which leads on translational research, and the National 
Cancer Research Network (NCRN) (includes the SCRN), which provides infrastructure for 
large, multicentre clinical trials. Both Networks collaborate to provide scientific support and 
an evidence base for cancer care. 
 
One of the key targets for the NCRI is to increase recruitment to clinical trials, and one 
means of achieving this was the establishment of a network of accredited trials units in the 
UK to deliver high quality cancer clinical research. The BWoSCC is part of this, in 
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collaboration with the Information Services Division (Edinburgh), as an NCRI accredited 
trials unit.  The aims of the network are to ensure cohesion and coverage of NCRI trials 
activity, to strengthen links with the NCRI Clinical Studies Groups, to respond to changing 
research governance and regulatory frameworks, and to integrate laboratory-based 
research into trial activity.   
 
With an increased focus on improving recruitment rates, leading to more patients 
consenting to clinical trials, it is even more important to ensure that ethical standards are 
not being compromised as a result of the focus on increasing recruitment.   
 
1.3.3 Ethical issues and informed consent 
The ethical issues associated with informed consent will be discussed in detail in Chapter 
3.  However, within the policy context it is useful here to highlight the European Union 
Directives in relation to clinical trials and the subsequent changes in UK law, as well as 
national and local developments in relation to consent. 
 
1.3.3.1 European Union Directives 
The European Union (EU) Directives represent one of the major initiatives to address 
issues of quality and standards in clinical trials. First came the EU Clinical Trials Directive 
in 2001 (2001/20/EC); it was followed by the EU Good Clinical Practice Directive in 2005 
(2005/28/EC).   
 
The EU Clinical Trials Directive (2001/20/EC) was developed to ‘simplify and harmonise 
the regulation of clinical trials across the European Union, thereby facilitating the internal 
market in medicinal products while protecting participants and public health’ (Woods, 
2004).  The EC Clinical Trials Directive (2001/20/EC) focuses on the conduct of clinical 
trials of medicinal products conducted on people, in particular the implementation of Good 
Clinical Practice.  Good Clinical Practice is a set of internationally recognised ethical and 
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scientific quality requirements, developed by the International Conference of 
Harmonisation (ICH). These requirements must be observed when designing, conducting, 
recording and reporting clinical trials that involve human subjects (ICH Guidelines for GCP 
1996).  Included in this is guidance on the content of clinical trial patient information, and 
the key elements/process of informed consent.  Compliance with this good practice 
provides assurance that the rights, safety and well-being of trial subjects are protected, 
and that the results of the clinical trials are credible.   
 
The Medicines and Healthcare products Regulatory Agency (MHRA) is the regulatory 
body that was responsible for drafting the UK legislation in response to the EU Directives.  
In 2004, this resulted in the Medicines for Human Use (Clinical Trials) Regulations (S.I. 
2004/1031) (Department of Health 2004).  UK law was amended in August 2006 to 
incorporate the EU Good Clinical Practice Directive (2005/28/EC), and resulted in the 
Medicines for Human Use (Clinical Trials) Amendment Regulations (Department of Health 
2006).  Patient consent to research is integral to these directives and the current UK law. 
 
1.3.3.2 Consent 
In addition to the EU directives, there are local and national developments aimed at 
improving standards in clinical trials.  The 2000 NHS Plan in England pledges that proper 
consent must be sought from all NHS patients and research subjects. To achieve this 
goal, the Department of Health set up the Good Practice in Consent initiative, and enlisted 
an advisory group made up of patient representatives, carers, clinicians, academics and 
NHS managers.   Part of the work of this group included the publication of a Good 
Practice in Consent Implementation Guide, which focuses on consent to examination and 
treatment (Department of Health 2001a). This was widely promoted via the Health Service 
Circular, Good Practice in Consent (Department of Health 2001b).  There is a distinct lack 
of reference to research in this guide; the only area covered is consent to tissue sampling, 
in a small section.  However, the principles for consent to research are the same as for 
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consent to examination or treatment, and the document has similar content to the 
guidance given specifically for clinical trials (e.g. ICH GCP 1996; local clinical trial consent 
forms; Scottish Executive 2001c). The Mental Capacity Act (MCA) came fully into force on 
1 October 2007.  Although it is a wide-ranging piece of legislation, some of its provisions 
are relevant to consent.  Consequently, the Department of Health plan to amend its 
consent guidance, and the model policy and consent forms, to reflect the provisions of the 
MCA. 
 
In Scotland, the Scottish Executive set up a working group to develop guidelines for 
writing patient information in the research context.  These were published in 2001, and 
offer comprehensive guidance concerning the key information to be included for patients 
(Scottish Executive 2001c).  The Scottish Government also addresses issues of consent 
to research in the Research Governance Framework for Health and Community Care in 
Scotland (Chief Scientist Office 2006), which is an updated version of the initial research 
governance framework published in 2001. 
 
At an individual health board/organisation level, there has been an increase in awareness 
of requirements for patient consent both within and outwith the research setting, and many 
organisations now have formal policies in place.  In NHS Greater Glasgow and Clyde (the 
organisation where the research was undertaken), there is a formal policy governing all 
aspects of patient consent, which also reflects the Scottish Executive Guidance (2001c).  
NHS Greater Glasgow and Clyde has also recently established an e-learning module on 
consent which is available to any member of staff wishing to undertake it.  This is actively 
encouraged for staff involved with patients in clinical trials. 
 
1.4 Summary  
In summary, the research was undertaken at The Beatson West of Scotland Cancer 
Centre, which is the second largest cancer centre in the UK.  It has a large, well 
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established clinical trials profile, and is well connected within the UK clinical trials 
networks.  The study was undertaken in the context of cancer as a national priority, and 
the substantial political pressure to increase clinical trial recruitment rates.  During this 
time, there was a focus on improving the quality and integration of clinical trials across 
Europe, which resulted in changes to UK law.  Also of relevance were the developments 
in both the cancer and the non-cancer local and national agendas in relation to consent 
policy, focussing professionals’ attention on the paramount importance of informed 
consent.   In addition to the literature, which will be discussed in the following three 
chapters, all of the factors discussed in this chapter contributed to reasons for undertaking 
the research, and to the design and conduct of the study itself. 
 
As discussed at the beginning of this chapter, the study was designed to test the impact of 
an audiovisual patient information intervention on recruitment to randomised cancer 
clinical trials.  The literature review will now highlight patient refusal, in the wider context of 
clinical trial recruitment, as a potentially useful focus for increasing patient recruitment.  It 
will highlight the lack of effective interventions for increasing recruitment and the lack of 
research into reasons for patient refusal. Chapter 2 identifies the key factors in the 
informed consent process in terms of recruitment, and highlights patient understanding as 
being particularly important. This is continued in Chapter 3, where theoretical aspects of 
informed consent are discussed prior to a review of the empirical literature, and patient 
understanding is identified as being fundamental to the concept. Chapter 4 then discusses 
audiovisual patient information as a means of improving patient understanding, and 
potentially consent rates, in the randomised cancer trial setting.  
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CHAPTER TWO:  INTRODUCTION TO THE LITERATURE REVIEW AND PART I - 
RECRUITMENT TO CLINICAL TRIALS 
 
 
2.1 Introduction to the literature review 
This literature review was conducted in three main areas to provide justification for the 
study, which was to investigate the effect of an audiovisual patient information intervention 
on informed consent and recruitment to cancer clinical trials. Although there was 
substantial overlap across the three areas, it was useful to address them individually 
owing to the large literature base, and in order to ensure that important papers were not 
missed.  Three separate literature searches were carried out and are discussed in detail in 
Chapters 2-4 as shown below: 
• Chapter 2 (Part 1 of literature review) - Recruitment to clinical trials  
(including barriers, influencing factors, patient refusal); 
• Chapter 3 (Part 2 of literature review) - Informed consent  
(including key components and measurement); 
• Chapter 4 (Part 3 of literature review) - Audiovisual patient information  
(including its role in the clinical trial setting). 
 
These are then brought together in the summary at the end of Chapter 4, leading to a 
statement of the aims and hypotheses for the study.  The main theoretical underpinning 
for the study is discussed in Chapter 3 in relation to informed consent theory. 
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PART I – RECRUITMENT TO CLINICAL TRIALS 
 
2.2 Introduction to recruitment to clinical trials 
This chapter focuses on recruitment to clinical trials.  Firstly, there will be a discussion of 
the search strategy which will be followed by discussion of the key areas of relevance for 
this study. An overview of clinical trials in cancer will be provided, with a particular focus 
on randomised trials.  This will be followed by a discussion of clinical trial recruitment rates 
and the factors affecting recruitment in relation to the clinician, the patient (including 
refusal rates and reasons), the trial and the organisation. Next, the influence of socio-
economic and socio-demographic factors will be outlined.  Finally, there will be a focus on 
strategies and interventions aimed at increasing clinical trial recruitment rates, which will 
be followed by a summary of Part I. An outline of the issues covered in this chapter is 
given in Table 2.1. 
 
Table 2.1. Outline summary of Chapter 2  
 
Literature search 
 
Clinical trials in cancer Randomised clinical trials 
 
Challenges with the literature reporting recruitment rates Recruitment to clinical trials 
Recruitment rates to cancer trials 
 
Health behaviour theory 
Patient refusal 
Reasons for patient refusal 
Randomisation 
Patient factors 
Relationship with physician 
Clinician factors 
Trial 
Organisational/system factors 
Factors affecting  
clinical trial recruitment 
Summary of factors 
 
General literature Age and education status 
Age 
Gender, education and disease stage 
Socioeconomic status 
Socio-demographic and 
socioeconomic factors Cancer 
Minority groups 
 
General literature  Strategies to increase clinical trial recruitment 
Cancer clinical trials 
 
Summary of recruitment 
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2.3 Literature search 
The literature in relation to clinical trial recruitment was searched using the following five 
concepts: 1) clinical trials; 2) recruitment to trials; 3) influencing factors; 4) cancer and 5) 
willingness/refusal/barriers.  Electronic databases searched were:  Ovid MEDLINE(R) 
(mesz), Ovid MEDLINE(R) In-Process and Other Non-Indexed Citations (prem), CDSR 
(coch), ACP Journal Club (acp), DARE, CCTR, British Nursing Index (brni), CINAHL 
(nursing), EMBASE (emez), PsycINFO (psyf).  The search strategy was devised with the 
input of an experienced medical librarian.  Additional references were located by 
searching the bibliographies of related papers, examining conference proceedings, and 
using the Google search engine. The combination of keyword (searched for specific words 
and phrases in titles and abstracts) and MESH subject heading resulted in the retrieval of 
large search sets, which then needed to be manually sorted; but this was the preferred 
strategy so as not to exclude any potentially relevant material. 
   
Due to the large number of potentially relevant articles identified, grouping was then 
carried out into ‘cancer’ and ‘non-cancer’ trials, and limits applied accordingly. The cancer 
group were limited to English language and the last 20 years. This resulted in a total of 
1579 articles whose abstracts were then assessed for relevance by the librarian who was 
familiar with the proposed research.  The majority of those excluded were papers 
discussing trials and their results, not the design/methodological aspects of the trial.  
Other excluded papers were comments/letters/editorials/abstracts from conferences and 
studies focussed on paediatrics or neonates.  A final total of 293 abstracts were identified 
for further consideration.    
 
The ‘non-cancer’ literature was restricted to English language, the last 10 years and to 
review articles.  When duplicates already identified by the cancer recruitment search were 
removed, this resulted in 336 which, following assessment, led to a final total of 86 
abstracts for further consideration.   
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Full details of the search strategy are shown in Appendix 2.1.  Summary information is 
presented in Tables  2.2 and 2.3.  The line number corresponds with that in the full search 
strategy in Appendix 2.1. 
 
 Table 2.2. Summary of literature search: recruitment – cancer 
  Combination of Terms 
 
Number of Hits 
Line 16  = clinical trials + recruitment + cancer and influencing   
   factors or willingness/refusal/barriers 
 
2384 
Line 20  = limited to last 20 years, English language, duplicates 
   removed  
 
1579 
Line 21 
 
= final total following assessment 
 
293 
 
 
 Table 2.3. Summary of literature search: recruitment – non-cancer 
  Combination of Terms 
 
Number of Hits 
Line 21  = clinical trials + recruitment + influencing factors 
 
5843 
Line 26  = clinical trials + recruitment + willingness/refusal/barriers 
 
4398 
Line 32  
 
= line 21 or line 26, limit to last 10 years and English   
   language, duplicates removed 
 
2760 
Line 33  
 
= additional duplicates already identified in ‘cancer’ search 
    removed 
 
2190 
Line 35  = limited to review papers 
 
336 
Line 36  = final total following assessment 
 
86 
 
 
Full papers were obtained for the majority of the selected 86 non-cancer review abstracts 
and the 293 cancer related ones.  Following some context setting about clinical trials, the 
main areas in relation to recruitment which are of relevance to this study will be discussed.  
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2.4 Clinical trials in cancer 
Clinical trials in cancer are essential to develop new treatments to improve patient care.  
There are well established processes in drug development which consist of four distinct 
phases of clinical testing.  These are briefly summarised in Table 2.4., to provide 
information on the context within which phase III cancer trials are carried out.  Each phase 
of testing builds on information from the previous phase.  Each new drug or treatment will 
undergo pre-clinical testing and then go through phases I - III, with some also undergoing 
additional evaluation (after being licensed) in phase IV. 
 
Table 2.4.  Phases of clinical trials 
Type of Trial Function / Description 
 
Phase I  Examine the new treatment's safety. Side-effects are identified and the 
appropriate dose determined. 
 
Phase II Continue the testing carried out in phase I and determine the new 
treatment’s effect against particular cancers. 
 
Phase III The drug or treatment looks promising from phase I and II testing and is 
expected to be at least as good as, hopefully better than the standard 
treatment available for a particular group of patients with cancer.  Phase 
III trials determine the effectiveness of the new treatment, and how well it 
works compared to older treatments. In some situations it may be 
appropriate to have a placebo or ‘supportive care’ as one of the 
randomisation arms. 
 
Phase IV These trials are carried out after the drug is licensed, often to monitor long 
term effectiveness/side-effects.  
 
 
 
2.4.1 Randomised clinical trials  
Randomised clinical trials - the focus of this research - are predominantly carried out at 
the phase III stage of clinical testing, although occasionally randomisation is also carried 
out in phase II.  Although there are scientific and ethical challenges in each phase of 
clinical research, the randomised clinical trial has been shown to be particularly 
problematic in relation to misinterpretation and poor understanding of patient information 
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(Appelbaum et al. 1987; Sutherland et al. 1990; Snowdon et al. 1997; Featherstone and 
Donovan 2002).  In addition, relatively high rates of patient refusal have been shown 
(Kotwall et al. 1992; Klabunde et al. 1999), compared with earlier phase studies (Gordon 
and Daugherty 2001; Cox 2002).  Phase III trials comprise the largest component of 
clinical research, in terms of the number of trials and number of patients involved.  These 
trials are therefore the major contributor to the worldwide problem of low recruitment rates 
to cancer clinical trials.   
 
2.5   Recruitment to clinical trials 
Recruitment to clinical trials generally, is a challenge both within and outwith the cancer 
setting, with various recruitment rates reported across specialties.   Owing to the wealth of 
information specific to cancer and the particular challenges of recruiting to cancer clinical 
trials (vulnerable patients, complex terminology), this section will focus predominantly on 
the cancer literature.  However, information will be drawn from the non-cancer literature as 
appropriate, in relation to the barriers to recruitment, and influencing factors. There is 
much less literature focussing on interventions designed to increase recruitment, and the 
health care literature generally will be referred to in this section since much of the ‘non-
cancer’ work is potentially relevant to the cancer setting. 
 
2.5.1 Challenges with the literature reporting recruitment rates 
It is difficult to compare rates across studies owing to the different interpretation of 
‘recruitment rates’. Some investigators consider the actual number of patients recruited 
within the context of the general population of those with the condition being studied.  
Others report rates as those patients that meet the inclusion criteria for the trial (all eligible 
patients), or the proportion of patients who are actually enrolled (all eligible patients who 
consent).  Ideally the percentage of the population that is eligible for recruitment and the 
percentage of eligible subjects that participate, should be described (Richardson et al. 
1998).  The majority of studies focus on newly diagnosed patients with cancer, as the data 
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on these cases is often easier to collect. However, it should be acknowledged that 
substantial numbers of previously diagnosed or established cancer patients are also 
potentially eligible for clinical trials and do participate.  An example of this is the study by 
Hunter et al. (1987) who reviewed community physician logs in order to understand 
selection factors in clinical trials.  They found that 20% of all log entries (cancer patients 
who were potentially eligible for clinical trial participation) were previously diagnosed or 
established patients with cancer.  Despite reporting this percentage, previously diagnosed 
or established patients with cancer were not included in their analysis. Concurrent with 
much of the literature, they focussed on new patients.   It is unclear why this was the case, 
but it appears to be as a result of incomplete data for established patients with cancer.   
 
Several studies of recruitment report hypothetical clinical trial situations where attitudes 
and intentions to participate are assessed (Llewellyn-Thomas et al. 1991; Llewellyn-
Thomas et al. 1995; Ellis et al. 1999b; Trauth et al. 2000; Comis et al. 2003; Solomon et 
al. 2003).  Some of the review papers have included these studies and some have not.  It 
is recognised that it is more helpful to consider actual rates, since what patients think they 
might do is not always what they actually do when faced with a real life situation.  
However, information from these studies will be drawn upon in relation to the barriers and 
interventions, as there are implications for the general education of the public in relation to 
clinical trials (Comis et al. 2003).  
 
2.5.2 Recruitment rates to cancer trials 
The following figures are mainly taken from review papers to give an overview of 
recruitment rates in cancer clinical trials. It is commonly reported that less than 5% of 
patients with cancer are recruited worldwide into clinical trials each year (Lara et al. 2005; 
Leitch et al. 2005; Du et al. 2006; Fayter et al. 2006).  Approximately 2.5-3% of patients 
newly diagnosed with cancer in the United States (USA) are enrolled into clinical trials 
each year despite estimates that 12-44% of patients with cancer are eligible for entry into 
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protocols (Gotay 1991; Morrow et al. 1994; Lara et al. 2001). Similar figures are reported 
in the UK usually on the basis of small scale studies, however, in a larger regional study in 
England in 2000/2001, the enrolment rate was also low at 3.5% (Corrie et al. 2003).  In a 
fairly recent report of the National Cancer Research Institute (NCRI) in the UK, the 
recruitment rate from the National Cancer Research Network was reported at 10.9% of 
incident cancer cases (NCRI 2004).   Prior to this, as discussed in Chapter 1, there was a 
major political focus on cancer clinical trials and additional government investment.  This 
has resulted in a better infrastructure, better organisation of trials and, as anticipated, 
increased recruitment rates.  
 
It is common for clinical trials not to reach their initial recruitment targets, and to require an 
extension to the recruitment period, because they have not recruited the number of 
patients required to answer the study question.  This is confirmed by the review, carried 
out in the UK, of multicentre studies undertaken by the Medical Research Council and the 
Health Technology Assessment Board (McDonald et al. 2006).  They looked at 114 trials 
between 1994 and 2002 and found that less than one third of trials achieved their original 
recruitment target, with half being granted an extension (McDonald et al. 2006).  Low 
recruitment rates are of concern because of the need to progress scientifically, but also 
because of the threat to clinical applicability and generalisation of results (Britton et al. 
1999). 
 
Recruitment to clinical trials varies for several reasons.  Some are potentially modifiable, 
some are not. Many barriers to recruitment have been identified in the literature and fall 
into four main groups – issues around the patient, clinician, organisation and the trial itself. 
In addition, there are other factors that may have an influence on recruitment, such as 
socio-demographic and socioeconomic characteristics, which will be discussed in Section 
2.7. 
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2.6 Factors affecting clinical trial recruitment 
Much has been written about factors affecting recruitment, with most of the work focussing 
on barriers to enrolment in clinical trials. This has been both generally (Prescott et al. 
1999; Ross et al. 1999; Afshar et al. 2005; Abraham et al. 2006; Mills et al. 2006) and in 
trials specific to cancer (Gotay 1991; Ho 1994; Morrow et al. 1994; Klabunde et al. 1999; 
Lara et al. 2001; Mills et al. 2006; Tournoux et al. 2006).  In the cancer literature, studies 
have focussed on barriers to recruitment generally, in relation to specific cancer sites (with 
the majority of work in breast cancer), with respect to a specific location (e.g. cancer 
centre, regional network), or in the context of a particular trial.   
 
The majority of the studies have investigated doctor or patient perceptions of clinical trial 
recruitment, with a major focus on barriers.  Doctors’ perceptions have been studied 
mainly via interviews and/or survey questionnaires (Hjorth et al. 1996; Langley et al. 2000; 
Lara et al. 2001; Baum 2002; Kornblith et al. 2002; Leitch et al. 2005).  Patients have also 
been surveyed (Brown et al. 2000; Jenkins et al. 2000; Lara et al. 2001; Kemeny et al. 
2003, Avis et al. 2006) and interviewed (Mills et al. 2003) to elicit their views.  Other 
approaches included interviewing Clinical Research Associates (CRAs) via focus groups, 
in Canada (Grunfeld et al. 2002; Wright et al. 2002), and surveying nurses in the USA 
(Burnett et al. 2001).  The vast majority of cancer studies have focussed on cancer 
treatment trials, although there is also relevant work specific to cancer screening and 
prevention trials, which have produced similar findings in relation to barriers. 
 
Two major reviews of note will be highlighted prior to discussion of specific studies in 
relation to factors associated with trial recruitment. The Mills et al. (2006) study is the only 
review that has looked specifically at patient reported barriers to cancer trials, and also 
attempted to quantify the importance of the issues.  The other review of note was 
undertaken by Fayter et al. (2006) and is particularly thorough, and again is specific to 
participation in cancer clinical trials.  
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Mills et al. (2006) analysed 12 qualitative studies (n=722) and 21 quantitative studies 
(n=5452) in a recent systematic review and meta-analysis of patient-reported barriers to 
participation in cancer clinical trials.  They estimated the frequency with which patients 
identified particular issues by pooling across the reviewed studies which had presented 
data on barriers as proportions. A coding template was developed by the authors, which 
categorised barriers to participation as a) protocol-related, b) patient-related or c) 
physician-related.  The data was then pooled to show the proportions of participants who 
noted concern for specific barriers identified in the template under these three headings.  
The most common reasons cited as barriers included: dislike of randomisation; general 
discomfort with the research process; complexity and stringency of the protocol; presence 
of a placebo or no treatment group; potential side-effects; being unaware of trial 
opportunities; the idea that clinical trials are not appropriate for serious diseases; fear that 
clinical trial involvement would have a negative effect on the relationship with their 
physician; and their physicians’ attitudes towards the trial.  It must be acknowledged, 
however, that the quantitative studies they assessed identified only a few of the barriers 
compared with qualitative studies, and that due to the small numbers of studies pooled, it 
is difficult to determine a sense of relative frequency.  The authors believe that the 
majority of concerns identified in their study can be alleviated with directed educational 
strategies (Mills et al. 2006).   
 
A comprehensive review of the barriers to participation, as well as the modifiers and 
benefits involved in participation in cancer clinical trials, was carried out by the Centre for 
Reviews and Dissemination at the University of York (Fayter et al. 2006).  This review 
included studies over ten years, from 1996, building on an earlier general clinical trials 
review by Prescott et al. (1999).  Fayter et al. (2006) identified a total of 12,816 references 
from literature searches, and selected 56 studies reported in 58 papers for the review.  
They grouped studies according to their perspective – patients or health care 
professionals (included doctors, nurses and clinical research associates).  This was a 
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thorough review which also assessed the quality of the research, and included 
unpublished work.  All types of study designs were included as long as they provided 
relevant outcomes.  Findings were reported as a narrative summary and in tabular form 
with data extraction tables and quality assessment tables. 
 
Fayter et al. (2006) reported difficulties assessing the quality of several of the studies due 
to lack of information about recruitment methods, study design and piloting.  There were 
also problems with data collection procedures with many of the studies, including the 
potential for the introduction of bias, the extent of which they found difficult to quantify. 
Owing to the methodological limitations of the studies as identified by the review, Fayter et 
al. (2006) are cautious about what should or should not be interpreted as a barrier.  They 
recommend instead that the particular interplay of barriers, modifiers and benefits relevant 
to participation in cancer trials should be prospectively identified by clinical investigators in 
light of the ‘themes’ identified by the review, and they provide checklists to assist with this 
task.  The themes were identified from two perspectives:  the patient and the health 
professional.  From the patient perspective, these were: 
• issues of treatment preference  
• the uncertainty patients feel about participating in trials 
• the role of knowledge and information  
• the need to time the request for trial  participation more carefully. 
From the health professional perspective, the themes were:  
• a range of system-related and organisational barriers   
• barriers inherent in a trial’s design  
• barriers connected with the attitudes of individual health professionals. 
(Fayter et al. 2006). 
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As well as being identified in the reviews, the factors comprising these themes have been 
consistently identified in both the general and cancer treatment and screening literature.  
These can be broadly grouped into four categories:  1) the patient; 2) the clinician; 3) the 
trial; 4) and the organisation.  An important additional factor, which has reportedly affected 
recruitment in the USA, is insurance coverage. However, insurance coverage is becoming 
less of an issue in some states in the USA due to policy and legal changes related to 
medical insurance (Martel et al. 2004).  Since the UK has a different system of health 
care, medical insurance is not of relevance to the clinical trial setting in the UK.   
 
In order to support and expand on findings from the two reviews already discussed 
(Fayter et al. 2006; Mills et al. 2006), relevant research will now be discussed in relation to 
the identified four categories: patient factors; clinician factors; the trial; and organisational 
factors 
 
2.6.1 Patient factors 
Several patient factors have been identified, by both health care professionals and by 
patients themselves, as being important in patients’ decisions about whether or not to 
participate in a clinical trial.  The majority of research in this area does not have any 
theoretical foundation, with the exception of a small number of papers that link trial 
recruitment to theories of health behaviour (Morrow et al. 1994; Sutherland et al. 1998; 
Verheggen et al. 1998).  This review of patient factors will begin with these studies. 
 
2.6.1.1 Heath behaviour theory 
Morrow et al. (1994) reviewed the literature on recruitment to oncology trials and 
developed a framework for integrating information about oncology trial accrual in relation 
to four core concepts implicated in patient-related health behaviour as shown in Table 2.5   
These are based on the central concepts from four theories of health-related behaviour:  
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the Health Belief Model, Subjective Expected Utility Theory, Protection Motivation Theory, 
and the Theory of Reasoned Action (Morrow et al. 1994).  From the literature, the authors 
organise the patient and physician factors thought to influence patient enrolment in clinical 
trials into the four behavioural concepts shown in Table 2.5.  
 
Table 2.5. Central concepts in understanding health-related behaviour (Morrow et al. 
1994) 
 
The probability that an unwelcome health event will happen to a patient 
The severity of that event if it does occur 
The effectiveness of a particular behaviour such as taking part in a clinical trial 
The cost of adopting that behaviour 
 
It must be noted that their ideas do not appear to have been tested in a prospective 
clinical trial situation, although aspects of them have been taken forward in relation to 
specific theories.   
 
Verheggen et al. (1998) carried out a hospital-wide survey in The Netherlands to provide 
more insight into the socio-psychological determinants of patient participation in clinical 
trials, and used an extended form of the Health Belief Model (HBM) to explain clinical trial 
participation.  In relation to explaining health actions, the HBM hypothesises that 
behaviour depends mainly on 1) the desire to get well if ill (or to avoid sickness if well) and 
2) the belief that a specific health action will restore health, or prevent or improve illness 
(Verheggen et al. 1998).  To be able to do this, the ‘cue of action’ must be evoked to 
trigger the decision-making process.  An individual’s personal perception and motivation, 
or information provided by the clinician, can evoke this cue of action (Veheggen et al. 
 28 
1998).  Verheggen et al. apply this theory to the decision about participation in clinical 
trials, and postulate that the decision may be explained by the extent to which a patient 
perceives a threat to his or her health, and the extent to which a patient believes that trial 
participation will be effective in reducing this threat, given the perceived effectiveness of 
standard treatment. In addition to these original features of the HBM, Veheggen et al. 
(1998) assessed ‘subjective norm’ which focussed on the self reported influence that 
important others may have on behaviour, locus of control, and a number of general health 
values and orientations of patients.  Using questionnaires, they interviewed 198 patients 
after they had made their decision about whether or not to participate in the trial, and 
claim that patients make a personal balance account when deciding about participation.  
This includes the physical and emotional added value that patients hope to gain from the 
trial treatment, as compared with the non-trial treatment, minus the risks they expect in the 
trial and the extra time they expect the trial to take.  They suggest that the extent to which 
patients feel physically threatened by their illness, and their opinions about medical care 
and care-givers in general, will also affect their decision (Verheggen et al. 1998). 
 
The Theory of Reasoned Action, which predicts that personal attitudes and ‘subjective 
norm’ are influential in determining intention to undertake a behaviour, was used as a 
conceptual framework for developing a questionnaire to elicit beliefs and attitudes about 
participating in a hypothetical chemotherapy trial (Sutherland et al. 1998). Sutherland et 
al. hypothesised that such a questionnaire could serve as a decision aid for patients 
deciding whether or not to take part in a clinical trial. The main purpose of the study was 
to understand the underlying beliefs of patients with cancer about taking part in clinical 
trials.  Two types of beliefs were identified – universal beliefs and trial-specific beliefs. 
Another group of beliefs – individual-specific beliefs - were not identified by the 
questionnaire, although they were highlighted by patients in the study as being important.  
The authors acknowledge that individual-specific beliefs could have had a substantial 
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influence on attitudes and intention to participate (Sutherland et al. 1998).  They found 
that, although there was support for the theory, once attitude was taken into account, 
‘subjective norm’ had only a small contribution to make.  Patients’ decisions on the whole 
did not appear to be influenced by the questionnaire, which in turn did not appear to 
contribute to the decision-making process.  Patients seemed to have made their decision 
about participation soon after first hearing about the trial.  However, it must be noted that 
a major limitation of this study was that actual behaviour (i.e. clinical trial participation) 
was not studied, only intention to perform the behaviour.   
 
Curbow et al. (2004) hypothesised that knowledge and beliefs play a central role both in 
patient understanding of the informed consent process and in their decision to accept 
participation in a trial.  They tested an intervention which increased knowledge but this 
was not associated with a change in beliefs. Beliefs are often hypothesised to be 
determinants of behaviour either directly (Health Belief Model) or through attitudes 
(Theory of Reasoned Action) (Curbow et al. 2004).  It has been suggested that pre-
existing knowledge can bias the processing of new information in a negative or positive 
way and that a high level of knowledge can stabilise beliefs, making them more likely to 
be associated with behaviours (Eagly and Chaiken, 1993 in Curbow et al. 2004). 
Unfortunately, the authors did not investigate the effect on actual consent rates. 
 
In cancer screening, models of health behaviour have been shown to be poor at 
consistently predicting behaviour (Bish et al. 2000 in cervical cancer, Yarbrough and 
Braden 2001 in breast cancer).  It is unclear how useful these models are at explaining or 
predicting behaviour within the cancer clinical trial setting, since as discussed, the 
research in this area is very limited.  Specific health beliefs, rather than the combination of 
factors within the models themselves, appear to be important in relation to clinical trial 
recruitment.   
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The literature shows a trend for patients with particular health beliefs to be more likely to 
participate:   
(1) patients with higher concern about their illness (Harth et al. 1992 in terms of parents’ 
status in paediatric trials; Gorkin et al. 1996 in cardiology;  and O’Connell et al. 2002 in 
HIV).  
(2) patients who were sicker or had advanced disease (Schwartz and Fox 1995 in MS; 
Gorkin et al. 1996 in cardiology; Charlson and Horwitz 1984 and Britton et al. 1999 in 
general health studies).  
 
As a way forward in health behaviour research, it is suggested that theory comparison is 
essential, as is the recognition of the similarity of health behaviour constructs (Noar and 
Zimmerman 2005). From the four models of health behaviour commonly tested in health 
research studies (previously discussed at the beginning of this section), two of the core 
common concepts are the probability that an unwelcome health event will happen to a 
patient, and the severity of that event if it does occur (Morrow et al. 1994).  ‘Higher 
concern about their illness’ is consistent with the probability concept, and ‘patients who 
were sicker or had advanced disease’ is consistent with the severity concept.  
 
More recently, Leventhal’s Common Sense Model of self-regulation (CSM) has received 
substantial attention in the literature and has been widely used to understand responses 
to illness (Marteau and Weinman 2006).  It has also been suggested to be useful in 
understanding risk information and behaviour (Cameron 2003, in Marteau and Weinman 
2006). There are two parallel components to the model:  the cognitive processing of how 
people regulate their responses to illness danger, and the person’s regulation of emotional 
control (Hale et al. 2007). Illness representations or lay beliefs about disease integrate 
with the existing, normative guidelines that people hold, to allow them to make sense of 
their symptoms and guide any coping actions (Hale et al. 2007). The five key domains of 
illness representations have been established as identity, cause, timeline, consequences 
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and control/cure (Leventhal et al. 2001).  Identity is the name given to conditions and 
symptoms; cause relates to a personal perception based on experience as well as 
professional information; timeline includes how long condition will last, acute v’s chronic; 
consequences reflect the personal belief of the physical and social impact from the 
condition; and cure/control is concerned with the personal beliefs about cure and control 
and the person’s perception of their influence over this. Cameron et al. (2005) used the 
CSM in their study of the role of illness beliefs, emotion regulation factors and socio-
demographic characteristics in decisions to participate in a group support program for 
patients with breast cancer. They found that participation appeared to be guided by 
cognitive and affective factors identified by the CSM.  However, the model does not 
appear to have been used in relation to the clinical trial participation decision.  For the 
CSM to be used effectively it would be necessary for researchers to be clear whether they 
were trying to influence trial participation in its own right or whether they saw trial 
participation as an intermediary to helping people manage their cancers. 
 
Because the majority of studies on clinical trial recruitment have no theoretical basis and 
do not address the complex relationship between knowledge, attitudes and behaviours, 
Fayter et al. (2006) suggest that future research uses a theoretical underpinning similar to 
that used by Vergheggen et al. (1998) (which was not specific to cancer), with an 
extended form of the HBM.  However in view of the lack of compelling evidence, health 
behaviour theory was not used as the main theoretical underpinning for this study, 
although specific components of health behaviour models, such as the severity of 
disease, were assessed. 
 
2.6.1.2 Patient refusal 
In many studies, patient refusal accounts for the largest proportion of clinically eligible 
patients not entered into trials (Kotwall et al. 1992; Klabunde et al. 1999; Lara et al. 2001).  
Although it is considered good practice to collect data on eligible patients who were not 
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entered into a trial (Altman 1996), including the proportion of patients who decline to 
participate, this is not always done and is often omitted from the study publication. This is 
an important issue which can result in difficulties determining representativeness of the 
results to the relevant patient population.  It is also difficult therefore to generalise about 
refusal rates for different types of trials. 
 
In the non-cancer literature, varying refusal rates have been reported:  35% in a sample of 
400 patients for a cardiac arrhythmia study (Gorkin et al. 1996), 67% in a sample of 789 
women considering a trial of oestrogen for stroke (Corbie-Smith et al. 2003), and 36% 
(n=871) of elderly patients (n=2403) in a trial of pharmacy practice research (Petty et al. 
2001). 
 
In cancer trials, similar rates have been reported: 28% (Jenkins and Fallowfield 2000); 
40% (Klabunde et al. 1999); and 49% (Lara et al. 2001).  Higher rates are typically 
reported in chemotherapy prevention/risk counselling studies, when compared with 
treatment trials; for example, in a trial of breast cancer risk counselling, this figure was 
53% (Rimer et al. 1996).  It has been suggested that the perceived likelihood of having, or 
being at risk of developing, cancer may be the determining factor on a patient’s decision 
about whether or not to participate in a cancer prevention trial (Morrow et al. 1994). Due to 
the severity of cancer and the negative connotations of the disease, it could be anticipated 
that this would be a powerful motivator for participation in prevention/risk counselling 
trials. It is interesting, then, to note that refusal rates are typically higher in these trials, a 
finding which challenges the idea that severity of illness is likely to increase participation in 
trials. This may be as a result of ‘optimism bias’, where people believe that they are 
invulnerable and consider their own chance of ill health to be below average (Weinstein 
1982).  Unrealistic optimism was present in cancer screening studies for prostate cancer 
and for breast cancer, in the majority of elements of the health behaviour models (Clarke 
et al. 2000). Patients were interviewed about their risk of getting the disease, perceived 
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severity of the disease, and benefits of and barriers to having screening (mammogram for 
breast cancer, PSA testing for prostate cancer).  Self-ratings were compared with mean 
scores for the ratings of others.  For example, in breast cancer, for ‘risk’, women were 
asked to estimate the percentage risk of getting breast cancer, giving a figure between 1 
and 100%. They estimated this at 25.7% for self and 44% for others (mean scores) which 
show unrealistic optimism in relation to perceived risk (Clarke et al. 2000).  Similar results 
were found in all HBM variables for prostate cancer and almost all for breast cancer (the 
exception was general barriers associated with having a screening mammogram) (Clarke 
et al. 2000). 
 
Some trials have asked participants to respond to hypothetical situations; these have 
reported refusal rates of 40% in chemotherapy trials (Sutherland et al. 1990) and 58% for 
a chemotherapy trial specific to colorectal cancer (Llewellyn Thomas et al. 1991). 
However, the limitations of trials that ask about hypothetical situations cannot give 
confidence that this is reflective of patients actually faced with the decision (Cassileth et 
al. 1982).   
 
An English cancer research network had one of the lowest refusal rates in the literature, at 
19%, which was in the context of a relatively high overall recruitment rate of 10% in 2002 
(Corrie et al. 2003).  There may be several reasons for this. This network is part of the 
National Cancer Research Network, which was set up, with investment, to increase 
recruitment to cancer clinical trials, predominantly by increasing the infrastructure to 
support clinical trials; as a consequence it may be that patients are better supported and 
that their informational needs are better met.  It is difficult to know, as this was not 
discussed, and data was not collected on reasons for patient refusal.  
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2.6.1.3 Reasons for patient refusal 
There are many reasons contributing to patients’ decisions to decline a clinical trial. 
Unfortunately, the literature is limited in this area and only a minority of clinical research 
papers report reasons for refusal.  The data has often been collected from clinicians or 
data managers, resulting in the question of how closely this would reflect reasons given 
directly by patients themselves.  Cox and McGarry (2003) reviewed the literature in 
relation to why patients don’t take part in cancer trials, and found a paucity of in-depth 
information from the perspectives of patients themselves about the underlying decision 
making processes and reasons why patients don’t participate.  
 
Most of the research that has been done directly with patients is in a hypothetical trial 
situation, where their attitudes or opinions are assessed in relation to clinical trial decision 
making.  Much has been learned from this work about attitudes and opinions, but, as 
already stated, it must be acknowledged that hypothetical situations are not always 
representative of real-life experience, and research has shown that patients can act 
differently when making personal decisions (Cassileth et al. 1982; Trauth et al. 2000).   
 
Surveys focussing on patients only, via self-report, will give good information about 
patients’ perceptions of the reasons they refused or accepted a trial.  However, this 
approach may miss important reasons affecting the decision that patients themselves are 
not aware of, such as poor understanding of the information.  A small number of studies 
have looked qualitatively at reasons why patients accepted or refused to participate in a 
clinical trial, and issues relating to information and understanding were identified (Paskett 
et al. 1996; Featherstone and Donovan 2002).  
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Taking into account the limitations of the literature, reasons for patient refusal include lack 
of trust in medical research, negative attitudes and beliefs towards clinical trials (from 
clinicians as well as patients), preference for treatment, additional demands of the trial, 
worry caused by uncertainty, concerns about information and consent, including difficulty 
understanding trial information and issues around randomisation (Gotay 1991; Morrow et 
al. 1994; Lovato et al. 1997; Klabunde et al. 1999; Ross et al. 1999;  Lara et al. 2001; 
Cohen-Mansfield 2003, Curbow et al. 2006).   Practical barriers included transport, cost 
and time (Fayter et al. 2006).  
 
Jenkins and Fallowfield (2000) surveyed both patients who agreed and those who 
declined clinical trial entry about the reasons influencing their decision. Two hundred and 
four patients completed a 16-item questionnaire designed for the purposes of the study.  
Altruism and trust in the doctor were reported as the main reasons for taking part.  Trust in 
the doctor was also cited as a main reason for declining participation; but, as 
acknowledged by the authors, in the absence of detailed interviews, it was not possible to 
know how this phrase was interpreted by patients, or the effect of the perceived benefits 
of standard treatment.  Another main reason given by patients for declining the trial was 
worry about randomisation.  As noted by the authors, it is not clear whether this is 
because patients did not understand the concept, or because they did.  
 
The type of trial, as well as, good communication with the clinician, were also powerful 
motivating factors for participation (Jenkins and Fallowfield 2000). Another important 
factor is whether or not a placebo or ‘no treatment’ arm is involved (Jenkins and 
Fallowfield, 2000).  In the Jenkins and Fallowfield (2000) study, 35 different oncology trials 
were reviewed involving 17 medical clinicians in the UK.  A significantly higher acceptance 
rate for trials providing active treatment in every arm (80.6%) was reported, as compared 
with those trials with a ‘no treatment’ arm (60.5%).  Refusal has been shown to be higher 
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among patients offered adjuvant phase III protocols (37%) compared with non-adjuvant 
protocols (29%) (Hunter et al. 1987). Refusal was also higher for cancer trials involving 
chemotherapy and radiotherapy, as compared with hormone therapy where there was a 
high acceptance rate of 85.5% (Jenkins and Fallowfield 2000).   However, Spiro et al. 
(2000) reported a refusal rate of 73.5% of potentially eligible patients to a lung cancer trial 
running in two centres in London. The trial involved patients receiving their primary 
treatment (surgery, radiotherapy or best supportive care) and then being randomised to 
either receive or not receive three courses of chemotherapy.  The high refusal rate could 
have been due to the very different treatment arms and patients having a preference for or 
against chemotherapy.  It could also be due to lack of understanding of equipoise and/or 
the information provided.  However, it is difficult to know since limited information was 
collected on reasons for patient refusal, with 44% of patients declining without giving a 
reason (Spiro et al. 2000). 
 
In some trials family members were found to influence patients against trial participation 
(Paskett et al. 1996 in breast cancer; Camerini et al. 1999 in breast cancer 
chemoprevention trials; Spiro et al. 2000 in lung cancer; and Wilt et al. 2003 in prostate 
cancer).  Reasons for this are not clear in the literature. 
 
2.6.1.4 Randomisation 
Patient understanding of the concept of randomisation is further discussed in Chapter 3. 
However, the focus here will be the effect on recruitment of poor understanding, 
acceptance and attitudes towards randomisation.  
 
Challenges with understanding the concept of randomisation, reluctance to be 
randomised, and attitudes to randomisation have all been associated with poor 
recruitment.  Reluctance to be randomised, was a major barrier for patients with breast 
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cancer who were surveyed about their attitudes to complementary and alternative 
medicine clinical trials (Melisko et al. 2005).  Understanding and acceptance of clinical 
equipoise were key to participants’ consent to randomisation in a prostate cancer trial 
(Mills et al. 2003).  Attitudes to randomisation have been studied by Fallowfield et al. 
(1998a), using a self report questionnaire: The Attitudes to Randomised Trials 
Questionnaire. This tool discriminated between three different patient groups: 
• Those who seem comfortable with the concept of randomisation. 
• Those with some concerns who, with fuller explanation of the concept, are willing 
to consider randomisation. 
• Those firmly against randomisation and participation in clinical trials, regardless of 
what information is provided. 
 
Out of 315 patients completing the questionnaire, only 141 (44.8%) would agree to 
participate in a trial if it was randomised.  When patients were given further information 
about randomisation, 119 (68.4%) of the 174 who initially said no to randomisation, or who 
were unsure, reported that they would change their minds and take part (Fallowfield et al.  
1998a). This suggests that by improving communication about, and understanding of, 
randomisation, clinical trial recruitment rates could be increased. This view is supported 
by Harrison et al. (2007), who studied patients’ and doctors’ willingness to participate in a 
hypothetical trial for rectal cancer.  Dislike of randomisation was a common reason for 
patient refusal. 
  
2.6.1.5 Relationship with physician 
The relationship between the patient and the physician (or clinician) is becoming of 
increasing interest to researchers studying clinical trial recruitment. Several factors have 
been shown to be important.  Mistrust in the clinician is often cited by patients as a barrier 
to participation: Abraham et al. (2006), in a review of surgical randomised trials, and Mills 
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et al. (2006), in a review of HIV drug trials.  The converse has also been shown to be the 
case.  ‘Trust in the clinician’ was identified as an important motivator for participation in a 
clinical trial for patients with prostatic disease (Featherstone and Donovan 2002) and in 
early anticancer drug trials (Cox and Avis 1996). In gynaecology, the patient-physician 
relationship has been shown to be important to patients considering clinical trial 
participation.  Patient level of familiarity with the physician-investigator was considered the 
most important factor affecting clinical trial participation when gynaecology patients 
entering clinical trials were compared with gynaecology patients not entered (Luck et al. 
2005).   
 
Patients’ perceptions of the health care professional, or the recommendations made by 
them, have been shown to be important in the patient’s treatment decision (Paskett et al. 
1996; Ellis et al. 1999b [both studies carried out in hypothetical conditions with a major 
focus on patients with breast cancer]; Grant et al. 2000).  Other factors affecting the 
doctor-patient relationship are discussed in the following section – clinician factors – in 
relation to communicative behaviour of clinicians. 
 
2.6.2 Clinician factors  
Clinician factors affecting clinical trial recruitment have been reported as: attitudes 
towards trials; motivations for participation; time constraints; worry about effect on doctor-
patient relationship; lack of staff and training; concern for patients; lack of professional 
autonomy; preference for treatment and difficulty with the consent procedure (Gotay 1991; 
Morrow et al. 1994; Klabunde et al. 1999; Prescott et al. 1999; Ross et al. 1999;  Lara et 
al. 2001; Abraham et al. 2006; Castel et al. 2006).  Physicians’ attitudes were considered 
to be the principle physician-related barriers according to CRAs (Grunfeld et al. 2002). 
These included their own personal beliefs about the trial, or their attitudes towards the 
suitability of a patient for a specific trial, despite meeting the eligibility criteria, for reasons 
such as anticipated logistic problems, or the belief that the patient would not understand 
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the information, or was too old to cope.  Fallowfield et al. (1997) also studied clinicians’ 
attitudes to clinical trials of cancer therapy and found that there were differences between 
professional groups within oncology: medical oncologists placed more emphasis on 
research than clinical activities, felt more pressure to take part in trials, and were more 
likely to value the resulting higher profile, nationally and internationally, of clinical trial 
participation, as compared with clinical oncology and surgical colleagues (Fallowfield et al. 
1997).  Other factors cited in the literature are reluctance to refer patients for clinical trials 
(Siminoff et al. 2000), and health professional gate keeping of a trial due to personal 
biases towards or against a study arm (Hjorth et al. 1996; Ellis et al. 1999a; Langley et al. 
2000; Westcombe et al. 2003).  In some situations there is also a lack of awareness of 
ongoing clinical trials, on the part of health care professionals (Siminoff et al. 2000; Fayter 
et al. 2006).  
 
Health care professionals as modifiers of clinical trial participation are becoming more 
frequently studied and discussed. Ruckdeschel et al. (1996) reported that one of the major 
factors determining whether patients will be successfully accrued to trials is the quality of 
the communication between the physician and the patients (and family members if 
present). Communicative behaviour of clinicians has been reported by patients in several 
studies as influencing their decision about whether or not to take part in a trial.  Grant et 
al. (2000) found that, for patients who said ‘yes’ to a cancer trial, physicians 
communicative behaviours and patient satisfaction were important factors in their 
decision.  For patients who said ‘no’, the motivations were less clear.  Rapport, awareness 
and understanding of randomised clinical trials were important reasons for patients with 
prostate cancer accepting a clinical trial (Eng et al. 2005).  Physicians who are supportive 
and responsive to patients’ concerns are likely to be the most effective at enrolling 
patients in studies (Albrecht et al. 2003).  It follows, then, that understanding patients’ 
decisions about trials, and improving the communication process, are key to improving 
clinical trial recruitment (Albrecht et al. 2003).   
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Albrecht et al. (2003) developed a model to explain patient decision making about clinical 
trials which is shown in Figure 2.1. This model posits that 1) the characteristics of the 
physician, 2) the nature of the trial protocol itself, 3) predisposing factors of the patient, 
and of the patient’s family member or significant other, affect a patient’s decision to enrol 
in a clinical trial.  The impact of all of these variables on the actual participation decision is 
mediated by the kind of communication that occurs between the individuals (Albrecht et al. 
2003). 
 
This model has not been widely tested to date, but a federally funded study is currently 
underway in the USA, to fully evaluate the model and to determine the extent to which all 
the components, as incorporated into a more elaborated structural equation model, 
independently and collectively explain patient perceptions of the physician and patient 
decisions regarding trial treatment (Albrecht et al. 2003).    
 
Figure 2.1.  Conceptual model of the factors affecting patients’ decisions about clinical 
trials (Albrecht et al. 2003) 
 
 
The importance of the interaction between the patient and the clinician, as highlighted in 
the literature, is consistent with Manson and O’Neill’s (2007) thinking in relation to 
Family Member 
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informed consent.  Manson and O’Neill discuss the transactional or interactive character 
of successful communication as being crucial to informed consent (p69); their argument 
will be discussed more in Chapter 3. This is consistent with ideas from a number of 
decision analysis perspectives, that it is the communication transaction that appears to be 
important.    
 
2.6.3 Trial  
There are a number of factors affecting recruitment which are associated with the trial 
itself.  These include: availability of trial, restrictive eligibility criteria, complicated trial 
design and challenges with the informed consent procedures, including the mode of 
presentation of information (Gotay 1991; Morrow et al. 1994; Klabunde et al. 1999; Lara et 
al. 2001; Fayter et al. 2006).  The scientific rationale of the trial is important in engaging 
health care professionals (Ellis et al. 1999a; Baum 2002; Wright et al. 2002; Westcombe 
et al. 2003; Fayter et al. 2006), with ‘insufficiently interesting research question’ identified 
as a barrier in the review by Prescott et al. (1999). 
 
2.6.4 Organisational/system factors  
Most of the issues in relation to organisational factors focus on the resource-intensive 
nature of running clinical trials, and the need for an adequate infrastructure and resources.  
In some cases, the consequence will be that the clinical trial will not take place at all. In 
others, the trial will be initiated, but will recruit low numbers of patients or none at all.  Lack 
of resources was identified by medical oncologists, radiation oncologists and surgeons as 
one of the major barriers to participation in breast cancer trials in Australia (Ellis et al. 
1999a). Similarly, in Germany inadequate infrastructure was identified as the main reason 
that German institutions do not take part in ovarian cancer trials (Sehouli et al. 2005).  
Somkin et al. (2005) investigated organisational barriers to clinical trial recruitment in the 
USA, highlighting the need for infrastructure, intra-organisational communication, and 
consideration of trial impact on internal health plan resources.  Furthermore, according to 
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Clinical Research Associates, ‘systems barriers’ were the main issues negatively affecting 
clinical trial accrual in Canada, specifically the impact of greater demands in a climate of 
decreasing health care resources (Grunfeld et al. 2002).   
 
In the UK, infrastructure and resources are substantial challenges, although this is 
improving due to the political investment in clinical trials discussed in Chapter 1.  The 
additional time involved discussing the trial, and obtaining consent, has been highlighted 
as a substantial component of the extra work generated by a clinical trial (Grunfeld et al. 
2002; Kornblith et al. 2002; Wright et al. 2002). Other institutional issues that have been 
identified are trials competing for the same patient population (Skeel et al. 1998; Goodwin 
et al. 2000). 
 
2.6.5 Summary of the patient, clinician, trial and organisational factors 
It is difficult to quantify the extent of influence of individual factors discussed, as the 
majority of studies do not address this.  As Fayter et al. (2006) point out, what is important 
is knowledge of these as potential issues for any trial, and a good assessment prior to 
initiation of the trial.  The relative importance of barriers will vary according to the context 
and the setting (Fayter et al. 2006). 
 
It is essential to address the barriers wherever possible, to optimise patient recruitment.  
Importantly, issues around patient information and communication, understanding and 
informed consent are identified in all four ‘barrier’ areas (patient, clinician, trial, 
organisational/system). This is one domain that is potentially modifiable and will be further 
discussed in Chapter 3.  This is especially important since many of the socio-demographic 
and socioeconomic factors discussed in the next section, whilst of interest, are not 
amenable to change and therefore not typically influenced by interventions to increase 
accrual (Morrow et al. 1994). 
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2.7 Socio-demographic and socioeconomic factors 
There are inconsistencies and conflicting findings, in both the general and the cancer 
literature, in relation to the influence of socio-demographic (SD) and socioeconomic (SE) 
factors on clinical trial recruitment rates. Much of the research is from the USA and it is 
difficult to know how this compares with other countries.  In addition, it has been 
suggested that differences in SD and SE characteristics between clinical trial populations, 
compared with real world populations, may impair extrapolation of results (Connolly and 
Low 2000).  As a result of the potential selection bias, there may be a predictive nature 
between SD characteristics and measured trial data points, such as treatment 
compliance, trial dropout, adverse event reporting and resource utilisation, which may 
impair a trial’s operational integrity and efficiency (Connolly and Low 2000). This is in 
addition to the potential influence on recruitment rates. SD and SE factors should be 
considered in the planning stages of a trial; however, it is acknowledged that this needs to 
be on a trial-specific basis, taking into account the clinical context, due to the 
inconsistencies in the literature across studies. 
 
2.7.1. General literature 
2.7.1.1 Age and education status 
In the general literature, studies showed no difference in recruitment rates with age (van 
Stuijvenberg et al. 1998, parents’ status in paediatric trials); gender (Ethier et al. 1999 in 
HIV); or education (Gorkin et al. 1996 in cardiology; Corbie-Smith et al. 2003 in stroke).  
The influence of education status on recruitment is unclear, with conflicting results from 
studies.  Better educated patients consented to trials for anxiety (Rapaport et al. 1995), 
HIV (Hankins et al. 1998) and a non-pharmacological intervention in the elderly (Whelton 
et al. 1997).   Poorly educated patients were more likely to consent in an HIV trial 
(Bartholow et al. 1997) and paediatric trials (parents were consenting) (Harth et al. 1992).  
A large cardiology study showed no difference in education status of participants; 
 44 
however, patients with a high understanding of the trial information were more likely to 
participate (Gorkin et al. 1996).  
 
2.7.2 Cancer 
In relation to cancer trials, the influence of socio-demographic and socioeconomic factors 
is also inconclusive.  
 
2.7.2.1 Age 
Despite conflicting findings, the majority of studies in cancer showed no difference in age 
(Llewellyn-Thomas et al. 1991 in colorectal cancer; Jenkins and Fallowfield 2000 in 
general oncology; Kemeny et al. 2003 in breast cancer; Movsas et al. 2007 for 
radiotherapy patients). Interestingly, although the study by Kemeny et al. (2003) showed 
no difference in participation as a result of age,  both age and stage of cancer were 
predictors of whether a patient was offered a trial (fewer older patients were offered).  
Movsas et al. (2007) also found that type of cancer was not predictive of enrolment in 
trials for radiotherapy patients.  
 
A trend in both directions for the influence of age has been reported in large scale studies.  
In an Ocular Melanoma study, older patients were more likely to participate (Diener-West 
et al. 2001).  In contrast, a study of breast cancer patients in Scotland found that older 
patients were less likely to participate (Twelves et al. 1998).  For newly diagnosed patients 
with a wide range of cancers, younger age was also a predicting factor for participation 
(Hunter et al. 1987). Melisko et al. (2005) explored attitudes towards complementary and 
alternative medicine (CAM) clinical trials in patients with breast cancer, and found that 
attitudes were significantly affected by patients’ age and stage of disease. Older people 
and those with earlier stage disease had more negative attitudes towards CAM trials.  
However, treatments given in CAMS trials are different to more aggressive anticancer 
treatments given in the majority of cancer clinical trials, for reasons including side-effect 
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profile and anticancer effect.  Caution should therefore be exercised in generalising 
results outwith the CAM trial setting.  
 
2.7.2.2 Gender, education, and stage of disease 
Similar to the more general literature, there was also no difference in gender (Hunter et al. 
1987 in newly diagnosed cancers; Llewellyn-Thomas et al. 1991 in colorectal cancer), or 
education (Llewellyn-Thomas et al. 1991) in relation to the participation decision. There 
was the same trend as in the general literature for patients who were more unwell: 
patients with more symptoms were more likely to participate (Diener-West et al. 2001).   
 
Interestingly, in trials of cancer prevention, screening and risk counselling, there is a trend 
for younger, married, more educated clients with a high perceived severity or disease risk, 
to participate (Mettlin et al. 1985; Rimer et al. 1996; Nijs et al. 1997).  These trials are 
intrinsically different to cancer treatment trials, which form the largest component of 
clinical cancer research, and involve patients without cancer.  Morrow et al. (1994) 
explains the distinction between the two types, discussed as ‘cancer treatment trials’ and 
‘cancer control trials’, in relation to key concepts from models of health behaviour. Issues 
of disease probability and severity have much more importance in prevention and 
screening trials (Morrow et al. 1994).   Despite the distinction, generalisations are being 
made from these studies to cancer clinical trials as a whole, by authors such as Kotwall et 
al. (1992).  This can result in an inaccurate picture of the influence of socio-demographic 
and socioeconomic factors in cancer clinical trials. 
 
2.7.2.3 Socioeconomic status     
SE status does appear to be related to recruitment to cancer clinical trials.  Sateren et al. 
(2002) considered 24,332 patients accrued to NCI sponsored cancer treatment trials in 
the USA over a 12 month period, and found that geographical areas with high SE levels 
had higher levels of clinical trial accrual.  Conversely, older women with breast cancer with 
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low SE status were less likely to take part in a trial (Gross et al. 2005).  Conflicting findings 
were reported in a study of patients with sarcoma (n=103) where there was no influence of 
socioeconomic status on recruitment rates (Barofsky and Sugarbaker 1979).  It must be 
acknowledged that this was a small scale study, with a specific patient group.    
 
2.7.2.4 Minority groups 
Research focusing on minority groups is not widely evident in the UK literature, although 
there is substantial work from the USA in relation to minority groups as a whole (Guiliano 
et al. 2000) and also focussing specifically on African Americans (Shavers et al. 2001), 
Asian-Americans (Nguyen et al. 2005), Latinos (Herman and Larkey 2006), Chinese 
American (Tu et al. 2005), American Indians and Alaskan Natives (Hodge et al. 2000).   
Much of what is reported is specific to cancer screening, with less research specific to 
cancer treatment trials.  It has been suggested that minority groups are less likely to enrol 
in cancer trials (Murthy et al. 2004).  Similar issues to those identified as barriers to 
participation in non-minority groups have been identified – lack of knowledge, 
communication challenges, fear, mistrust, attitudes and beliefs, financial costs, low 
socioeconomic status as well as cultural characteristics (Guiliano et al. 2000). Trust in the 
physician was an important theme influencing recruitment in several of the studies 
(Shavers et al. 2001).   
 
There have been several successful initiatives in the USA to increase recruitment in 
minority groups.  For example, the Eastern Cooperative Oncology Group in California 
introduced clinical trials education programmes for patients, families and clinicians (Pinto 
et al. 2000). Brown et al. (2000) used culturally targeted mass mailings and media 
presentations, based on acquiring an understanding of the minority community, to 
increase recruitment of minority women in cancer screening, prevention and treatment 
trials.  
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2.8 Strategies to increase clinical trial recruitment 
Due to the complexity of barriers that need to be addressed to improve recruitment to 
clinical trials, the interventions that have been tested have been diverse (McDaid et al. 
2006).  There are a number of good systematic reviews that summarise the evidence in 
this area. 
 
2.8.1 General literature 
Within the general clinical trial setting, Mapstone et al. (2007) reviewed strategies to 
improve recruitment to research studies focussing on RCTs and Quasi RCTs.  They found 
15 eligible trials, which included a total of 33,719 participants.  Trials of monetary 
incentives, additional questionnaire at invitation, and treatment information on the consent 
form all demonstrated benefit.  However, the authors acknowledge that these specific 
interventions from individual trials are not easily generalisable.  They conclude that it is 
not possible to predict the effect most interventions will have on recruitment (Mapstone et 
al. 2007). 
 
Watson and Torgerson (2006) carried out a systematic review of recruitment intervention 
studies from 1996 - 2004.   Hypothetical and ‘mock’ trials were excluded, and included 
studies had to have used random allocation.  They identified 14 papers with 20 
interventions and reported similar findings to the Mapstone review.  Effective interventions 
included telephone reminders, questionnaire inclusion, monetary incentives, using an 
open rather than a placebo design, and making trial material culturally sensitive (Watson 
and Torgerson 2006).   
 
Another systematic review investigated interventions to improve research participants’ 
understanding during the informed consent process (Flory and Emanuel 2004).  
Hypothetical or simulated studies were included in the review, with the main outcome of 
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interest being improved understanding, although data on willingness to participate in 
clinical trials was also reported.  Forty-two studies were included: 12 reporting multimedia 
interventions; 15 enhanced consent forms; 5 extended discussion; 5 of test/feedback 
interventions (where participants were tested on the information they received and 
received feedback on incorrect answers); and another 5 were classed in a miscellaneous 
category.  Twelve studies reported accrual or willingness to participate as a secondary 
aim of the study, and there was a willingness to join a randomised trial in 3 of these.  
However, these were all simulated scenarios with unknown relevance to a real situation.  
The authors recommend that further studies avoid using hypothetical scenarios.   
 
2.8.2 Cancer clinical trials 
A high quality systematic review of interventions to increase participation of cancer 
patients in randomised controlled trials (RCTs) was recently carried out by the Centre for 
Reviews and Dissemination at the University of York (McDaid et al. 2006).  They reviewed 
studies of any intervention to improve cancer patient participation in RCTs which reported 
participation rates.  Eight studies were identified, with the majority concerned with some 
aspect of the consent process. Only three were concerned with interventions implemented 
within a UK context (McDaid et al. 2006).  In the first study, Donovan et al. (2002) used 
qualitative research to successfully increase recruitment (from 40% - 70%) in a treatment 
trial for prostate cancer by changing the nature and emphasis of information and 
presentation to patients. They carried out in-depth interviews to explore patients’ 
interpretation of study information, and tape-recorded recruitment appointments to enable 
scrutiny of content and presentation of study information by recruiters. Results showed 
that recruiters had difficulty discussing equipoise and presenting treatments equally, and 
unknowingly used terminology that was misinterpreted by participants. This information 
was then used to determine changes to content and presentation of information, namely 
changes to the order of presenting treatments to encourage emphasis on equivalence, 
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avoidance of misinterpreted terms, redefining of the non-radical arm, and a more 
convincing presentation of randomisation and clinical equipoise.  In the same trial, 
reported in a separate paper, Donovan et al. (2003) found that nurses and urologists were 
equally effective at recruiting patients with nurses being more cost effective.  In the other 
study, doctors were provided with information about patient preferences for information 
and their attitudes towards trials, before they discussed the trial with the patient.  Trial 
participation rates were then compared between this group of patients and a comparison 
group where doctors did not receive prior information.  No difference in recruitment rates 
was found (Fleissig et al. 2001).  
 
McDaid et al. (2006) concluded that there is not a strong evidence base for interventions 
that increase cancer patient participation in clinical trials, and that good quality RCTs are 
needed in this area.  Another important point highlighted by this review was that due to the 
dangers of coercion, research involving interventions targeted at the informed consent 
process as a means of increasing trial participation should not be considered in isolation 
from the quality of the informed consent process (McDaid et al. 2006).   
 
2.9 Summary of Part I - Recruitment  
There is no shortage of studies investigating the problems of low recruitment to clinical 
trials, with many identifying lists of barriers in relation to the patient, clinician, trial and the 
organisation. The literature is unclear about the effect of age, gender and education 
status, but suggests that higher socioeconomic status and poorer prognosis/unwell 
patients are more likely to consent to a cancer clinical trial. 
 
Few trials have been undertaken of interventions designed to improve trial recruitment.  
Those which have attempted to address some of the barriers to recruitment are generally 
small scale and difficult to generalise. A recent review assessing effectiveness of 
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interventions to increase recruitment in randomised cancer treatment trials concluded that 
there was no effect in any of the studies reported, but that the evidence was not of 
sufficient quality to conclude that the interventions do not work (McDaid et al. 2006).  
Further research in this area is much needed to determine effective interventions.  
 
Patient refusal is the most common reason for potentially eligible patients not participating 
in cancer trials.  However, there is a lack of high quality research addressing the reasons 
why patients refuse.  Lists of reasons have been cited by patients and clinicians as being 
important influencers; however, further work is necessary to determine the relative 
importance of individual factors from a patient perspective, but also to investigate other 
reasons that may influence refusal that patients themselves are unaware of, for example 
lack of understanding of clinical trial information and concepts such as randomisation.  
Issues around patient understanding and informed consent were widely identified as 
factors negatively affecting recruitment and contributing to patient refusal rates.  This will 
be further discussed in Chapter 3 in relation to informed consent and clinical trial decision 
making. 
 
Major conclusions from the literature  
 
 Conclusion 1 
There is a need to develop effective interventions to increase the numbers of patients 
recruited to cancer clinical trials. 
 
Study implications 
• This study uses an experimental design to evaluate an intervention designed to 
specifically address this issue. 
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• It is important to evaluate AVPI against standard practice, and with an experimental 
design, so that any effect is likely to be as a result of the intervention.   A randomised 
design with a ‘standard practice’ control arm was employed in the study. 
• To minimise selection bias, studies examining recruitment should focus on all 
potentially eligible patients as was the case in this study. 
 
 Conclusion 2 
Patient refusal is the most common reason that clinically eligible patients do not take part 
in clinical trials but there is limited research into the reasons why this is the case. Reasons 
for patient refusal should be evaluated from the patient’s perspective and also to 
determine factors that patients may be unaware of, such as lack of understanding of what 
is required in the trial.  
 
Study implications 
• Patient refusal was the primary endpoint in this study. 
• Reasons for refusal from a patient perspective were evaluated. 
• Patient understanding was objectively assessed via a knowledge test, as well as via 
patient self-report. 
 
 Conclusion 3 
Issues around patient understanding and informed consent (such as difficulty with the 
concept of randomisation) have been identified as contributing to low recruitment in terms 
of factors affecting the patient; clinician; trial; and the organisation. 
 
Study implications 
• Patient understanding is a key focus for this study. 
• The concept of randomisation is addressed in detail in the intervention. 
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• Patients’ understanding and acceptance of randomisation is assessed in the 
knowledge and the clinical trial decision questionnaires.   
 
 Conclusion 4 
Factors associated with the clinician such as trust, communicative behaviour, quality of 
the interaction, have also been associated with both consent and refusal to clinical trials. 
 
Study implications 
• Although factors associated with the clinician was not a major focus in the AVPI study, 
personal perceptions of influencing factors on the clinical trial participation decision 
were assessed by patient self-report and included issues such as trust and the 
influence of the doctor. 
 
 Conclusion 5 
The literature is inconclusive in terms of the effects of socio-demographic (SD) and 
socioeconomic (SE) factors in clinical trial recruitment.  An exception to this is SE status in 
cancer trials, where high SE levels were associated with higher recruitment and 
conversely patients with low SE levels were less likely to take part in a trial.  In addition, 
patients with a higher concern about their illness, and those who are sicker or have 
advanced disease appear to be more likely to participate in a clinical trial.   
 
Study implications 
• Patient characteristics assessed at baseline included SD and SE factors - age, 
gender, education status and deprivation category.  
• Analysis tested for associations between patient characteristics and clinical trial entry. 
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• Data were collected on tumour type and whether the patient had limited or advanced 
disease, to determine whether there was any association between these factors and 
clinical trial entry.  
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CHAPTER THREE:  LITERATURE REVIEW PART II – INFORMED CONSENT 
 
 
3.1      Introduction to informed consent 
From Chapter 2, it appears that recruitment can be increased by improving informed 
consent, particularly by improving patient understanding. The aim of this chapter is to 
examine the informed consent process from both an ethical and practical perspective; to 
determine its key components, and specifically to examine the role of understanding; to 
review interventions aimed at improving the process; and to identify effective measures for 
evaluating informed consent.  It will be argued that informed consent can be viewed as an 
autonomous action, and that patient understanding is fundamental to it. There are 
substantial challenges in evaluating informed consent, and it will be demonstrated that 
focussing on patient understanding is an appropriate way of doing this.  
 
Informed consent is a complex, difficult concept, but at a basic level incorporates at least 
four dimensions: 
• What the patient needs to know [or understand] (information) 
• How that information is conveyed [to maximise understanding] (disclosure) 
• The extent to which the patient understands the information conveyed 
(understanding) 
• The extent to which the patient’s consent meets the criteria for decision making in 
this context – competence and voluntariness [understanding is essential for 
competence and voluntariness] (decision making). 
 
These four dimensions will guide the discussions in this chapter and it will be shown that 
patient understanding, in addition to being the explicit content of the third dimension, is 
crucial to the other three.  In view of the breadth of information covered in this chapter, 
Table 3.1 is intended to provide clarity on the structure of the chapter.   
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Table 3.1. Outline summary of Chapter 3 
 
Literature search 
Definitions 
Ethical and legal background 
 
THEORETICAL PERSPECTIVE 
 
Autonomy 
 
Understanding 
Noncontrol 
Autonomous actions 
Competence 
 
Beneficence 
Justice 
Informed consent as part of a wider ethics of communication 
Implications of theory 
 
EMPIRICAL LITERATURE 
 
Introduction 
 
Overview 
Randomisation 
Clinical equipoise v personal equipoise 
Patient-centred equipoise 
Information 
Equipoise 
Therapeutic misconception 
 
Overview 
Medium 
Disclosure 
Interaction 
 
Overview 
Knowledge and understanding 
Understanding 
Knowledge and anxiety 
 
Decision aids Within context of informed consent 
Shared decision making 
Voluntariness 
Decision making 
Consent capacity/competence 
 
Overview Measure of informed consent 
Measures 
 
Chapter summary 
 
This chapter will draw on much of the literature concerning informed consent in clinical 
trials. The cancer literature, in terms of consent and treatment decision making, will also 
be referred to where relevant. Following the literature search, definitions of informed 
consent will be given, followed by the ethical and legal background, in order to set the 
context for the subsequent discussions. The focus will then be on the theoretical 
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perspectives and models shaping current thinking. Following this, the empirical literature 
will be discussed in terms of the four dimensions of information, disclosure, understanding 
and decision making, referring to the theory as relevant.  Attention will then be given to the 
measurement of informed consent, with reference to further discussion of the measures in 
Chapter 7. The chapter will conclude with a summary. 
 
3.2   Literature search 
The main purpose of the literature search was to: 
• Identify the principles and processes of informed consent, and determine the role of 
patient understanding; 
• Review measures of informed consent. 
 
In view of the large literature base, two searches were initially undertaken.  The 
differences between the searches were that one included ‘measures’ as a key word and 
the other did not. The first search involved the following five concepts: 1) clinical trials; 2) 
consent (including choice); 3) understanding/knowledge/anxiety; 4) measures and 5) 
cancer/non-cancer.  The second search focused on 1) clinical trials; 2) consent (including 
choice); 3) understanding/knowledge/anxiety; and 4) cancer. These were expanded upon 
in various ways, as shown in the full details of the search strategy, and then combined 
(Appendix 3.1). The informed consent literature searches were undertaken after the 
searches for part I (recruitment) and part III (audiovisual patient information); duplicates 
already identified in these two searches were consequently removed from this one.  
Relevant papers are, however, included in the discussion of the literature. 
 
Electronic databases searched were:  Ovid MEDLINE(R) (mesz), Ovid MEDLINE(R) In-
Process and Other Non-Indexed Citations (prem), CDSR (coch), ACP Journal Club (acp), 
DARE, CCTR, British Nursing Index (brni), British Nursing Index Archive (bnib), CINAHL 
(nursing), EMBASE (emez), PsycINFO (psyf).  The search strategy was devised with the 
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input of an experienced medical librarian.  Additional references were located by searching 
the bibliographies of related papers, examining conference proceedings, and using the 
Google search engine. Terms were combined as shown in Table 3.2.  The line number 
corresponds with the full details of the search strategy in Appendix 3.1. 
 
 Table 3.2. Summary of literature search: informed consent 
  Combination of Terms 
 
Number of Hits 
Line 16  = clinical trials + consent/choice +  
   understanding/knowledge/anxiety + measures 
 
3612 
Line 17  = cancer + clinical trials + consent/choice +  
   understanding/knowledge/anxiety + measures 
 
819 
   Line 16 or 17  
 
3388 
Line 25 = limit to English language, last 10 years, duplicates  
   removed 
 
1888 
Line 26 = cancer + clinical trials + consent/choice +  
   understanding/knowledge/anxiety 
 
1152 
Line 30 = limit to English language, last 10 years, duplicates  
   removed 
 
342 
   Line 25 or 30 
 
380 
   Final total with duplicates removed 
 
337 
 
As shown in the table, the search was limited to the last 10 years. This was owing to the 
large volume of literature, and it is acknowledged that there will have been relevant 
papers prior to this time.  However, it was anticipated that important papers would be 
identified in the review articles, and that they would also be referred to in the more current 
papers.  In addition, the researcher had a large volume of literature on informed consent 
which had been collected over several years, some of which is also referred to in this 
chapter.  
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Full articles were requested for the majority of the final 337 abstracts.  Papers that were 
identified in the search but later excluded were about informed decision making in cancer 
prevention, genetic counselling, and screening, rather than consent to treatment or 
research. Others included those concerned with paediatrics, neonates and parental 
consent.  
 
3.3 Definitions of informed consent 
There have been various definitions of informed consent, with most reflecting the decision 
making component in addition to the informational one. Most of the literature refers to the 
concept in terms of its components. There is general agreement that the four key 
elements of informed consent are: disclosure, comprehension, voluntariness, and 
competence (Bosk 2002), with a fifth - consent/decision making - also often cited 
(Beachamp and Childress 2001, p79).  Faden and Beauchamp (1986) define an informed 
consent as.... “an autonomous action by a subject or a patient that authorises a 
professional either to involve the subject in research or to initiate a medical plan for the 
patient (or both)…….Informed consent is given if a patient or subject with (1) substantial 
understanding and (2) in substantial absence of control by others (3) intentionally (4) 
authorises a professional to do…” (Faden and Beauchamp 1986, p278). This is the 
traditional, most common way of considering informed consent, with an emphasis on 
autonomy, which will be discussed later in the chapter. 
 
Other writers claim that informed consent is broader than this, and that the context is 
important (for example, Manson and O’Neill 2007). Although definitions of informed 
consent have traditionally emphasised respect for autonomy, the meaning and values on 
which informed consent is based are grounded in society and in the practicalities of social 
relationships (e.g. shifting boundaries in the doctor-patient relationship, developments in 
information technology, and increasing bureaucratic regulation of informed consent)  
(Miller and Boulton 2007).  An example should help to illustrate this point.  Ethics 
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committees now sometimes insist that patients are not approached initially by the 
researcher but rather by their clinician, in a gatekeeper-type approach.  Although this is 
done in an attempt to protect the patient’s privacy, it can distort the basis of informed 
consent by linking the researchers to individuals and organisations with whom patients 
already have a relationship (Miller and Boulton 2007).   
 
Boulton and Parker (2007) summarize the biomedical ethics literature and, within the 
context of current regulations and guidelines, identify three criteria by which the validity of 
consent could be assessed.  First, potential research participants must be given all the 
information relevant to their decision about participation, and understand it. Second, the 
decision about participation must be voluntary and made without any form of coercion.  
Third, the person giving the consent must be competent to do so. These criteria give rise 
to obvious questions, such as: How much and which types of information are essential for 
consent?  What constitutes undue coercion? Who should judge if a person is competent 
to make such a decision, and how should this be done?  (Boulton and Parker 2007).  
These questions have been the subject of much debate, and remain unresolved, although 
there is guidance in the literature which helps researchers to address some of the issues, 
and which will be discussed throughout the chapter. 
 
3.3.1  Informed consent and informed choice 
As already discussed, ‘informed consent’ is a well established concept, used to describe 
the process in which patients are first informed and then invited to make a decision about 
whether to undergo a treatment, or enter a clinical trial.  ‘Informed choice’ is another 
concept used in the literature to denote the information-giving and patient decision making 
process, but it is almost exclusively referred to in relation to consent for screening, rather 
than consent to clinical trials.  Jepson (2005) argues that the difference between the two 
concepts is a matter of population, context and setting, although both are concerned with 
promoting patient autonomy by providing information on the risks and benefits of an 
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intervention or treatment/trial.  In screening, healthy individuals are usually sent a letter 
inviting them to attend for screening; hence they make an informed choice about whether 
or not to attend.  In informed consent, the patient is actively seeking, or is encouraged, to 
have some form of treatment, which may be part of a clinical trial.  Despite the widespread 
use and acceptance of the term ‘informed consent’ rather than ‘informed choice’ in the 
clinical trial setting, both in the literature and in practice, the ‘choice’ component of the 
process in clinical trials – in terms of whether a patient chooses to accept or refuse the 
trial – is important, and will be discussed more in Section 3.15. 
 
3.4 Ethical and legal background to informed consent 
3.4.1 Ethical background 
Informed consent is the ethical underpinning of clinical research. The concept has an 
interesting ethical and legal history, and remains one of the most controversial issues in 
the ethics of medical research.  The idea of informed consent surfaced in the early part of 
the nineteenth century and challenged the paternalistic view set out in the Hippocratic 
Oath (Edwards et al. 1998).  It is based on the notion that ‘a person of competent mind 
has a right to determine what is done to him/her and the right to determine what is not 
done’ (Edwards et al. 1998).  Informed consent as a concept was only really accepted in 
medicine in the mid-twentieth century, as a result of case law (Faden and Beauchamp 
1986, p101).  
 
Ethical codes or statements focussing on the protection of research participants have 
been established over the years to offer guidance to clinical researchers on the ethical 
conduct of clinical trials, and include informed consent as a key component.  One of the 
most important early statements of ethical principles for research was the Nuremberg 
Code in 1947. This was established as a result of the Nazi war crimes tribunals, and the 
exploitation of prisoners of war who were forced to take part in medical experiments, often 
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with horrific consequences. The Nuremberg Code consisted of ten principles to govern 
ethical research, of which ‘voluntary consent’ is central.  
 
Since then, the most well known and established ethical code to be developed is the 
Declaration of Helsinki, which was constituted, from within the profession, by the World 
Medical Association in 1964, and has undergone several amendments since. The 
Declaration of Helsinki remains an integral part of research guidance today, and specifies 
consent to be a central requirement of ethical research. Helsinki 2004 requires 
researchers to use explicit written and documented procedures in requesting and 
obtaining consent, and to seek specific consent to research (Manson and O’Neill 2007).  
This includes information about the aims of the study, methods, sources of funding, 
conflicts of interest, institutional affiliations of the researcher, and anticipated benefits and 
risks. It has been suggested that these standards may demand too much, since many 
patients fail to understand common features of trial design, such as randomisation and 
placebos.  Their consent will then not meet Helsinki standards (Manson and O’Neill 2007). 
Patient understanding is discussed in more detail in Section 3.14. 
 
3.4.2 Legal position for informed consent  
The legal position on informed consent has been predominantly concerned with informed 
consent to treatment, rather than research, and became more formalised in the USA in 
1972 when a new judicial standard was introduced: the reasonable person standard, 
under which “the decision about whether a patient should have been informed of a risk is 
based on whether a reasonable person in that patient’s position would want to be 
informed” (Mazur 2003).  Prior to this, the professional standard of consent to treatment 
had been adopted, whereby, in a court case, another professional would be called into the 
court and asked for his/her opinion on what they would have done in a similar situation. In 
the USA, both the professional standard and the reasonable person’s standard are 
currently followed, depending on the specific American state; Mazur (2003) estimates that 
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an approximately equal number of states have adopted each condition.  In the UK, 
adequacy of information in law is assessed by the Bolam test, whereby “whether the act 
or omission complained of accorded with what a reasonable body of professionals would 
have done at the material time” (Powers 2003).  In terms of clinical research, the 
European Directives discussed in Chapter 1 have influenced the legal context in many 
countries, including the UK.  As reported by Boulton and Parker (2007), informed consent 
is now a well-established concept which has been incorporated into national legislation in 
most industrialised countries. 
 
THEORETICAL PERSPECTIVE 
3.5   Introduction  
The theoretical underpinnings of informed consent have been derived mainly from 
bioethics, and especially research ethics (Corrigan 2003).  Much of this section is 
influenced by the writings of Tom Beauchamp and Ruth Faden, eminent professors in the 
field of biomedical ethics. Faden and Beauchamp (1986, p4) discuss two foundational 
frameworks in terms of informed consent: a legal approach and a moral approach. The 
legal approach has been almost exclusively concerned with consent in clinical contexts 
(and was briefly described in Section 3.4.2), whereas the moral approach has been more 
influenced by the research agenda.  Since the law relies on moral principles and test 
cases to shape its development, in this section the focus will be on the ethical framework 
for informed consent. 
 
Faden and Beauchamp (1986) argue that three broad ethical principles - respect for 
autonomy, beneficence and justice - are sufficiently comprehensive to provide an 
analytical framework for informed consent.  It is acknowledged that there is sometimes 
conflict between the principles, and that there is no consensus about whether autonomy is 
the only, or even the primary, justification for informed consent requirements.  When 
principles conflict, they need to be weighed against each other (sometimes called 
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balancing ethical principles), and a judgement must be made about which one should take 
precedence.  However, O’Neill (2003) argues that a more important issue (than 
autonomy) in informed consent is the need for patients and others not to be deceived or 
coerced. She asserts that consent procedures should be designed to give others control 
over the amount of information that they receive, and also the opportunity to rescind 
consent that they have already given.  Although O’Neill offers this as an alternative view of 
informed consent, it does not seem that the approaches are mutually exclusive. Surely 
what O’Neill proposes is also a fundamental part of acting autonomously?  
 
3.6 Autonomy 
The principle of respect for autonomy broadly refers to the right of self-determination, self-
governance, freedom and choice, and is the most commonly cited ethical principle in 
relation to informed consent. However, there are different interpretations of the concept, 
and no obvious consensus as to its scope.  Faden and Beauchamp (1986, p9) believe 
that autonomy within the context of informed consent incorporates the right to privacy and 
the principle of veracity; that is, wherever a moral right to privacy, or the principle of 
veracity is invoked, it is treated as either reducible to, or a derivative from, an autonomy 
right.  
 
Most existing analyses take as central the autonomous person, someone who has the 
capacity to act independently and make his/her own personal choices, based on past 
experiences, values and beliefs. However, Faden and Beauchamp prefer to talk about 
autonomous actions, a concept which they take to be more central than the concept of an 
autonomous person.   
 
3.7 Autonomous actions 
The distinction between autonomous persons and autonomous actions is important.  
Faden and Beauchamp (1986, p235) discuss informed consents as “acts of autonomous 
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authorising”. Autonomous actions are often performed by autonomous persons but can 
also be performed by non-autonomous persons.  Faden and Beauchamp (1986) believe 
that “informed consents and informed refusals are particular actions; the goal of informed 
consent requirements is to enable patients and subjects to perform these actions, that is 
to make substantially autonomous choices about whether to authorise a medical 
intervention or research involvement”.  But what is a ‘substantially autonomous choice’? 
  
There is no widespread agreement in the literature about what constitutes an autonomous 
person or what constitutes an autonomous action. Faden and Beauchamp (1986, p237) 
suggest that the autonomous person has the capacity for, and frequently exhibits, 
autonomous action - which would include resistance to social conformity and coercion, as 
well as reflectiveness, understanding and insight.  A generally autonomous person may 
sign a consent form without reading it; or, in the cancer trial setting, he/she may be very 
distressed after receiving a diagnosis of cancer, and consequently not be able to act 
autonomously. These examples suggest that being a generally autonomous person is not 
always sufficient. What is more significant is whether a particular action can be considered 
autonomous. 
 
Faden and Beauchamp (1986, p238) suggest that the three conditions necessary for 
autonomous action are intentionality, understanding, and without controlling influences, 
which they refer to as noncontrol (other authors refer to noncontrol as voluntariness). 
These three conditions are logically different. As far as intentionality is concerned, patients 
actions are either intentional or not (a dichotomous variable). However, ‘understanding’ 
and ‘noncontrol’ are continuous variables. This is best illustrated by Faden and 
Beauchamp’s continuum, which shows understanding and noncontrol in terms of 
autonomous actions (Figure 3.1).   
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      Fully             Substantially      Fully 
autonomous            autonomous           nonautonomous 
 
 
 
            Fully         Fully 
  understood        ignorant 
 
 
    Completely        Completely 
noncontrolled        controlled 
 
 
Figure 3.1. Degrees of autonomy of intentional actions (Faden and Beauchamp 1986, 
p239) 
 
 
The main difficulty here is the area designated ‘substantially autonomous’.  Although ‘fully 
autonomous’ would be the ideal, in reality, in most areas of practice – including the clinical 
trial setting – this is very unlikely for the reasons already discussed.  ‘Substantially 
autonomous’ would be a reasonable compromise, so what is meant by substantial is of 
particular importance. There is no conceptual guidance in this area, and it will depend on 
the clinical and social context as to how much understanding and noncontrol is 
acceptable.  For all three conditions, understanding is necessary if the patient’s decision is 
to be intentional and voluntary. However, ‘understanding’ is also something that must be 
examined independently. 
 
3.7.1 Understanding 
As noted above, in informed consent theory, understanding is emphasised as a key 
condition of autonomous actions; it is therefore one of the main endpoints in the AVPI 
study described in this thesis. However, the view that understanding should have such a 
prominent position is not unanimous, and it has been argued that disclosure is more 
important, and that understanding should not be a condition of informed consent at all 
(Screenivasan 2003). This is partly due to the challenges in achieving understanding on 
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the part of the patient, and in particular an understanding of risks and benefits.  In the 
discussion that follows, it is acknowledged that full understanding is an ideal that is 
difficult, if not impossible to achieve; it will be suggested, however, that it is possible, and 
important, for a substantial degree of understanding to be present prior to patient decision 
making about participation.   
 
According to Faden and Beauchamp (1986, p299), if the understanding condition of 
informed consent is satisfied, the conditions of intentionality and authorisation will usually 
also be satisfied as a consequence of meeting the condition of understanding.  Another 
important consideration is that the more information a person understands, the greater the 
likelihood of autonomous action (Faden and Beauchamp 1986, p239).  As already 
discussed, substantial autonomous action is dependent on the condition of substantial 
understanding.  But what is this, and how can it be achieved?  Faden and Beauchamp 
(1986, p303) believe that substantial understanding requires apprehension of important 
descriptions (those that are important to the person’s decision from their perspective, but 
not necessarily decisive), but not all the relevant or possible descriptions. ‘Relevant 
descriptions’ are those that contribute in any way (even a minor way) to the apprehension 
of a situation.  A person could therefore be completely ignorant of relatively trivial or 
unimportant, but nevertheless relevant, propositions about a proposed trial, but still give an 
informed consent to the trial. 
 
Understanding is a complex concept, and it has been suggested that there are three main 
types which are set out below (Faden and Beauchamp 1986, p250): 
1) Understanding how (to do something) is equated with knowing how; 
2) Understanding that (something is true). This is a propositional knowledge claim where 
understanding is reducible to the analysis of knowledge; for example, understanding that I 
am being asked to consent to this trial; and 
3) Understanding what (has been said); for example, what the trial entails. 
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For informed consent, understanding that you are being asked to decide about taking part 
in a trial, and understanding what is communicated about the trial, are the key parts of 
understanding that are important. Faden and Beauchamp (1986, p308) believe that 
substantial understanding is best achieved with a core disclosure of the key facts, followed 
by a more personal discussion which is focussed on what the patient needs or wants to 
know. The core disclosure is often determined by regulatory requirements and would 
consist of: information usually considered important in trial decisions; what the 
professional thinks is important; and information about the purpose of seeking consent as 
an act of authorisation (Faden and Beauchamp 1986, p308). 
 
With such a major focus on individual autonomy, the issue of patients having false beliefs 
is important and puts pressure on the investigator/clinician to address this, wherever 
possible, by correcting misconceptions. If understanding is based on false beliefs, then 
understanding will be ‘less than correct’, and the action (for example, to consent to a trial) 
cannot be autonomous (Faden and Beauchamp 1986, p253).  It is difficult sometimes to 
judge whether or not a belief is false, and Faden and Beauchamp (1986, p254) discuss 
the justified belief standard as a potential solution to this problem…. “the justified belief 
standard captures the common sense conception of reasonable (even if not true) belief 
and assertion that underlies ordinary social agreements about what is veridical”  They do 
however acknowledge the limitations to this, in that there is little agreement about what 
makes a belief ‘justified’ 
 
3.7.2 Noncontrol 
In Faden and Beachamp’s theory of autonomous action, noncontrol is fundamental.  This 
means that the person is acting independently, with no external controls on his/her action. 
In the literature, noncontrol has been linked to voluntariness, which has also been 
discussed within the context of autonomy; however, Faden and Beauchamp (1986, p258) 
prefer to discuss coercion, manipulation and persuasion as the influences on control, and 
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to avoid the term ‘voluntariness’ because of its wide and varied usage. They provide 
definitions for ‘coercion’, ‘manipulation’ and ‘persuasion’, but acknowledge that it is difficult 
to define what degree of noncontrol is needed for an autonomous decision, partly because 
of the subjective nature of the issues and the fact that people are very different in how they 
respond to these influences. 
 
3.7.3 Competence 
Competence is important for autonomous action, and hence informed consent. 
Competence is also referred to in the literature as ‘capacity to consent’ or ‘decision-making 
capacity’ and much has been written about the concepts, particularly in relation to how 
they are assessed.   It has been suggested that competence can also be portrayed as a 
continuum, from incompetent to fully competent (Faden and Beauchamp 1986, p290). A 
threshold would then need to be established, representing the point on the continuum 
where a person is considered competent enough to consent or refuse a trial.  A patient 
considering clinical trial participation would need to understand the information, and the 
implications of it, in order to be competent to make the decision about participation. 
 
Assessment of competence is a difficult challenge as will be discussed in Section 3.15.3. It 
is essential to address assessment, in order to determine whether a person is considered 
competent to make the decision about clinical trial entry. As Berghmans and 
Widdershoven (2003) assert, the current dominant approach towards decisional capacity 
is cognitive and rational. This means that choices are made according to logical 
procedures of rational thinking.  Berghmans and Widdershoven (2003) report that the 
literature identifies assessment of decision making capacity as having four criteria: “the 
capacity to make a choice; the capacity to understand relevant information; the capacity to 
evaluate the character of the situation and possible consequences; and the capacity to 
handle information rationally.” They suggest alternatives to this which consider the 
relevance of emotion and mood, meaningfulness to the patient, and promoting the patient-
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physician interaction to discuss values (personal to patient, and values of treatment). 
These factors should also be considered when capacity to consent is being assessed. 
 
3.8 Other relevant ethical principles 
3.8.1 Beneficence 
The principle of beneficence is a key principle of medical ethics, and is concerned with 
maximising good and promoting the welfare of others. It includes the following four 
elements:  “(1) one ought not to inflict evil or harm; (2) one ought to prevent evil or harm; 
(3) one ought to remove evil or harm; and (4) one ought to do or promote good”  (Faden 
and Beauchamp 1986, p10). 
 
In terms of consent to research, the investigator would be expected to adopt this principle, 
primarily in relation to the patient, but would also have beneficence responsibilities to 
future patients and the population as a whole, the employing authority, and the study 
sponsor.  Details of the risks and benefits involved in the clinical trial should be fully 
disclosed to patients. Patients need to have an appreciation, and an understanding, of 
these risks and benefits. 
 
3.8.2 Justice 
“A person should be treated according to what is fair, due or owed” (Faden and 
Beauchamp 1986, p14).  Faden and Beauchamp give the example, within the clinical trials 
setting, of the controversy surrounding the use of prisoners as subjects in research, and 
questions whether it is right or ‘just’ to do this.  Even if the principles of beneficence and 
autonomy are met, which in this case it could be argued that they are (there is likely to be 
benefit to society as a whole, and the subjects have autonomously given their consent to 
participate), there is still an issue about the principle of justice. But should the principle of 
autonomy take precedence?  Although Faden and Beauchamp discuss justice as relevant 
to informed consent, they are very clear that the most important principles are autonomy 
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and beneficence; and they claim that the major ethical and conceptual problems with 
informed consent are not justice-based.  However, an important consideration is the 
inclusion of marginalised groups in research: ethnic minorities, people living in remote 
communities, people with communication impairment. This further highlights the 
importance of the social context in informed consent. 
 
3.8.3 Balancing the principles in informed consent 
Prior to the introduction of informed consent in the mid-twentieth century, the beneficence 
model was overwhelmingly dominant in medical ethics and health care practice.  With the 
introduction of informed consent and the focus on the patients’ right to self-determination, 
the principle of autonomy is becoming increasingly important. It is generally believed that 
autonomy is the most important ethical principle in informed consent, and that this should 
never be overridden, regardless of the context or circumstances (Kottow 2003).  Faden 
and Beauchamp (1986, p19) do not support this view, although they do support enabling 
autonomous choice as the goal of informed consent requirements.  They do not believe 
that autonomous choice, or the underlying principle of autonomy, always outweighs other 
ethical considerations. They acknowledge that in some situations, beneficence and justice, 
as well as role responsibilities (such as providing the best professional care), may have 
sufficient weight to override respect for autonomy (Faden and Beauchamp 1986, p19). 
 
3.9 Informed consent as part of a wider ethics of communication 
Manson and O’Neill (2007, pp. xi and 40) challenge traditional thinking on informed 
consent, and contest the claim that appeals to autonomy provide justification for informed 
consent procedures.  They argue that informed consent is best thought of as a wider 
ethics of communication, and discuss eight key aspects of communication that they claim 
tend to be ‘obscured or ignored’ by the current heavy reliance on conduit and container 
metaphors, which they claim shape the way we think about informed consent.  These eight 
key aspects suggest that informing is: (1) context-dependent, (2) norm-dependent, (3) 
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propositional, (4) rationally evaluable, (5) referentially opaque, (6) inferentially fertile, (7) a 
type of rational action, and (8) audience-specific (Manson and O’Neill 2007, p41).  The 
‘conduit’ metaphor refers to, for example, transferring the content of information, and the 
‘container’ metaphor implies the idea that information is contained, for example, in the 
human mind, email, or text.  Information that exists in one container is transferred to 
another.  If information is then viewed as content rather than action, as per the 
conduit/container model, it is likely that some elements of information and communication, 
such as knowledge, will be emphasized, while many significant features of communication 
that depend on agency, such as context and relationships, will be downplayed or ignored 
(Manson and O’Neill 2007, p48). 
 
Manson and O’Neill (2007, p69) suggest that the agency model of communication 
provides a framework for recognising the interactive or transactional nature of successful 
communication, emphasising what is said and what is done by both parties.  They claim 
that this approach allows a deeper and more plausible justification of informed consent 
than autonomy-based justifications that centre on disclosure for decision making. Informed 
consent is thought of as a communicative transaction between agents. As communication 
transactions, informed consent transactions must respect the norms that are required for 
successful communication: intelligible, relevant, accuracy and truth/truthfulness (Manson 
and O’Neill 2007, p85). 
 
In some cases a patient may base his/her decisions on his/her background knowledge - 
that “certain kinds of communicative action, or reason-giving or forms of respectful 
behaviour”, have taken place - and not on the content of the informed consent disclosure 
(Manson and O’Neill 2007, p32).  This fits with understanding the role of information as 
making people feel involved, and helping to manage expectations rather than being used 
to making choices, per se. Faden and Beauchamp (1986, p307) also advise that 
professionals should move their emphasis away from the traditional focus on disclosure, 
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and focus more on the communication aspect of the relationship to determine the specific 
needs and concerns of the patient, and to encourage a setting where the patient is 
comfortable to ask questions.  There is still an important role here in optimising patient 
understanding of the clinical trial information. 
 
Corrigan (2003) suggests that the traditional bioethical model of consent, whose core 
foundation is autonomy, can be equated with an ‘empty ethics’ model in which the context 
is not considered and the consent process becomes a rational-choice model of action. She 
emphasises the importance of considering informed consent in its clinical and social 
context, and offers her study of patients in clinical drug trials as evidence. Corrigan (2003) 
asserts that informed choices, based on an adequate understanding of the clinical trial 
information, and consideration of the potential benefits and risks, are difficult to achieve in 
practice because of the importance of the type of illness a patient is suffering from, 
anxiety, treatment expectations, and trust in the doctor and medical science (Corrigan 
2003).  It is acknowledged that adequate or substantial understanding is difficult to achieve 
in practice, as has been highlighted by Corrigan; however, it can still be argued that it is an 
important aim, that it is possible to secure it in the clinical and social context, and that it 
can be optimised when taking these individual factors into account.  
 
3.10 Implications of the theory 
It would seem, from reviewing the theoretical perspectives, that maximising opportunities 
for autonomous actions, based on understanding, is important for informed consent, but 
that this needs to take account of the individual context and the communicative 
transaction. Other important areas for autonomous action are noncontrol (voluntariness) 
and competence to consent (decision making capacity), both of which depend on patient 
understanding. 
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Informed consent theory is implicated in all four dimensions of informed consent as 
discussed at the beginning of this chapter – information, disclosure, understanding and 
decision making. The theoretical context was not formally discussed under these headings 
so as not to fragment the main focus of the argument, which is centred on informed 
consents as autonomous actions, with the key component being patient understanding.  
However, it is important to clarify the link with the four dimensions, as these will form the 
basis of the discussion for the empirical literature.  Understanding is obviously the basis 
for the understanding dimension, but is also implicated in the information dimension, in 
terms of understanding ‘what’ is important (e.g. randomisation, equipoise, voluntariness of 
consent), and also the disclosure dimension, since factors such as the medium and 
clinician/patient interaction can have a positive or negative effect on the patient’s 
understanding of the information disclosed. The other conditions for autonomous actions - 
noncontrol (voluntariness) and competence (capacity) to consent - require patient 
understanding in order to be fully met, and are integral to the decision making dimension.  
 
The empirical literature will now be discussed in terms of the four key dimensions, linking 
back to theory as appropriate. 
 
EMPIRICAL LITERATURE 
3.11 Introduction 
Much of the empirical literature discusses ‘barriers’ to informed consent.  However, 
following a strategy akin to the one used by Verheggen et al. (1996) in their review of 
informed consent in clinical trials (Figure 3.2), this review assesses the relevant research 
in two key domains: informed and consent. The difference from the Verheggen model is 
that within the informed domain, information disclosure is split into two categories:  
‘information’, including content, volume and presentation, and ‘disclosure’, the information-
giving process. Comprehension (understanding) is the third component of the informed 
domain.  The consent domain consists of decision making and motivation to participate 
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(Figure 3.2). ‘Decision making’ and ‘motivation to participate’ will be combined in order to 
make the model consistent with the four key informed consent dimensions identified at the 
beginning of this chapter: information, disclosure, understanding and decision making. 
Motivation to participate is not discussed in this chapter since it has already been 
addressed in Chapter 2. 
 
 
Figure 3.2. Summary of informed consent (modified from Verheggen et al. 1996) 
 
 
On a practical level, patients must receive appropriate information that they can 
understand, to enable them to make decisions about whether or not to take part in a 
clinical trial.  The informed consent process is “an opportunity to provide accurate and 
non-judgemental information regarding trial procedures and potential risks and benefits, 
correct any misconceptions and allay any unfounded fears, and provide sufficient time and 
resources to facilitate the thoughtful consideration necessary for the best possible 
personal decisions” (Barrett 2002).   
 
Various interventions have been developed with the aim of improving informed consent, 
many of which will be referred to in the relevant subsequent sections of this chapter.  
Informed Consent 
‘Informed’ ‘Consent’ 
• Information 
• Disclosure 
• Comprehension 
• Decision-making 
• Motivation to 
participate 
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Interventions aimed at improving informed consent focus on different aspects of the 
process, with the majority centred on the information-giving process or on increasing 
patient understanding.  
 
3.12 Information 
3.12.1  Overview  
Content, volume, readability and presentation have all been shown to be important in 
optimising informed consent procedures in terms of understanding. These, together with 
public knowledge about clinical trials, are briefly discussed here.   
 
Information content for patients being considered for clinical trials is governed, to a large 
extent, by regulations and guidelines (e.g. ICH Good Clinical Practice Guidelines (1996) 
and Research Governance Frameworks), as discussed in Chapter 1.  Faden and 
Beauchamp (1980) (in Fureman et al. 1997) suggest that, in medical settings in which the 
subjects are less familiar with the treatment options (which would be the case in 
randomised cancer trials), information provided may have a proportionately greater effect 
on decision making.  Furthermore, as already discussed, informed consent theory 
suggests that in addition to the core components identified in guidelines, and what the 
professional believes to be important, there should be a focus on the specific informational 
needs of the individual, to ensure that personal issues are addressed in the consultation 
(Faden and Beauchamp 1986, p308).  Particularly difficult for patients to both understand 
and to accept, in randomised clinical trials, are the concepts of randomisation 
(Featherstone and Donovan 1998; Hietanen et al. 2000) and clinical equipoise (Mills et al. 
2003; Madsen et al. 2007). As a consequence, these will be addressed separately, later in 
the chapter (Sections 3.12.2 and 3.12.3).  
 
There are different views on the volume of information necessary for informed consent in 
clinical trials, with the majority of studies showing that patients are satisfied with what they 
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receive (Ferguson 2002).  Edwards et al. (1998) carried out a review of informed consent 
in clinical trials and found that there seems to be an optimal level of information about 
side-effects, a level which avoids overburdening with detail, but which provides enough 
information for the most important risks to be understood.  Studies which have compared 
simple, shortened or ‘easy to read’ consent forms with the standard more complex version 
found that more information was retained with the shortened versions (Dresden and Levitt, 
2001) and that more patients reported reading the shortened versions (98% v 68%) 
(Dresden and Levitt 2001).  Anxiety was lower, and satisfaction was higher, with the easy 
to read version (Coyne et al. 2003). In the non-clinical trial setting (the injection of 
intravenous contrast material into patients for radiological purposes), brief information 
reduced patient anxiety, whereas detailed information increased it, as assessed by the 
Spielberger State-Trait Anxiety Inventory (Yucel et al. 2005). Comparably, in consumer 
decision making for hospital choices in the USA, a ‘less is more’ approach to information 
about health care quality, with the important information highlighted, led to better 
understanding and better decision making, especially for those lower in numeracy (Peters 
et al. 2007). 
 
A number of studies have investigated the readability of clinical trial consent forms, many 
specific to oncology trials, and have consistently found them to be aimed at too high a 
reading level, and to be too difficult to understand (Morrow 1980; Grossman et al. 1994; 
Sharp 2004).  If the written information is not being understood by patients, then this puts 
pressure on the investigator/clinician, and requires greater emphasis on the quality of the 
interaction with the patient and the effectiveness of communication, to ensure that consent 
is genuinely informed.   
 
Information can be presented in different ways.  For example, linguistic analysis followed 
by changes in information leaflets, improved readability and understanding in a Danish 
clinical drug trial (Bjorn et al. 1999).  Framing information positively (for example, 
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focussing on chance of survival over time rather than chance of death over time) is 
associated with higher levels of understanding, and increased likelihood of consent to 
treatment (Armstrong et al. 2002).  Tailoring information (for example to specific 
situations, patient groups, individual preferences or requirements) was shown to be 
effective in a meta-analytic review of the literature (Noar et al. 2007).  Further discussion 
on the effects of framing and tailoring information can be found in Chapter 4, focussing on 
audiovisual patient information, as was relevant to the AVPI study. 
 
Several authors have emphasised the value of the population being more aware of clinical 
trials (Edwards et al. 1998; Trauth et al. 2000; Apolone and Mosconi 2003; Fisher 2006).  
Public knowledge about clinical trials is known to be poor (Apolone and Mosconi 2003; 
Comis et al. 2003; Fisher 2006), and Manson and O’Neill (2007, p67) argue that all 
communication is rooted in background knowledge and inferential competences.  This 
would suggest that, by improving the general public’s baseline knowledge of clinical trials, 
it may be possible to enhance the communication process in informed consent.  In 
addition, the more that people know before they are invited to take part in a trial, the better 
equipped they are to cope with the informed consent procedure (Edwards et al. 1998).  
Although this was not an aspect that was addressed in the AVPI study, patients’ past 
experience of clinical trials was assessed within the context of their baseline knowledge of 
clinical trials. Patients who had had previous experience of clinical trials would be 
expected to have additional knowledge in this area.  
 
3.12.2 Randomisation 
Randomisation means that trial participants have an equal chance of receiving any one of 
the treatment arms in a clinical trial. Randomisation is considered optimal in experimental 
design on effectiveness, with ethical justification dependent on the acceptance of 
equipoise. However, randomisation is frequently misunderstood (Appelbaum et al. 1987; 
Sutherland et al. 1990; Snowdon et al. 1997; Edwards et al. 1998; Ellis et al. 1999b; 
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Hietanen et al. 2000; Madsen et al. 2007).  Even when patients (or potential research 
participants) do understand it, many of them find it difficult to accept (Featherstone and 
Donovan 1998, 2002; Robinson et al. 2005; Madsen et al. 2007).  The effect on 
recruitment has already been discussed in Chapter 2, Section 2.6.1.4.  This section 
discusses randomisation in the context of informed consent. 
 
Despite being given information about randomisation (a necessary requirement of written 
patient information for research governance), and an explanation of the process (although 
what this entails varies), many patients still believe that the doctor chooses the treatment 
for them (Ellis et al. 1999b; Hietanen et al. 2000).  In a UK study investigating how 
oncologists explain randomised trials to their patients, Jenkins et al. (1999) found that 
verbal information from doctors about randomisation was variable; and, while there was 
much discussion about proposed treatments and side-effects, reasons for randomising 
treatment were kept to a minimum (Jenkins et al. 1999). Over the last few years, UK 
guidance has been developed with the aim of improving the content and readability of trial 
information, and this has been incorporated into multicentre research ethics application 
procedures; so there is now some degree of standardisation for written information (Kerr 
et al. 2004). In terms of randomisation, the guidelines advocate the description: “The 
groups are selected by a computer which has no information about the individual”. 
 
Poor understanding of randomisation raises concerns that patients may be giving consent 
without understanding what is involved, and is an area that has attracted substantial 
research interest over the last ten years. Research questions focus mainly on whether 
patients understand the concept, and on whether they accept it. There has been a mix of 
quantitative and qualitative approaches to studying randomisation, with the majority of 
studies asking patients directly, either by interview or questionnaire. There has also been 
some work with lay people, with similar study outcome measures (Kerr et al. 2004; 
Robinson et al. 2005). Another approach has been to determine patients’ preferences for 
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different descriptions of the term randomisation. A recent study involving 600 patients with 
cancer showed the CancerBACUP description to be the most preferred, and the more 
technical description of randomisation, from the National Cancer Institute in America, to 
be least liked (Jenkins et al. 2005). 
 
Kerr et al. (2004) gave leaflets to 130 adults attending a UK further education college, 
giving them scenarios illustrating randomisation, and interviewed 12 of the sample to gain 
a deeper understanding of understanding and acceptability of the concept. Findings from 
both the quantitative and qualitative data showed that the majority of participants were 
able to judge when the allocation methods were random, but they did not find the method 
of random allocation acceptable.  In general, participants did not appreciate the scientific 
value or purpose of the method, a finding which is supported by other studies: Robinson 
et al. (2004) with adult students; Featherstone and Donovan (1998) with clinical trial 
patients (prostatic disease); and Stead et al. (2005) with diabetes clinical trial patients.  In 
Kerr et al’s (2004) study, when information about the scientific value of randomisation was 
given to the participants, acceptability of only one method - allocation by computer - was 
increased.  This supports the current UK guidelines, as noted above.  When informing 
patients about randomised trials, Kerr et al. (2004) recommend focussing on the scientific 
purpose of random allocation. 
 
Featherstone and Donovan (2002) carried out a qualitative study of patients’ experiences 
in randomised trials.  They interviewed 33 men with lower urinary tract symptoms related 
to benign prostatic disease, exploring their recall and understanding of trial information 
and how they were allocated to a treatment.  They found that while most patients recalled 
major aspects of trial design, including allocation by chance, they also had other views 
about their treatment allocation, which were sometimes contradictory. The patients were 
trying to understand it in relation to their own beliefs, recall and actual experiences of the 
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trial (Featherstone and Donovan 2002). The resultant outcome was either the placing of 
trust in the clinician, or the development of distrust (Featherstone and Donovan 2002). 
 
3.12.3 Equipoise 
Clinical equipoise is an important ethical and scientific justification for randomisation.  In 
patient information for trial participation, equipoise is usually expressed in terms of 
uncertainty about which treatment is best, or about the benefits of a new treatment. 
Equipoise has been discussed as a precondition to an ethical trial (Olson 2002).  It has 
also been said that the ethical recruitment of patients to trials requires the presence of 
clinical equipoise (Mann and Djubegovic 2003). Most research on equipoise has focused 
on participants’ awareness of this uncertainty (Robinson et al. 2005), and both qualitative 
and quantitative approaches have been used.  Interestingly the term ‘equipoise’ has been 
replaced by ‘indifference’ by Veitch (2002 and 2007), a term which appears to be a 
clearer, more comprehensive way of referring to equipoise.  Veitch speaks of “indifference 
about which treatment’s expected benefit/harm package is preferred”, and further asserts 
that “one may be quite uncertain about some set of scientific facts, and still be very clear 
that one has a preference for one treatment over an other”.  
 
Equipoise is important to both patients and investigators, and different types of equipoise 
are discussed in the literature, the main difference being whose view of equipoise is taken 
to be definitive. The main types identified are: scientific (community) equipoise, also 
referred to as theoretical equipoise (Freedman 1987), clinical (community) equipoise 
(Veitch 2002), individual clinician (personal) equipoise (Veitch 2007), and patient (centred) 
equipoise (Olson 2002), also referred to as individual subject indifference (Veitch 2002).  
Scientific equipoise is when scientists must be uncertain about which treatment is 
scientifically best. This can be different to clinical equipoise; this is determined by 
clinicians, who will have a broader perspective, as it concerns their patients and includes 
the effect of very different treatment options, side-effects and life-style costs, among other 
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considerations (Veitch 2007). The literature focuses predominantly on clinical equipoise, 
which is the most popular view. 
 
3.12.3.1 Clinical equipoise v personal equipoise 
Problems can arise if a trial has been developed by a team of experts who believe it to 
have clinical or communal equipoise, and the clinician-investigator at a certain study site 
is expected to recruit to the trial, but does not personally share the uncertainty, and so 
does not have personal equipoise. The frequency of this situation is unknown. Jenkins et 
al. (1999) reported that, whilst oncologists expressed uncertainty about treatment 
decisions in nearly all of the consultations studied, in only 14.6% was this uncertainty 
personal. It cannot be assumed, however, that personal equipoise existed only for 
oncologists involved in these 14.6% consultations, since this number may be higher as a 
result of oncologists not disclosing their opinions to patients.  This could be non-intentional 
(an omission), or could be deliberate, so as not to negatively affect the doctor-patient 
relationship. In situations where the clinician is lacking in personal equipoise, Alderson 
(1996) and Freedman (1987) both advise accepting the communal equipoise view. The 
individual clinician may not have access to all the data, may only have experience with a 
small skewed sample of patients, or may have personal values which influence 
assessment of benefits and harms (Veitch 2002). 
 
As with randomisation, patients find it difficult to accept and believe in equipoise (Mills et 
al. 2003). Mills et al. (2003) interviewed 21 men with localised prostate cancer from three 
UK clinical centres and found that, although recall and understanding of the major 
principles of the randomised design were good, clinical equipoise caused difficulty and 
influenced trial consent rates; patients who found equipoise acceptable tended to consent, 
whereas those who could not accept it tended to refuse participation. In another study, 
involving 355 adult students, approximately half were reluctant to accept that the doctor 
might genuinely not know which treatment is best (Robinson et al. 2004).  
 82 
Although the widespread view is that clinical equipoise is of both scientific and ethical 
importance, this view is not unanimous. Indeed, it has been suggested that equipoise is 
irrelevant, and that only the subject’s evaluation of the options is morally relevant (Veitch 
(2007). According to Veitch (2002) it is rare for a clinician to be indifferent between two 
treatment options. It has also been questioned whether equipoise in a strict sense is 
possible to achieve (Meran 2003). 
 
3.12.3.2 Patient-centred equipoise 
Despite claims that equipoise is irrelevant, Veitch (2002) appears to argue for patient-
centred equipoise as one of the moral conditions for RCTs. He claims that individual 
subjective indifference provides the moral justification for randomisation, and should 
replace other types of equipoise as the basis for justifying randomisation (Veitch 2002). 
 
On a similar note, Olson (2002) argues for ‘patient-centred equipoise’ and asserts that, 
since the decision to enrol is the patient’s and it is their interests that should be advanced, 
it is not relevant what the investigator thinks.  A trial would then be in equipoise for a 
patient when enrolling gives them the same chance of a good outcome as not enrolling. 
However, Olson does not appear to mean that the patient makes the judgement about 
whether enrolling/non-enrolling will give them the same chance of a good outcome, but 
rather that clinical trials inherently provide this opportunity. Olson (2002) argues that for 
most trials, this will be the case because:  
“1) patients in trials receive superior care,  
2) trial enrolment minimises the risk of being a victim of a therapeutic disaster and 
3) health professionals make mistakes, and a 50% chance of receiving the worse 
treatment until a trial reports is always better than any chance of receiving the worse 
treatment indefinitely” (Olson 2002). 
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It is difficult to accept these justifications and the blanket approach, since patients will not 
always receive superior care in a trial; and due to the nature of cancer, life expectancy is 
often poor, with trials often taking several years to complete enrolment, prior to reporting.  
Although Olson appears to support the idea of patient centred equipoise, her description 
of it is unconvincing. For patient-centred equipoise to be meaningful, it would seem more 
appropriate to support Veitch’s (2002) perception of individual subject indifference, and to 
consider patients own personal values and their perceptions of the influences on the 
consent decision, as the fundamental requirement. It is therefore the patient’s judgment 
that is important, based on their understanding, in terms of whether or not a trial is in 
equipoise for them.  
 
3.12.3.3 Therapeutic misconception 
A denial of both equipoise (patient assumes that the doctor knows what is best for them) 
and randomisation (patient assumes the doctor will choose a treatment for them) can 
result in the therapeutic misconception (Robinson et al. 2005):  the belief that “every 
aspect of the research project…was designed to benefit (one) directly” (Appelbaum et al. 
1987, p20).  Patients assume that they are allocated to a particular treatment based on 
their individual need. The therapeutic misconception has been highlighted as an issue 
affecting the ethics of randomised trials and informed consent by a number of authors (for 
example: Snowdon et al. 1997; Featherstone and Donovan 1998; Daugherty et al. 1999; 
Screenivasan 2003).  A way of addressing the therapeutic misconception is to improve 
patient understanding and acceptance of randomisation and clinical equipoise. 
 
3.13 Disclosure 
3.13.1  Overview  
Although information and disclosure are closely linked, disclosure here will focus on the 
information giving process, building on the previous section, which was concerned with 
the content and volume of information. The timing of the decision-making process, the 
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time allowed for it, and the presence of family and friends during the process, will be 
briefly discussed, prior to a consideration of the medium and professional/patient 
interaction. 
 
The timing of the process, along with the time afforded to patients to consider the 
information and hence their decision, are important in clinical trials. The timing of the 
process is difficult to address in cancer RCTs, since the trial treatment has to be initiated 
soon after the initial clinic consultation, since it is often part of a therapeutic treatment plan 
for the disease.  There is therefore limited scope for varying the timing, and the challenges 
of discussing trial participation with cancer patients are well documented (Tabak 1995; 
Daugherty 1999; Huizinga et al. 1999).    
 
Studies have shown that patients need varying amounts of time to make an autonomous 
decision about participation.  For example, Hietanen et al. (2000) found that only 68% of 
255 patients felt they had enough time to decide about a randomised trial of adjuvant 
therapy for breast cancer, and that less educated and older patients needed more time. 
Morrow et al. (1978), in a randomised trial, found benefits of increased understanding in 
radiation oncology patients taking their consent form home prior to signing, compared with 
patients who signed at the clinic. Presumably this is due to the additional time afforded to 
these patients for reading and digesting the contents of the consent form, and also 
perhaps as a result of family involvement and support.   
 
It is generally agreed that where possible, as well as acceptable and desired by patients, 
family and friends should be involved in the process, as they can be a substantial source 
of support.  Caution should be exercised, however, as they can influence the patients’ 
actual decision, as discussed in Chapter 2, Section 2.6.1.3. It is difficult to know whether 
the presence of family and friends influences the patient by persuasion, or even coercion, 
or whether it assists them in the decision-making process by helping them to understand 
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the research information, and to reduce anxiety by their presence.  It is likely that both can 
and do occur, depending on the context and relationships involved. 
 
3.13.2  Medium 
The medium in which the information is given is also important for patient understanding.  
A variety of methods for delivering patient information have been studied, in different 
situations. Trevena et al. (2006) carried out a systematic review on communicating with 
patients about evidence, and found that communication tools in most formats (written, 
verbal, video, provider delivered and computer based) will increase patients’ 
understanding, but are more likely to do so if structured, tailored and/or interactive. Chelf 
et al. (2001) reviewed ten years of evaluation of cancer patient education, and found that 
one of the most effective mediums, in terms of increasing knowledge and understanding, 
is audiovisual. Faden and Beauchamp (1986, p324) also support the use of audiovisual 
aids, and suggest that these methods may be particularly helpful in achieving substantial 
understanding, as discussed in Section 3.7.1.  As the intervention in this study, 
audiovisual patient information is the focus of the next chapter, and so will be discussed in 
no more detail here. 
 
3.13.3 Interaction 
The main factors in clinician-patient interaction which have been studied and shown to be 
important are physicians’ behaviour and communication skills (Albrecht et al. 1999; Grant 
et al. 2000). Albrecht et al. (1999) found that patients were more likely to take part in 
research when their physician discussed with them, face to face, the items normally 
included in the consent form, and when they behaved in a ‘reflective, patient-centred, 
supportive and responsive manner’. The importance of clinicians’ attitudes and interaction, 
in terms of decision making and recruitment, has already been discussed in Chapter 2.  
Here, the focus will be on the informed consent process, rather than on the decision itself. 
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There is a wealth of literature on interaction and communication in the general cancer 
setting, including a useful review of physicians’ communication behaviour by Arora (2003), 
and papers reporting effective interventions, such as training packages, to improve 
communication skills, attitudes and behaviours of oncology clinicians (Fallowfield et al. 
2002; Jenkins and Fallowfield 2002; Fallowfield et al. 2003).  There is much less literature 
specific to the cancer research setting, although it is a growing area of interest.  
 
Albrecht et al. (2005) examined the cancer research literature to determine the extent to 
which effective communication occurs during the informed consent process. Despite the 
increasing interest in the ‘interaction’ aspect of the consent process, and the widespread 
agreement that the personal interaction between health care providers and patients is an 
important part of the process, Albrecht et al. (2005) found that little is known about the 
actual ways in which treatment and clinical trial information is explained by oncologists 
and other health care providers to patients and their significant others. They highlight the 
benefits of using video as a research tool to capture the depth of the communication 
process. This would build on previous studies, which, although having provided useful 
data (Brown et al. 2004, as discussed below), are limited by being audio-taped. 
 
There have been a number of interventions designed to improve the doctor-patient 
interaction in the cancer clinical trial setting. These have predominantly been targeted at 
the doctor, usually involving communication skills guidance or training (Fallowfield et al. 
1998b; Fleissig et al. 2001; Brown et al. 2004; Jenkins et al. 2005; and Hietanen et al. 
2007). 
 
Brown et al. (2004) developed a set of ‘communication strategies’ to assist doctors in 
discussing RCTs with patients.  These communication strategies were underpinned by 
ethical, linguistic and psychological theory, and were informed by research involving 26 
consultations with 10 oncologists. The themes identified were:  
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• shared decision making (at the patient’s preferred level of involvement);  
• sequence of moves in the consultation (includes the order of information given and 
the structuring of patient and doctor input to promote patient understanding, 
ensure equal weight of standard and trial treatment, and avoid coercion);  
• type and clarity of the information provided (for example, avoiding jargon, using 
analogies and summaries);  
• disclosure of controversial and potentially coercive information (such as 
information that is often not revealed to patients, for example, financial incentives 
for doctors) (Brown et al. 2004).  
 
These themes were identified as being important in seeking consent to clinical trials, and 
were the four key areas in communication strategies developed to assist doctors in 
communicating with their patients. The authors have recently reported an evaluation of a 
training programme (one day workshop) which was based on these strategies (Brown et 
al. 2007).  The evaluation involved 10 oncologists from 3 Australian cities, and 90 
patients. Ninety informed consent consultations were audio-taped, before and after the 
training, and then transcribed.  Patients and doctors also completed satisfaction 
questionnaires. Some benefits of the intervention were identified; for example, doctors 
used less coercive behaviour and used more aspects of shared decision-making 
behaviour.  However, several areas were not improved, such as the structure of the 
consultation; doctors did not structure their consultations in the recommended fashion, as 
taught in the workshop.  Further work is now underway to evaluate an extended training 
programme, incorporating these communication strategies, in a larger randomised 
controlled trial (Brown et al. 2007). 
 
There is a lack of research on patient outcomes (such as understanding) as a result of 
improving the communication skills of clinicians and clinician/patient interaction. In a 
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Finnish prospective case-controlled intervention study, Hietanen et al. (2007) investigated 
the effect of a one-day communication skills training course (for physicians and research 
nurses), designed to improve the quality of the informed consent process, which they 
assessed by giving patients the Quality of Informed Consent Questionnaire (QuIC) 
(described in Chapter 7, Section 7.2.2.2.1). They found a significant increase in 
satisfaction and understanding among the patients in the intervention group, and 
recommended that similar types of training be included in the clinical trial planning 
process (Hietanen et al. 2007). 
 
Another intervention study designed to improve communication in the randomised cancer 
trial setting involved examining patient information preferences, and attitudes to trials, 
prior to seeing their doctors. The doctors were then either shown these questionnaires 
(intervention) or not (control) (Fleissig et al. 2001). Findings showed that patient and 
doctor satisfaction, and length of consultation (as well as trial accrual), were not 
associated with the intervention. However, limitations of the study, as noted by the 
authors, include: the doctors rarely referred to the questionnaires during the consultation; 
a formal evaluation of doctors’ views was not performed (although anecdotal evidence 
suggests that they did find the questionnaires useful); and the Preference for Information 
Questionnaire did not discriminate between patients in terms of their information 
preferences (Fleissig et al. 2001). This is an important issue, as the study was designed to 
allow the doctors to tailor the explanations given to each patient according to their 
information preferences. Although the questionnaire did not discriminate, it did show that 
patients with cancer want specific details about their illness and treatment (Fleissig et al. 
2001). Question prompt sheets have been used effectively to increase patient involvement 
in the cancer consultation process (Brown et al. 1999) and, as noted by Fleissig et al. 
(2001), this may be worth further investigation in the cancer trial setting, along with 
questionnaire interventions such as that described in Fleissig’s own study. 
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Communication skills needed by physicians caring for people with cancer are discussed 
by Back et al. (2005) in terms of the disease trajectory, with a section focussing on 
offering clinical trials to patients.  This article provides useful practical guidance, drawing 
from the general cancer literature. The authors also discuss some of the newer, 
(interactive) approaches to communication skills training (mainly targeted at doctors), 
which have been developed in cancer care, and which are reported to have improved 
communication skills of clinicians (for example, Fallowfield et al. 1998b; Back et al. 2003). 
Since this publication, there have been other interesting studies published on teaching 
communication skills in the cancer trial setting.  Of note is the work by Jenkins et al. 
(2005), who evaluated the Cancer Research UK training programme, which aimed to 
improve health care professionals’ communication with cancer patients in the context of 
randomised trials.  This is an intensive training programme using video and interactive 
exercises.  The evaluation involved 33 clinicians and 68 research nurses throughout the 
UK.  Communication (with actors) was videotaped before and after the intervention, and 
the actor and participant were both asked for their assessment of the communication, in 
addition to an objective evaluation of the videotape against pre-set key criteria for good 
communication, and compliance with ethical and informational standards. Results showed 
that the intervention improved participants’ confidence and competence when 
communicating about RCTs. 
 
Although there is useful guidance in the literature about clinician-patient interaction during 
the consent process, some of which has been discussed, it is clear that further work is 
necessary to understand more about the process and patient outcomes, and to design 
effective interventions to improve it. 
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3.14 Understanding 
3.14.1  Overview  
As discussed throughout this chapter, understanding is a key component of informed 
consent. Understanding is sometimes referred to as ‘comprehension’ in the literature 
(Faden and Beauchamp 1986, p301), and the terms have been used interchangeably.  
For clarity, in this thesis the term ‘understanding’ will usually be used rather than 
‘comprehension’, since this is consistent with the terminology of much of informed consent 
theory.  Where ‘comprehension’ is used in relation to specific studies, it can be considered 
to be synonymous with ‘understanding’. Recall, on the other hand is different to 
understanding. Recall is “the function of the access one has to the stored memory of an 
event and it can be influenced by the salience of information and the passage of time” 
(Reynolds and Nelson 2007).  Reynolds and Nelson (2007) point out that the 
understanding of some aspects of informed consent may be equivalent to recall, but that 
this is not the case with every aspect. 
 
Many authors advocate the need to improve patients’ understanding of clinical research 
(Hunter et al. 1987; Jenkins and Fallowfield 2000; Barrett 2002; Brown et al. 2004), and it 
is known that misconceptions about clinical trials (for example those surrounding 
randomisation, equipoise, placebo and an overestimation of the effect of standard 
treatment), exist among patients and the public (Hietanen et al. 2000; Joffe et al. 2001a; 
Featherstone and Donovan 2002; Comis et al. 2003; Stead et al. 2005).  This is 
particularly worrying in view of the fact that decisions about trial entry may be based on 
incomplete or incorrect information. Several authors have highlighted the difficulties of 
defining and measuring understanding (Barrett 2005; Sugarman et al. 2005; Cohn and 
Larson 2007).  This lack of clarity, and a generally disjointed approach, has led to slow 
progress in learning more about, and subsequently improving, patient understanding and 
the informed consent process. 
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Despite this, several reviews of informed consent have identified useful findings in terms 
of understanding. Sugarman et al. (1998) reviewed consent in older adults, and found that 
diminished understanding was associated with older age and fewer years of education. 
Schaeffer et al. (1996) looked at the impact of disease severity on the informed consent 
process, and found that the information that patients retained was related to disease 
severity; for example, severely ill phase I trial patients retained the least information about 
risks and side-effects compared with other groups, including healthy volunteers who 
retained the most. Interestingly, the consent form was also rated less useful by subjects 
with more advanced disease (Shaeffer et al. 1996).  Cox et al. (2006) also found in their 
review that understanding was poor for patients consenting to phase I trials. 
 
Various suggestions have been made to improve patient understanding, such as 
improving national guidance and pre-testing information sheets (Stead et al. 2005), using 
audiovisual patient information (Chelf et al. 2001), telephone based nursing interventions 
(Aaronson et al. 1996), corrected feedback (Wirshing et al. 1998; Dunn and Jeste 2001), 
simplified consent forms (Dunn and Jeste 2001), informed decision making checklists 
(Verheggen et al. 1996) and communication skills training for health care professionals 
(Hietanen et al. 2000). Although individual intervention studies have shown benefits in 
understanding (for example, Aaronson et al. 1996; Cull et al. 1998; Danino et al. 2005), 
Cohn and Larson (2007), in their review, reported that no single intervention strategy was 
consistently associated with improved understanding. They analysed studies published in 
the previous ten years, with the aim of identifying promising interventions.  Given the lack 
of clarity in the literature about ‘knowledge’ and ‘understanding’, and the fact that different 
authors have used the terms synonymously (see next Section – 3.14.2), a substantial 
limitation to Cohn and Larson’s (2007) study is that they did not include ‘knowledge’ as a 
key word.  This would have undoubtedly resulted in potentially relevant studies being 
missed. 
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3.14.2  Knowledge and understanding 
‘Understanding’ is a difficult concept to define, and this has led to a lack of clarity in the 
use of the term and in its relation to ‘knowledge’. Considering the context is helpful in 
clarifying the concept.  Based on Faden and Beauchamp’s (1986) theory of informed 
consent, understanding that you are being asked to decide about taking part in a trial, and 
understanding what is communicated about the trial, are the key parts of understanding 
that are important. The literature is unclear about what the differences are (if any) 
between ‘knowledge’ and ‘understanding’, and the terms are frequently used to mean the 
same thing, with no clear distinction. 
 
The dictionary (Oxford English Reference Dictionary 2002) definitions are as follows: 
‘Knowledge’ – a theoretical or practical understanding of a subject. 
‘Understanding’ – the ability to perceive the meaning of (words, person, a language etc). 
It is interesting that ‘understanding’ forms part of the ‘knowledge’ definition; and, if 
knowledge can be thought of as a ‘theoretical or practical understanding of randomised 
clinical trials’, then the terms can be regarded as synonymous.  It is acknowledged that it 
may be possible to distinguish between the terms, and that the distinction may prove to be 
useful and significant.  However, because of the lack of clarity in the literature, this study 
has not attempted to distinguish between the concepts.  Here, ‘understanding’ is based on 
Faden and Beachamp’s (1986) description of understanding that and understanding what, 
and is the main term used in the study.  Throughout the thesis, the terms are used 
interchangeably; and in the results chapter, as a matter of terminological convenience, the 
questionnaire used to assess ‘Patient Understanding of Research’ is referred to as the 
‘Knowledge Questionnaire’. 
 
There have been a variety of approaches to assessing knowledge/understanding, both 
subjectively and objectively.  These are discussed in detail in Chapter 7, which justifies 
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the rationale for developing a new tool to assess understanding in the randomised cancer 
trial setting. 
 
3.14.3  Knowledge and anxiety 
Patient anxiety levels are often high due to a number of factors, including having a recent 
cancer diagnosis and cancer treatment (Kelly et al. 2002).  In most cases, anxiety is part 
of a normal reaction to cancer. There is evidence that situational stress can evoke anxiety 
states, and strong support for the distinction between state (how one feels at the moment) 
and trait (how one generally feels). The concepts of state and trait anxiety were first 
identified through research involving factor analysis in 1961 (as reported in Gaudry et al. 
1975), and since then there have been several studies to define the concepts and develop 
procedures for their measurement, such as the Spielberger State-Trait Anxiety Inventory.  
 
Although an appropriate treatment for anxiety is to provide adequate information and 
support (Kelly et al. 2002), the evidence on whether anxiety levels are increased by 
knowledge/understanding in the clinical trial situation is inconclusive.  Some studies have 
found that patients with better knowledge or understanding were more anxious (Simes et 
al. 1986), but the majority of studies have found patient anxiety to be unchanged or 
reduced (Edwards et al. 1998; Ellis et al. 2001; Hewison et al. 2001).  In the Edwards et 
al. (1998) review of informed consent for clinical trials, high levels of knowledge were 
significantly associated with less anxiety. There are several well established tools 
available to assess patient anxiety, and the justification for the approach used in this study 
forms part of the methodology discussion in Chapter 5.  
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3.15 Decision making 
3.15.1  Decision making in the context of informed consent  
In addition to the information given by the clinician, and patient understanding of that 
information, decision making in the context of informed consent to clinical trials requires 
voluntariness and competence to consent, both of which will be discussed in this section.  
 
The underlying assumption of researchers evaluating informed consent to clinical trials 
seems to be that research subjects adhere to basic principles of rational choice (Reynolds 
and Nelson 2007). Rationality is defined as “decision making consistent with the principles 
of probabilities”, where a rational choice is “one in which the option with the highest 
expected utility is selected” (Holmes-Rovner and Wills 2002). In the clinical trial context, 
patients would understand the required information about a trial, weigh up its importance, 
and make the decision about participation based on the best expected value of outcomes 
(Lidz 2006).  However, heuristics and biases have been found to influence decision 
making based on probabilities, with the result that patients’ decisions may not be based 
on their personal values (Holmes-Rovner and Wills 2002).  In addition, one of the key 
criticisms of rational choice models is the influence of a variety of socio-cultural and 
affective factors on decision making - for example, information gained from sources other 
than health care professionals, cultural norms and emotion (Holmes-Rovner and Wills 
2002).  Since the focus for the theoretical underpinning of the work was informed consent 
theory, a detailed discussion of the theories of decision making is outwith the scope of this 
thesis.  Nevertheless, it is important to acknowledge this field of work, which will be 
referred to in the discussion, as a potential area for future research.  
 
Decision making is especially challenging in randomised cancer trials since patients are 
asked to consider participating in a clinical trial at a time when they have just received a 
diagnosis of cancer, or have just learned that they need further treatment because their 
disease has spread or recurred.  Information retention and decision-making capacity may 
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be compromised when patients are already anxious, frightened or upset, and may also be 
experiencing physical symptoms as a result of their illness. Patients are often required to 
make the decision about participation within a relatively short period of time (usually one 
week), because of the urgent need to start anticancer treatment.   
 
Studies have shown that often patients make the decision about whether or not to take 
part in a clinical trial immediately after receiving information about it. (Huizinga et al. 1999, 
in phase III cancer trials; Länsimies-Antikainen et al. 2007, in a trial for patient with a 
metabolic syndrome). These were both small qualitative studies where almost all the 
patients reported having made their decision instantaneously.  The quality of the decision 
in this situation is questionable. Decision aids have been suggested as a way of 
supporting patients more effectively, and of encouraging them to take their time and ask 
questions.  
 
3.15.1.1 Decision aids 
Decision aids have been identified as interventions to help individuals focus on a 
deliberate choice between two or more treatment options (O’Connor et al. 1999; Bekker et 
al. 2003). They typically contain evidence-based information, presented in a simple 
graphical manner, with the aim of helping patients to clarify their values and to weigh up 
the pros and cons of the options before making the decision (O’Connor et al. 1999; 
Juraskova et al. 2007). It is not clear why they work, but it has been suggested that their 
effectiveness can be explained in terms of either the facilitation of cognitive strategies or 
changes to emotional processes (Bekker et al. 2003). 
 
Benefits associated with the use of decision aids for health treatment or screening 
decisions are: less decisional conflict, higher knowledge/understanding scores, more 
active involvement of patients in decision making and, in some cases, greater satisfaction 
with the decision-making process, as well as more satisfaction with the decision itself 
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(review by O’Conner et al. 1999; review by O’Conner et al. 2003; Whelan et al. 2003; 
Tiller et al. 2006; Krist et al. 2007; review by Waljee et al. 2007).  Blank et al. (2006) 
reviewed studies of cancer patients’ treatment-related decisions, and found considerable 
evidence that decision aids can improve the quality of decisions across a range of 
illnesses, although they do acknowledge that the data for cancer treatment decision 
making is limited. They also acknowledge that a key area for further research is the 
participation decision for randomised clinical trials. Decision aids have rarely been 
evaluated in the context of clinical trials (Juraskova et al. 2007). Juraskova et al. (2007) 
have just completed a pilot study of a decision aid (booklet plus personalised worksheets) 
to help patients decide whether to take part in a large breast cancer trial or to choose the 
standard care option. Benefits of the intervention include high levels of understanding 
(both subjectively and objectively measured), and strongly positive attitudes to the trial.  
Patients liked the booklet, particularly the visual presentation of information. The decision 
aid is now being evaluated with patients from Australian and New Zealand centres taking 
part in a large international breast cancer trial (Juraskova et al. 2007). 
 
3.15.1.2 Shared decision making 
There has been increasing interest in the concept of shared decision making in the cancer 
setting, which has resulted in interventions being designed to increase patient involvement 
in the decision making process.  An example of this is the study by Brown et al. (2006), 
who tested a package of a patient information booklet and video about treatment decision 
making (intervention), against a generic cancer patient information booklet (control). The 
package was designed to facilitate shared decision making, and was administered before 
seeing the oncologist.  The first consultation was audio-taped and transcribed, and 
patients also completed questionnaires.  Results showed that patients receiving the 
package were more likely than controls to declare their information and treatment 
preferences in the consultation, as well as their thoughts on costs, side-effects and 
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benefits of treatment. Considerably more themes were introduced by doctors to patients 
receiving the package, compared with the controls.   
 
It has been suggested that informed consent and shared decision making are 
synonymous (Katz 1982 and 1984, in Beauchamp and Childress 2001, pp77-78). 
However, shared decision making is not common in informed consent.  According to 
Holmes-Rovner and Wills (2002), this is because of the tension between allowing an 
investigator to take part in the patient’s decision making and the danger of coercion. As 
asserted by Beauchamp and Childress (2001, p78), shared decision making neither 
defines nor displaces informed consent. According to MacLean (2006, p677), a 
deliberative model of shared decision making should be the goal of physician-patient 
relationships (which they view as a consent-giving relationship), because they consider 
this to be the only model that is suitable for constructing preferences and values.  It is 
unclear if shared decision making improves patient understanding, and the role of shared 
decision making in informed consent is an area in need of further research, which would 
benefit from drawing on the preference construction literature (Lichtenstein and Slovic 
2006). 
 
3.15.2  Voluntariness  
Although Faden and Beauchamp (1986) prefer to avoid the term ‘voluntariness’ and 
instead refer to ‘noncontrol’, (Section 3.1.3.4), ‘voluntariness’ is widely used in the 
literature, and is referred to by Beauchamp and Childress (2001, p80), along with 
‘competence’, as a precondition for informed consent. There is little research that 
specifically examines the voluntariness of decisions to take part in research, and there is a 
lack of a coherent model, or tools for measuring it (Nelson and Merz 2002). Nelson and 
Merz (2002) reviewed the literature and assert that voluntariness is viewed as a matter of 
self-control.  Threats to voluntariness can arise from the vulnerability of potential subjects 
(e.g. diminished capacity, socioeconomic status: prisoners, students, the poor, and other 
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role constraints such as family influence and poor prognosis), and the characteristics of 
the researcher and research setting (e.g. the authority of the physician and researcher 
behaviours such as persuasion, manipulation and coercion) (Nelson and Merz 2002).  
Potential research subjects need to have an understanding of the research, and what it 
means to them, in order to have the competence to consent (or refuse) and therefore 
make a voluntary decision about whether to enrol in a clinical trial. 
 
3.15.3  Consent capacity/competence to consent   
In the literature, ‘consent capacity’ is also referred to as ‘competence to consent’ or 
‘decision making capacity to consent’. Competence has already been highlighted earlier in 
this chapter as a key factor in informed consent theory (Section 3.7.3). Much of the work 
assessing consent capacity/competence to consent has been carried out with patients 
who were expected to have impaired capacity, often as a result of their illness or 
condition; for example, patients with mental illness (Kim et al. 2001 with Alzheimer’s 
patients; Palmer et al. 2007 with bipolar patients and schizophrenia patients).  Wendler 
(2004) describes consent capacity as having a set of abilities to be able to give valid 
informed consent. “This set of abilities includes the capability: 
1) to understand the research in question 
2) to appreciate how the research applies to one’s own situation, and 
3) to make a voluntary decision whether to enrol in the study in light of this understanding” 
(Wendler 2004). 
The central role of understanding in this description of capacity is clear. 
 
Studies of instruments designed to assess decisional capacity for clinical research or 
treatment (1980-2004) were reviewed by Dunn et al. (2006). They identified six 
instruments focussing on understanding of disclosed information, and eleven that 
assessed understanding, appreciation, reasoning and expression of a choice.  They found 
substantial variation in reliability and validity of the instruments, the degree of 
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standardisation of disclosures, flexibility of item content, format, and scoring procedures.  
Limitations of the instruments included a lack of supporting psychometric data and a lack 
of generalisability across contexts (Dunn et al. 2006).  Dunn et al. (2006) report that the 
MacArthur Competence Assessment Tools (MacCAT) for Clinical Research and 
Treatment had the most empirical support, but that other tools may be equally suited or 
better suited depending on the context. Robinson et al. (2005) identified a potentially 
important aspect that is ignored in Appelbaum and Grisso’s (2001) MacCAT procedure – 
patient understanding about why the trial is being conducted in a particular way (for 
example randomisation).   If these gaps in understanding are not noticed, the patient may 
make his own interpretations, which may lead to important misconceptions (Robinson et 
al. 2005).  
 
Assessing capacity to consent would appear to be important; however, it has been 
suggested that it may be of more value to assess the actual consent, since people who 
have the capacity to consent do not always give valid consent (Wendler 2004). Wendler 
advocates that all potential research subjects should have a formal evaluation of their 
informed consent.  He argues that the best way to determine whether a patient has the 
capacity to understand, and to give voluntary consent, is to determine, after adequate 
explanation, whether they do actually understand and give voluntary consent (Wendler 
2004). This would seem appropriate, and was one of the reasons that assessment of 
understanding was chosen for the AVPI study, and the reason why competence/capacity 
to consent was not assessed. 
 
3.16 Measures of informed consent 
3.16.1 Overview 
There are several challenges in measuring informed consent.  As previously discussed, 
there is no widely agreed definition of informed consent, although there is some 
agreement about what the elements of informed consent are.  For these elements, there 
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is a lack of definition about what is meant by the relevant terms, such as ‘understanding’, 
‘competence’ and ‘voluntariness’.  A variety of different measures have consequently 
been developed. Some have focussed on the individual elements, whereas others have 
tried to measure the whole process.  
 
3.16.2 Measures of informed consent 
Discussion of the measures and associated studies can be found in Chapter 7, where the 
justification is provided for developing a new instrument to measure understanding. 
Measurements of competence have already been discussed in Section 3.15.3 of this 
chapter.  Another approach to measuring informed consent has been to focus on patient 
satisfaction with the process, often by questionnaires designed for specific studies 
(Montgomery and Sneyd 1998 in clinical trials for anaesthesia; Sorenson et al. 2004 in 
randomised controlled trials for cancer; Feldman Stewart et al. 2007 in prostate cancer). 
Most of the satisfaction studies report high levels of patients’ satisfaction with the informed 
consent process and, although an interesting aspect of consent is to determine how 
patients feel about the process, it was considered important to focus on a more objective 
measure. Patients satisfied with the process may still not be adequately informed, or 
understand the implications of their decision. In this study, the decision was taken to focus 
on ‘understanding’, since it is a key ethical requirement for informed consent, appears to 
have an effect on recruitment to clinical trials, and was considered to be amenable to 
improvement by the intervention. 
 
3.17 Summary of Part II - Informed Consent 
Informed consent can be viewed as comprising four main dimensions, where patient 
understanding is integral to all: 
• What the patient needs to know [or understand] (information) 
• How that information is conveyed [to maximise understanding] (disclosure) 
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• The extent to which the patient understands the information conveyed 
(understanding) 
• The extent to which the patient’s consent meets the criteria for decision making in 
this context – competence and voluntariness [understanding is essential for 
competence and voluntariness] (decision making). 
 
Major conclusions from the literature  
 
 Conclusion 1 
Informed consent can be viewed as autonomous choice and, as a consequence, requires 
patient understanding as the key component, along with voluntariness and competence. 
Patient understanding is viewed as understanding that you are being asked to take part in 
a clinical trial, and understanding what is communicated about the trial.  
 
Study implications 
• Patient understanding is a major endpoint in the study.  
• This includes a focus on voluntariness and competence in the content of the 
video/DVD/CD-ROM. These are assessed via a self-report questionnaire which 
includes subjective and objective assessment of understanding. Questions include 
voluntariness of the participation decision (understanding that), understanding of 
freedom to withdraw from the study, and understanding about what happens if they 
refuse to participate in the clinical trial. 
• Understanding what includes content as discussed in Conclusion 2, with a focus on 
aspects identified in the literature as particularly problematic to patients, such as 
understanding and acceptance of randomisation and clinical equipoise. 
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 Conclusion 2 
‘Substantial understanding’ is essential for autonomous actions, and requires that patients 
receive (and understand) core disclosure of key facts, as well as important information 
from their own perspectives. 
 
Study implications 
• The standard written information already addresses core information about the trial, 
according to regulatory requirements, and includes what a body of expert clinicians 
has deemed important, prior to initiation of the trial. 
• The video/DVD/CD-ROM highlights the key generic clinical trial core facts. 
• Patients were involved in the development of the content of the video/DVD/CD-ROM 
and advised on issues that were important to them. 
• At an individual level, the patient is advised in the video/DVD/CD-ROM to have a 
verbal discussion with their doctor about the important issues for them. 
 
 Conclusion 3 
The context is important for patient understanding and informed consent, in particular the 
clinician/patient interaction, as well as personal factors according to the patient (e.g. 
implications of the trial as it affects them). 
 
Study implications 
• AVPI as an intervention allows and encourages further discussion with the health care 
team about issues important to patients in their decision. 
• AVPI facilitates and encourages active involvement of family and friends in the 
information discussion (at home and in clinic). 
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• Decision questionnaire assesses important reasons for patients in their decision, from 
a social and practical perspective, as well as specific to the health care setting. 
• Patients’ perceptions of aspects of the patient/clinician interaction are assessed in the 
decision questionnaire. 
 
 Conclusion 4 
Other important ethical principles are beneficence and, to a lesser extent, justice. 
 
Study implications 
• Risks and benefits for each clinical trial are disclosed in the study-specific information 
sheet, which patients routinely receive prior to decision making, and this was retained 
in the study.  There is a clear link via the video/DVD/CD-ROM referring patients to the 
information sheet for this discussion. 
• The audiovisual approach in this study, by its very nature, may be useful for difficult-to-
reach patient groups who are often excluded from clinical trials, such as low-literacy 
individuals and patients with communication impairment. 
 
 Conclusion 5 
There are substantial challenges in relation to defining informed consent and its various 
elements, which has led to difficulties in measuring and evaluating it in practice. Despite 
this, it is clear that patient understanding is crucial and has been integral to most 
approaches to measuring informed consent. There are a variety of different approaches to 
measuring patient understanding but none specifically address the issues in the UK 
randomised cancer trial setting. 
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Study implications 
• Patient understanding is used as the measure of evaluation of informed consent in this 
study. 
• A new questionnaire was developed specifically for patients in randomised cancer 
trials.  
 
 Conclusion 6 
There is a lack of clarity in the literature about what constitutes patient knowledge and 
what constitutes patient understanding.  No evident distinction is made, and the terms are 
used interchangeably.  What appears to be important is not the terminology, but whether 
or not the message is ‘received’ by the patient 
 
Study implications 
After much consideration, no attempt at distinction has been made in this study, so as to 
avoid adding to the confusion.  Both terms are used – ‘understanding’ mainly in relation to 
the theoretical discussions, and ‘knowledge’ in the results chapter, for ease of reporting on 
the knowledge questionnaire. 
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Other conclusions from the literature and their implications for the study 
Conclusion from Literature Implication for AVPI Study 
 
Information 
Most consent forms are too difficult in terms of readability. AVPI can assist with this as a good supplement to written information, 
to emphasise key points. 
Patient understanding is better with shorter, easy to read consent 
forms. 
The AVPI study consent forms were kept short and focussed on key 
facts. The patient information sheet for the AVPI study underwent 
assessment for readability. 
Tailoring patient information can improve understanding. Information was tailored in the video/DVD/CD-ROM, as discussed in 
Chapters 4 and 6. 
Baseline public knowledge of clinical trials is important. 
 
Past experience of clinical trials was assessed within the context of 
patients’ baseline knowledge. 
 
Disclosure 
Patients need time to consider their decision about trial participation. 
 
Wherever possible, patients were given at least a week between clinic 
appointments to consider their decision. 
Some patients find benefit from family/friend involvement in their 
decision. 
 
Close family members are included in consent discussions routinely in 
the centre, if acceptable to the patient. 
If randomised to the intervention group, patients were given the 
video/DVD/CD-ROM home between clinic appointments to view and 
discuss with family if desired.  
The decision questionnaire assessed to what extent patients did 
discuss their decision with their family/friends. 
Selection of an appropriate medium for information transfer, is 
important for patient understanding and consent, with the audiovisual 
route particularly effective. 
Audiovisual route selected as the intervention for this study. 
 
Interaction between patients and clinicians is important in terms of the 
communication process in informed consent, although not clear how 
this relates to patient understanding. 
Patients asked in questionnaire about some of the factors associated 
with the interaction process (e.g. trust in the clinician) but interaction is 
not investigated in any detail, as this would be a study in its own right. 
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Conclusion from Literature Implication for AVPI Study 
 
Understanding 
Diminished understanding was associated in the literature with older 
age, less education and disease severity. 
These factors were determined for each patient in the AVPI study at 
baseline, and compared with levels of understanding 
There are a variety of different approaches to measuring 
understanding but none specifically address the issues in the 
randomised cancer trial setting, relevant to the UK setting. 
A new tool developed for this purpose in the AVPI study. 
It is important when increasing knowledge/understanding, not to 
increase anxiety. 
Anxiety was assessed in this study. The tool used was the Spielberger 
State-Trait Anxiety Inventory which is consistent with previous 
research and has good reliability and validity in the clinical trial setting 
 
Decision Making 
Decision making about trial participation is particularly difficult for 
patients in the cancer trial situation 
Questionnaires were kept short and no additional patient visits were 
introduced as part of the AVPI study, compared with routine care. 
There was continuity in terms of the same researcher seeing the 
patient at both visits. 
Studies about patients’ decisions should be in a real patient setting, 
faced with the actual decision and not in a hypothetical context, as 
results may be different.   
The present study was undertaken in a real life cancer clinical trial 
setting. 
Decision aids appear to be effective in other specialties in improving 
understanding and assisting patients with decision making, but have 
not been tested extensively in the cancer trial situation. 
AVPI can be considered as a decision aid and patients were asked 
about its effect on their decision about clinical trial participation. 
 
Voluntariness and competence are important for decision making These are discussed in the video/DVD/CD-ROM and evaluated via 
patient questionnaire. 
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Informed consent will always be a challenge, and will never be perfect in the cancer 
clinical trial situation, owing to factors that are difficult to change, such as the vulnerability 
of patients and complex treatments.  However, there is a wealth of literature and some 
well established theory to guide clinical practice and optimise the information-giving and 
consent process. Increasing patient understanding will improve informed consent, and 
perhaps increase clinical trial recruitment rates.  Audiovisual patient information has been 
shown to be an effective means of improving patient understanding, and will now be 
discussed in Chapter 4. 
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CHAPTER FOUR: LITERATURE REVIEW PART III - AUDIOVISUAL PATIENT 
INFORMATION 
 
 
4.1    Introduction to audiovisual patient information 
Audiovisual patient information (AVPI) was identified in the previous chapter as worthy of 
further investigation in the clinical trial setting, in terms of improving informed consent and 
also clinical trial recruitment rates. This chapter will provide more detailed information 
about AVPI and explain why this method was chosen as the study intervention.    
 
AVPI has been studied extensively in health care mainly as a tool for patient education, 
sometimes in relation to improving compliance, but also with the aim of assisting patients 
with decision making.  Several outcome measures to determine its effectiveness have 
been used, with the majority focussing on knowledge or understanding of a health care 
procedure. Other areas studied include the effect of AVPI on patient satisfaction, quality of 
life, management of symptoms and side-effects, anxiety levels, compliance, behaviour, 
and the effect on the decision itself.  Most of the methodologies employed have been 
structured questionnaires, some of them established tools (for example, to measure 
anxiety or quality of life), but many being developed for the purposes of the individual 
study, most commonly in relation to knowledge or understanding.   
 
The literature will be discussed in relation to the types of AVPI, use of AVPI in health care, 
content and presentation of the information, and AVPI as a tool to improve the consent 
process and consent rates within the clinical trial setting.  Limitations of previous research 
in this area will be discussed prior to summarising the relevant literature. Table 4.1 
provides an outline summary of the chapter. 
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Table 4.1. Outline summary of Chapter 4 
 
Literature search 
 
Format Types of AVPI 
Comparison of approaches 
 
Overview 
Health promotion 
Screening 
Surgery and rehabilitation 
AVPI use in health care 
Cancer care 
 
Tailoring information 
Framing information 
Content of AVPI 
Tailoring and framing AVPI 
 
Clinical trials in health care generally Clinical trials 
Cancer clinical trials 
 
Introduction 
Generally 
AVPI and recruitment to clinical trials 
Evaluation of studies 
Cancer setting 
 
Limitations of previous work 
 
Summary of AVPI literature 
 
Summary of literature review: Parts I-III (Chapters 2-4) 
 
Aims of the study 
 
Hypothesis Hypotheses 
Null hypothesis 
 
 
4.2 Literature search 
For the purpose of searching the literature for areas of relevance in terms of audiovisual 
patient information, the following five concepts were used and expanded upon as shown 
in the full details of the search strategy (Appendix 4.1). 
1. cancer 
2. audiovisual (AV) material 
3. clinical trials 
4. recruitment/participation 
5. patient information/education/knowledge/understanding 
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Electronic databases searched were:  Ovid MEDLINE(R) (mesz), Ovid MEDLINE(R) In-
Process and Other Non-Indexed Citations (prem), CDSR (coch), ACP Journal Club (acp), 
DARE, CCTR, British Nursing Index (brni), British Nursing Index Archive (bnib), CINAHL 
(nursing), EMBASE (emez), PsycINFO (psyf). The search strategy was devised with the 
input of an experienced medical librarian. Additional references were located by searching 
the bibliographies of related papers, examining conference proceedings, and using the 
Google search engine. 
 
Terms were combined to focus on key areas of interest, which resulted in four main areas 
as shown in Table 4.2.  The line number corresponds with the full details of the search 
strategy in Appendix 4.1. 
 
 Table 4.2. Summary of literature search: audiovisual patient information  
Combination of Terms Number of Hits 
Line 16  = AV material + clinical trials + patient information    1415 
Line 17  = cancer + AV material + clinical trials + patient 
   Information 
 
301 
Line 18  = AV material + clinical trials + recruitment 439 
Line 19  = cancer + AV material + clinical trials + recruitment  114 
Line 20  = line 16 or 17 or 18 or 19 1617 
Line 24  
 
= limit to English language, last 20 years, duplicates  
   removed 
 
1049 
Line 25  = final total following assessment 325 
 
Although duplicates had been removed across databases, it was anticipated that there 
would be a substantial number of duplicates across these four lines (Lines 16-19 in Table 
4.2).  For ease of further searching, results from the four combined terms were then 
merged together to eliminate duplicates across the sets (Line 20 in Table 4.2).  Due to the 
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large number of potentially relevant articles identified, this was limited to English language 
and the last 20 years.  This resulted in a total number of 1049 hits.  These titles and 
abstracts were then searched manually for relevance which resulted in an overall total of 
325 potentially useful articles for consideration.  Abstracts that were removed as part of 
this process were concerned with video-assisted procedures (e.g. endoscopy, surgery), 
using audiovisual aids to educate health professionals (e.g. communication skills training 
for junior doctors), paediatrics and neonates, and letters/comments/abstracts from 
conferences. Full articles were requested for the majority of the final 325 abstracts, and 
are drawn upon in the following discussion.   
 
4.3    Types of AVPI 
4.3.1 Format 
Audiovisual patient information is a term used to include a variety of formats for the 
delivery of patient information.  The most popular and the most widely studied is video, 
although studies have also involved CD-ROM, and more recently DVD, interactive 
computer programmes and multimedia packages. Other novel approaches include using 
power point slide shows (Mittal et al. 2007, clinical trial information for Alzheimer’s 
disease) or visual illustrations (Brotherstone et al. 2006, in relation to flexible 
sigmoidoscopy). With some formats and newer technologies, there is the opportunity for 
the approach to be interactive and tailored to individual patients (e.g. De Bourdeaudhuij et 
al. 2007, a nutrition programme for company employees).  Interactive computer systems 
and web based packages have been shown to improve patient information, but have 
significant practical challenges including cost and restricted access even with broadband 
internet, as shown by Cumbo et al. (2002).  In addition, some formats such as videodisk 
require specialised equipment, which is often set up in a kiosk, with the user having to go 
to the location of the kiosk (Agre et al. 2002).   
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4.3.2 Comparison of approaches 
There has been limited work comparing different types of audiovisual approaches to 
patient information in relation to knowledge and understanding, behaviour and its effect on 
decision making. What is available is inconclusive, as is now discussed.  
 
Frosch et al. (2003) compared video information with an internet website for Prostate 
Specific Antigen (PSA) testing.  This was a randomised study where 226 patients received 
either the video information or were allocated the internet information.  Patients in the 
video group were more likely to review the materials and had a significantly greater 
increase in knowledge about PSA, but were also more likely to decline the PSA test.  
Patients in the internet group who reviewed the entire presentation showed similar 
increases in PSA knowledge to the video group (Frosch et al. 2003). 
 
Ader et al. (1992) compared three different approaches: interactive videodisc, videotape 
and the surgeon only, in relation to dental extraction and found that patients’ receiving the 
videotape had more knowledge about the procedure.  Patients viewing the videodisc were 
more satisfied with the amount of preparation.  However, it must be noted that this was a 
small scale study (n=60). 
 
Emmett et al. (2005) compared a decision analysis tool with the combination of written 
and video patient information in patients with newly diagnosed hypertension.  They found 
no difference between the groups in relation to blood pressure control, behaviour and 
compliance with medication.  On the other hand, Agre et al. (2003) compared four 
methods of presentation - standard consent, video, computer program and booklet - in 
relation to knowledge of consent information in 441 participants (comprised of three 
groups: patients deciding whether to take part in a clinical trial; their family/friends; 
individuals from the waiting area in a surgical day hospital).  Computer and video groups 
had a better understanding compared with the booklet and standard consent procedures.  
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Video was superior to the computer format for complex protocols and for minority 
participants (Agre et al. 2003). 
 
Moseley et al. (2006) assigned 90 medical students to one of three groups considering 
informed consent to cataract surgery.  All groups received a presentation about the 
surgery, with one of the groups also receiving diagrams and the other receiving a video.  
The video group had a better knowledge of facts and risks associated with cataract 
surgery.  The aim of the study was to assess understanding, and it is interesting that this 
is done via a multiple choice knowledge test and that the terms knowledge and 
understanding are used interchangeably.  This is not uncommon in the literature and has 
already been discussed in Chapter 3.  A limitation of this study is that it does not involve 
patients and is carried out in a hypothetical context.  Gomez et al. (1999) also interchange 
the terms knowledge and understanding in a study of AVPI for end stage renal disease 
and its effect on treatment selection. They say that they assess knowledge via a 
questionnaire but conclude that there was a significant improvement in knowledge and 
understanding.   This was a non randomised study which only compared patients to their 
baseline scores, so it is not possible to tell if the intervention had any effect on treatment 
selection.   
 
Audiovisual methods are considered to be more expensive than other methods of patient 
information such as written.  French et al. (1999) challenge the idea that video in 
particular, is too time-consuming and expensive to produce. They used computer-based 
video production to develop and evaluate high quality, low cost patient education videos 
using digital imagery which improved patient comprehension of radiotherapy.  Compared 
with interactive computer packages, video and CD-ROM are cheaper and more flexible in 
relation to viewing.   
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In oncology, video and CD-ROM have both been shown to be acceptable and useful 
media for information transfer (Thomas et al. 2000; Agre et al. 2002).  In 1999 in a UK 
oncology study, 89% of patients had access to a video player at home (Thomas et al. 
1999).  With the developments in technology in this area since this study was undertaken, 
and the advent of DVD, the figure having access to audiovisual playing facilities can be 
anticipated to be substantially higher now.  Patients’ particularly appreciate being able to 
view the information in their own homes (Reid and DePalma 2001; Agre et al. 2002; 
McGregor 2003). In addition to patients valuing being able to view information at home, 
Deshler et al. (2006) reported benefits of home viewing in relation to increased 
satisfaction with the information and an increase in understanding and awareness of 
services. They evaluated a patient information programme in a cancer centre in the USA 
by comparing a video and information booklet mailed home with a video and booklet seen 
in class or via hospital drop in sessions.  
 
In summary, although there is a lack of research comparing the different types of AVPI, 
there is substantially more evidence in the literature about the usefulness of video as 
compared with other formats.  Both video and CD-ROM, in addition to DVD, are 
acceptable and now widely accessible to patients, as well as being relatively low cost 
compared with other multimedia computer approaches including interactive packages. 
 
4.4 AVPI use in health care 
4.4.1  Overview 
The majority of the literature evaluating AVPI, evaluates it in combination with standard 
practice, and compared with standard practice, which is often written information and a 
medical consultation.  Studies that have used AVPI as an alternative to written information 
and/or interaction (counselling or one-to-one consultation) have usually found that the 
communication aspect should not be replaced, and advocate administering AVPI in 
addition to standard practices (Thomas et al. 2000; Proctor et al. 2006).  An exception to 
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this was in radiology where video was evaluated as an alternative to written information to 
inform patients about the use of intravenous contrast material (Hopper et al. 1994).  
Knowledge was increased for women receiving the video, but no difference was found in 
men.  This led to the authors recommending that video be used as an alternative to the 
written consent form in this setting.   Another exception was in illiterate populations where 
audiovisual consent was obtained for a genetic study with Guarani Indians living in 
Paraguay (Benitez et al. 2002) This is now standard practice for clinical research carried 
out within illiterate populations in the coordinating study centre in France (Benitez et al. 
2002).  A key benefit of audiovisual patient information is in relation to low literacy groups, 
for whom important information can be simplified using graphical presentations, which can 
be sensitive to cultural needs.  Studies have shown clear benefits of video in terms of 
understanding and compliance among low literacy and minority groups (Thomas et al. 
1999, in a large study of patients for pneumococcal vaccination; Tu et al. 2006 in 
screening for faecal occult blood with Chinese Americans). 
 
Often, studies have involved multimedia education packages, which include AVPI with 
one-to-one counselling, enhanced written patient information, group education sessions 
and other visual tools; for example, Yeh et al. (2005) with printed nursing guides in 
addition to a CD explaining hip replacement.  Patient education packages have also 
effectively combined practical teaching with AVPI; for example, videotapes, hearing aid 
fitting and home education as a package for older adults with hearing impairment and their 
significant others (Kramer et al. 2005).  When these interventions are shown to be 
effective, as was the case in the two examples given, it is difficult to know how much the 
AVPI contributed to the effect, since the design did not isolate the AVPI as a distinct 
entity.   
 
Audiovisual patient information, particularly video, has been shown to be effective in a 
variety of areas in health care, most notably in health promotion, screening, surgery and 
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rehabilitation, as well as cancer care, which will be further discussed in Sections 4.4.2 - 
4.4.5.  Effects on behaviour, as well as on knowledge and understanding, were noted in a 
large number of the studies.  Less frequently, the effect of AVPI on quality of life and 
patient symptoms has been investigated, with benefits shown in reducing pain associated 
with whiplash injuries (Brison et al. 2005; Oliveira et al. 2006), emotional recovery 
following coronary artery bypass grafting (Sorlie et al. 2007), and an improvement in 
quality of life and resumption of pre-operative activities in patients undergoing surgical 
repair of an inguinal hernia (Zieran et al. 2007).  However improvement is not always 
maintained in the longer term (Zieran et al. 2007).   
 
Video appears to have a role in service redesign. It has been used to reduce consultation 
times in a family health clinic in Edinburgh, which was struggling to cope with the 
increasing demand for breast cancer risk counselling (Cull et al. 1998). They found that by 
using video, subjective and objectively assessed patient understanding improved, without 
an increase in patient distress.  When the video was given before the consultation, 
consultation times were reduced.  As a result of this study the authors recommend that 
video be used as an aid to, but not a substitute for, improved communication about 
inherited susceptibility to breast cancer (Cull et al. 1998).  Agre et al (1994) also advocate 
the use of video information as a time saving tool for doctors. They studied video use in 
patients prior to colonoscopy, and reported that one of the benefits of the approach is that 
it permits the doctors to focus on a more personalised discussion (Agre et al. 1994). 
 
Patient adherence to treatment is an ongoing challenge in many aspects of health care, 
and ways of improving it are valuable.  Patient education is an important part of the 
process and different ways of delivering the information to patients, such as video, may 
have an impact on whether or not the patient adheres to treatment.  Jean Wiese et al. 
(2005) used video education about treatment (Continuous Positive Airway Pressure - 
CPAP) with patients with Obstructive Sleep Apnoea Hypopnoea Syndrome.  Adherence to 
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CPAP is often poor with this patient group.  However, in this RCT, comparing the video 
group with a control group, patients receiving the video had better adherence to treatment.    
So et al. (2003) found a similar improvement in adherence to treatment as a result of 
video and written information about silicone gel sheeting for burns, which resulted in a 
better scar outcome for patients. 
 
AVPI has been used as a decision aid in a number of specialist areas including cardiology 
(Holbrook et al. 2007), cancer (McGregor 2003; Brown et al. 2004), screening (Hewison et 
al. 2001; Van Roosmalen et al. 2004), surgery (Deyo et al. 2000) and general practice for 
hypertension and benign prostatic hypertrophy (Shepperd et al. 1995), generating patient 
perceived benefits as well as improvements in knowledge.  Substantial numbers of 
patients felt that the AVPI as part of a decision aid helped them in making their decision 
about treatment:  96% in the cardiology study and 71% of patients with hypertension or 
benign prostatic hypertrophy (Shepherd et al. 1995; Holbrook et al. 2007).  Studies have 
also shown differences in actual decisions for patients receiving AVPI (Deyo et al. 2000 in 
relation to back surgery; Van Roosmalen et al. 2004 in genetic screening for breast 
cancer). 
 
4.4.2 Health promotion 
AVPI has been widely used in health promotion and has been shown to be a useful tool in 
this setting.  Video has been used effectively to increase knowledge and preventative 
health behaviour in osteoporosis (Kulp et al. 2004), to increase breast self-examination in 
postmenopausal women (Janda et al. 2002), and to improve tooth brushing with an 
electric toothbrush (Addy et al. 1999; Renton Harper et al. 1999).  In prenatal care, 
pregnant women who were shown a video as part of a health education package had a 
higher smoking quit rate, reported in the last month of pregnancy, compared with those 
who did not receive the video, but who otherwise received the same aspects of the 
education package concerned (Secker-Walker et al. 1997). Findings were validated by 
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exhaled carbon monoxide levels.  In a UK study of a health education initiative for 
malignant melanoma, comparing an interactive video with matched controls, the group 
receiving the video had a higher knowledge, reported more protective skin behaviours and 
were more likely to report mole checking (Glazebrook et al. 2006). 
 
In Canada, Cook et al. (2003) evaluated a video addressing brain and spinal cord injury 
prevention for ice hockey. Knowledge transfer and behavioural outcomes were evaluated 
in 11-12 year old hockey players who viewed the video.  Concussion knowledge and the 
incidence of aggressive penalties were assessed before and after viewing the video.  
Results showed that knowledge was better in the video group, a difference which was 
maintained at three months.  There was no significant change in the total penalties, 
although specific body-checking related penalties (which are considered a high injury risk) 
were significantly reduced.  This was an interesting study in that behaviour was objectively 
assessed. 
 
CD-ROM was used to increase fruit and vegetable intake in low income women  (Block et 
al. 2004), and an interactive computer programme to increase factory workers’ use of 
hearing protection (Lusk et al. 2003).  Both these studies were randomised and relatively 
large scale: 481 participants (Block et al. 2004) and 2831 participants (Lusk et al. 2003).   
 
A review of video intervention studies in relation to improving knowledge and treatment 
compliance at sexually transmitted disease (STD) clinics was carried out in the USA 
(Healton and Messeri 1993).  This showed that the largest effects were those for video on 
knowledge and attitudes about STDs and condoms.  Lower effects were found among 
interventions targeting treatment compliance outcomes, which is consistent with prior 
prevention studies that have demonstrated difficulty in achieving behaviour change.  
However, this review was reported fourteen years ago, and since then there have been 
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large randomised studies in this area which have shown behaviour change. Of note are 
the studies by O’Donnell et al. (1995 [a and b] and 1998), as discussed below.   
 
A video to promote condom acquisition was tested in a three group RCT of 1653 black 
and Hispanic patients attending a clinic in New York.  Patients were randomised to 
receive either a control, video viewing or video viewing plus an interactive group session. 
Both the video groups had an increase in knowledge, attitudes and behaviour with higher 
rates of condom acquisition.  The group receiving the interactive group session in addition 
to the video had higher levels than the video alone group (O’Donnell et al. 1995a).  Similar 
results were shown in another study in New York with 3348 African American and 
Hispanic patients (O’Donnell et al. 1995b). 
 
STD infections were assessed in African American and Hispanic men subsequent to an 
STD clinic visit where clients were randomised (n=2004) to receive video based education 
or the control arm (received routine clinic services only).  There was a reduction in STD 
infections in those who received the video. The authors conclude that video to supplement 
regular STD clinic services and provider interactions can be effective in reducing rates of 
new STD infections, particularly among those at greatest risk (O’Donnell et al. 1998). 
 
Audiovisual methods, mainly video and CD-ROM, have been used, with mixed success, 
for health education in schools. Studies have addressed promoting a healthy diet and 
exercise, sexual health, and orthodontic treatment. Casazza and Ciccazzo (2007) 
randomised pupils to one of three groups: CD-ROM; traditional teaching on nutrition and 
physical activity; or a control group.  They found that although knowledge increased in the 
two intervention groups, this was accompanied by more positive lifestyle changes only in 
the CD-ROM group, where there was a self-reported change in eating behaviours and an 
increase in physical activity.  In relation to orthodontic treatment, pupils were randomised 
to receive a video about the treatment, or to a control group (Anderson and Freer 2005).  
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Knowledge and attitudes were improved in pupils viewing the video.  Although there was a 
small increase in willingness to have treatment, this was not statistically significant 
(Anderson and Freer 2005).  Similarly, a CD-ROM about sexual health was associated 
with an increase in knowledge in a study by Yom and Eun (2005); however, there was no 
difference in attitudes.  In all of these studies, any behaviour change was self-reported 
with no objective assessment being undertaken. 
 
4.4.3  Screening 
Another popular area for the development and use of AVPI is screening. The format most 
commonly used is video, with the majority of studies related to cancer screening, although 
video has also been used to deliver patient information about screening for Downs 
Syndrome (Hewison et al. 2001).  The main outcome measure used in screening studies 
is uptake of screening, with knowledge the most common secondary outcome measure. 
 
In colorectal cancer, screening uptake was increased when video was part of an 
educational intervention also involving other methods.  Pignone et al. (2000) used video 
as part of a decision aid package, which also included a targeted brochure and a chart 
maker.  This was an RCT testing the intervention video, containing information about 
colorectal cancer screening, against a control video which addressed automobile safety. 
Participants receiving the educational package containing the screening video more 
frequently requested screening tests (self-reported by participants), and had increased 
completion of screening tests which was determined objectively from review of case-
notes.   Tu et al. (2006) showed an increased uptake of screening as a result of an 
educational intervention for colorectal cancer screening, compared with usual care.  In 
addition to video, the intervention included a health educator, a motivational pamphlet, an 
informational pamphlet and faecal occult blood testing (FOBT) instructions and cards.  
Powe et al. (2004) assessed knowledge as well as screening uptake and found that 
patients with greater knowledge of colorectal cancer were more likely to participate in 
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FOBT.  Again the video was part of a larger educational intervention.  Other aspects were 
posters, brochures and fliers.  
 
Also in colorectal cancer, no effect on the overall screening rate was found in a study by 
Zapka et al. (2004), who compared a video on its own with the usual care.  However, it is 
acknowledged that results may not be generalisable, as the sample was predominantly 
white middle class and there was already a high baseline screening rate (almost 25%).  
There was also substantial public media attention to colorectal cancer screening during 
the timeframe of the study, which is acknowledged by the authors.  
 
In prostate cancer screening, a video increased knowledge when compared with a group 
not receiving the video, but there was no difference in screening behaviours (Volk et al. 
2003).  Taylor et al. (2006) specifically looked at prostate cancer screening in African 
American men, and randomised patients to three groups: AVPI (video), written information 
(booklet) and waiting list control.  Both the video and the booklet groups had a significant 
improvement in knowledge, reduced decisional conflict about colorectal cancer screening, 
and increased self-reported screening rates, which were no different between the two 
intervention groups. 
 
In mammography screening, Avis et al. (2004) compared a pamphlet with an informational 
video and found a small effect on screening uptake. Van Roosmalen et al. (2004) 
compared video plus written information with a control group among women being tested 
for gene mutation (breast cancer). The intervention contained information on screening 
and prophylactic surgery.  Results showed that the intervention group had increased 
knowledge (which was subjectively and objectively assessed), were more satisfied with 
the information, and more frequently considered prophylactic surgery. 
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In screening for Downs syndrome, video was used in an RCT involving 2000 patients 
(Hewison et al. 2001).  Test uptake, knowledge, and psychological stress were assessed.  
All women also received written information about screening, and had a discussion with 
the midwife at their booking visit.  The intervention resulted in an increase in knowledge 
without increasing anxiety, but there was no difference in screening uptake (Hewison et al. 
2001). 
 
In relation to screening, video appears to have most benefit as part of a wider education 
package which has been shown to improve cancer screening uptake.  However, in some 
situations, as shown in the study of screening for Downs syndrome, an increase in 
knowledge does not always result in an increase in screening uptake (Hewison et al. 
2001). 
 
4.4.4 Surgery and rehabilitation 
Benefits have been shown with AVPI in improving knowledge and understanding of a 
surgical procedure (Mason et al. 2003 in female sterilisation; Rossi et al. 2004 and 2005 in 
orthopaedic surgery; Danino et al. 2005 prior to aesthetic surgery; Sahai et al. 2006 in 
laparoscopic nephrectomy), without increasing anxiety (Mason et al. 2003; Danino et al. 
2005).  As part of describing the surgical intervention, graphic illustrations and video 
footage of the procedure itself have been included in AVPI, for example in laparoscopy 
urology (Sahai et al. 2006). The main outcome measures, in terms of evaluating AVPI and 
patient consent to surgery, have been knowledge, understanding, anxiety, and patient 
satisfaction.  Video is the most commonly used format. 
 
A review of RCTs in media-based patient education about anaesthesia was carried out by 
Lee et al. (2003), who assessed the outcomes of knowledge, anxiety and patient 
satisfaction.  They found that video and/or printed materials can increase knowledge and 
reduce anxiety; however, patient satisfaction was similar in both the intervention and no 
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intervention groups.  The review concludes by supporting the use of video before surgery 
to inform patients about the process and risks of anaesthesia (Lee et al. 2003). 
 
Henrotin et al. (2006) studied patient information for low back pain, and found that the 
majority of information available is in written format and is effective in improving patients’ 
knowledge.  With physician-related cues (such as the association of the message with the 
patient’s physician throughout the text, or an educational session with the physician or 
nurse), this was also effective in increasing adherence to exercise in some cases.  They 
found no evidence that video programmes alone are able to reduce low back pain, 
disability and health care costs, although it must be noted that only three of the studies 
included in the review involved video.  One study showed no difference with the video, 
another involved a video as part of an internet intervention involving other multimedia 
approaches.  In the third study involving video, knowledge of treatment options was 
greater in the group that viewed a video in addition to the standard written information, 
when compared with the group receiving the written information alone (Phelan et al. 
2001).  In this study, patients had a lower preference for surgery if they had viewed the 
video, although this was not statistically significant (Phelan et al. 2001).  However, the 
review is limited by the fact that despite focussing on randomised trials, the three video 
studies were all considered to be of low quality, according to the list of criteria for the 
methodological quality of RCTs, as recommended by the Cochrane Back Review Group 
and discussed by Henrotin et al. (2006). 
 
Similar results were found in a review focussing on RCTs of pre-operative education for 
hip or knee replacement, to determine whether it improves post-operative outcomes 
(McDonald et al. 2004). Only nine studies met the inclusion criteria, with three of these 
including video.  In light of this, the authors found little evidence to support the use of pre-
operative education over and above standard care. The value of AVPI in this setting is 
therefore unclear due to lack of evidence and the need for further research. 
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Studies of AVPI in rehabilitation include an RCT of a home-based exercise program 
(which included video) for ankylosing spondalitis (Sweeney et al. 2002); an RCT of 
customised videotapes in patients with Chronic Obstructive Pulmonary Disease (Petty et 
al. 2006); and an RCT of a diet and exercise video given to patients prior to hospital 
discharge following coronary artery bypass grafting (Mahler et al. 1999).  All of these 
studies showed changes in behaviour although it is acknowledged that, in most cases, 
this was only via self-report and was not objectively assessed (Mahler et al. 1999; 
Sweeney et al. 2002). 
 
4.4.5  Cancer care 
AVPI is becoming more commonly used for patient education within cancer care. Video 
has been used to describe treatments with the aim of improving knowledge and reducing 
anxiety (Bakker et al. 1999; Thomas et al. 2000; Dunn et al. 2004; Hahn et al. 2005; 
Orringer et al. 2005; Walker and Podbilewicz-Schuller 2005), and to assist in decision 
making about treatment choices (McGregor 2003; Wilkins et al. 2006).  Within cancer 
care, video has been shown to increase knowledge (Hahn et al. 2005; Orringer et al. 
2005), increase patient satisfaction with information (Thomas et al. 2000; Dunn et al. 
2004; Hahn et al. 2005; Walker et al. 2005), reduce anxiety (Thomas et al. 2000; Orringer 
et al. 2005) and improve symptoms (Clotfelter 1999).  Studies in the cancer setting have 
predominantly evaluated video on its own rather than as part of a wider educational 
intervention.  In addition to the benefits of AVPI for patient information, several studies 
also emphasise the importance and value of the clinical encounter/interaction with the 
health care professional (Bakker et al. 1999; Orringer et al. 2005; Gysels and Higginson 
2007). The potential benefits of tailoring videos to individual diagnoses and patient 
subgroups is also highlighted (Hahn et al. 2005). 
 
A systematic review of randomised controlled trials of effective methods of information-
giving to cancer patients and their families was carried out by McPherson et al. (2001). 
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Ten studies were identified which met the inclusion criteria: RCTs that evaluated methods 
of information giving where the intervention was aimed primarily at educating rather than 
counselling.  Outcomes directly related to the intervention included objective measures of 
knowledge acquisition, recall and understanding, and the use of educational resources. 
The greatest improvements were seen in relation to knowledge and understanding. The 
review was limited in that it focused on studies that included patients with heterogeneous 
cancer types and excluded studies focussing on just one type of cancer (e.g. breast 
cancer).  Studies of medical procedures such as surgery, chemotherapy and radiotherapy 
were also excluded.   Of the studies included, only one involved video and was of small 
scale and limited to elderly patients with cancer (Clotfelter 1999).  In this study video was 
used with written information relating to cancer pain.  Significantly less pain intensity was 
reported by the patients receiving the intervention, as compared with patients in the 
control group; however, the difficulty generalising these results is acknowledged (Clotfelter 
1999).  
 
Gysels and Higginson (2007) reviewed the literature specifically in relation to interactive 
technologies and videotapes for patient education in cancer care.  This was carried out as 
part of a programme of systematic literature reviews on service configurations for 
supportive and palliative cancer care for the UK National Institute of Clinical Excellence.  
Gysels and Higginson (2007) looked specifically at the effect of technology on knowledge 
and satisfaction.  They included studies that evaluated interventions providing patient 
education to improve knowledge, satisfaction, decision making, treatment choice or care 
management by using videotapes or computer programmes in cancer care. They 
excluded studies using hypothetical choices, informed consent to take part in a trial, 
screening for cancer prevention, and paediatrics.  Nine RCTs were identified. These were 
from Canada, America, Australia and the UK and had a total of 1678 patients. Three of 
these involved video and six involved computer technologies. Of the three video studies, 
two involved consent to a procedure (Agre et al. 1994; Thomas et al. 2000), while the 
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other was designed to promote shared treatment decision making (Brown et al. 2004).  
The review supports the use of video for patient education in cancer care as an aid to (but 
not a substitute for) communications with health care professionals. 
 
4.5 Content of AVPI 
Both tailoring and framing information has been studied in relation to AVPI, with benefits 
shown in some areas, as discussed below.  
 
4.5.1 Tailoring information 
Tailoring information to specific patient groups or interventions appears to be beneficial, 
although there has been a variety of degrees and approaches to tailoring, making it 
difficult to compare results.  A meta-analysis of 20 studies testing the efficacy of tailored 
interventions found that, in 50% of the studies, tailored interventions were more effective 
in promoting health behaviour than standard interventions (Ryan and Lauver 2002).  Since 
this review, Lusk et al. (2003) have used a tailored computer intervention to increase 
factory workers’ use of hearing protection in a large study in the USA (n=2831). Pender’s 
(1987) Health Promotion Model and Bandura’s (1986) Social Cognitive Theory provided 
the theoretical foundation, and guided the process for creating the intervention to change 
workers’ behaviour regarding the use of hearing protection.  Individuals responded to a 
survey questionnaire based on the important predictors of the Health Promotion Model, 
such as perceptions of benefits, barriers, self-efficacy, interpersonal and situational factors 
(Pender 1987, in Lusk et al. 2003), prior to receiving their information via a computer 
booth in the workplace.  The information they received was influenced and hence tailored 
by their responses to the survey questionnaire. Other factors which contributed to the 
tailoring were the workers’ self-reported existing practices in relation to hearing protection, 
and their perceived hearing ability. 
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Travena et al. (2006) carried out a systematic review on communicating with patients 
about evidence.  They included 10 systematic reviews of RCTs and 30 additional RCTs 
and found that communication tools in most formats (for example written, verbal, 
audiovisual) will increase patients’ understanding, but are more likely to do so if 
structured, tailored and/or interactive.  Illustrations also appear to aid understanding 
(Travena et al. 2006). Unfortunately, clinical trial communication about participation was 
excluded from this review. 
 
Jerant et al. (2007) studied the effects of a tailored interactive multimedia computer 
programme on the determinants of colorectal cancer screening.  A personally tailored 
colorectal cancer screening programme (interactive multimedia via computer) was 
compared with a non-tailored ‘electronic leaflet’ (also available as an interactive 
multimedia programme via computer). This study found no difference in knowledge or 
perceived benefits to screening between the two groups, with the tailored group showing 
increased self-efficacy, less perceived barriers, and a greater state of readiness for 
screening.  However, there were substantial limitations to this study, which was small and 
did not reach its target number (54 v 88).  In addition, they did not assess the impact of 
the intervention on actual screening uptake. 
 
A different approach to tailoring was investigated by Petty et al. (2006) in Chronic 
Obstructive Pulmonary Disease.  Physicians selected from a library of 49 exercise 
segments, and chose from three different intervention times for their patient group 
(customised video group).  These patients were then compared with patients who 
received a standard video about pulmonary rehabilitation, and a control group who 
received the usual care from their physicians.  Patients in the customised video group 
showed an improvement in quality of life, reduction in fatigue, and an increase in exercise 
compliance compared with the other two groups.  Patients in the standard video group 
showed an improvement in exercise compliance compared with the control group. 
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Within the cancer setting, Hack et al. (2007) evaluated the effect of a general audiotape 
about the trial (breast cancer, radiation) compared with a specific audiotape of the 
patient’s consultation about the same clinical trial.  The specific audiotape performed the 
function of an ‘aide-mémoire’ to the patient’s medical consultation. They found no 
difference in knowledge or perception about being informed, but patients preferred the 
individual consultation tapes, as compared with the more general ones (Hack et al. 2007). 
 
4.5.2 Framing information  
There is mixed evidence in the literature about the effect of framing the information 
contained in AVPI, although framing and manipulating information was shown to be 
important in relation to written information in a good qualitative study by Donovan et al. 
(2002).  They increased consent rates from 40% to 70% in a difficult-to-recruit prostate 
cancer trial by altering the way clinical trial information was presented, based on results of 
in-depth interviews with patients exploring interpretation of study information. This 
included the avoidance of misinterpreted terms and changes to the order of presenting 
treatments to encourage emphasis on equivalence.   In relation to AVPI (video), Lewis et 
al. (2003) found that framing the information for mammography screening had no effect, 
but that the video was effective in all groups in correcting misconceptions and improving 
knowledge. Llewellyn-Thomas et al. (1995) also showed no effect of framing in patients' 
reported preferences for participating in treatment decision making and for trial entry.  
However, a conflicting finding was reported by Wragg at al. (2000), who did show a 
difference in patients’ views as a result of framing in a trial of hormone replacement 
therapy (HRT).  They compared two different videos: (1) information was framed to 
emphasise the current state of uncertainty about the costs and benefits of HRT (thus 
justifying the trial); and (2) the same information was framed to offer explicit numerical 
detail about currently known facts.  The second group (focussing on numerical detail and 
not uncertainty) were more likely to hold stronger views about whether or not they would 
take HRT, and were more likely to refuse entry to the trial.  A substantial limitation of this 
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study was that patients were asked about an imaginary trial of HRT and were therefore in 
a hypothetical situation; they may have felt differently when faced with the actual decision. 
 
4.5.3  Tailoring and framing AVPI  
Tailoring information has been shown to be a useful approach in terms of understanding, 
and also in changing behaviour.  However, the usefulness of framing in AVPI is unclear 
from the literature and further research is warranted 
 
4.6 Clinical trials  
4.6.1 Clinical trials in health care generally 
There is less research about AVPI as a tool to improve consent in clinical trials in health 
care, as compared with the literature concerned with AVPI and health education/consent 
outwith the clinical trial setting.  AVPI has been used indirectly as a tool for decision 
making in many of the areas already discussed through its function of information 
provision. It has been used directly as a decision aid (or part of a decision aid) in 
screening, and prior to consent to anaesthesia and surgery, as previously discussed.   
 
It has been suggested that the use of informational videos may enhance the informed 
consent process for clinical research, and that the understanding of difficult concepts such 
as randomisation may be improved by using visual examples (Jimison et al. 1998; 
McLaughlin et al. 2002).  Jimison et al. (1998) developed a prototype multimedia tool 
based on focus groups and interviews with health care professionals, and three groups of 
patients with depression, breast cancer and schizophrenia. Patients could access the 
interactive programme to obtain both generic and specific trial information. The content of 
the specific modules was based on a drug trial that had already taken place. The 
approach was well accepted by patients, but was unfortunately not tested prospectively in 
a specific trial situation.  
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McLaughlin et al. (2002) identified the potential benefits of AVPI and registered a 
Cochrane protocol to undertake a review to examine the effects of providing an 
information video, alone or in conjunction with standard forms of information provision, to 
potential clinical research participants, compared with the provision of standard forms of 
information alone.  They planned to assess understanding, satisfaction, recall of study 
information, level of anxiety and participant discussion.  It is unclear if this work was 
undertaken as nothing appears to have been reported in the literature since the protocol 
was posted, and attempts to contact the author were unsuccessful.  
 
In Flory and Emmanuel’s (2004) systematic review of interventions to improve research 
participants’ understanding in informed consent for research (from 1966 to 2004), 12 of 
the trials they reported on involved multimedia interventions.  Five of these showed 
benefits in understanding, including two studies which showed delayed improvement in 
retention of knowledge several weeks after the consent procedure, but not immediately 
after disclosure (Fureman et al. 1997; Weston et al. 1997).  The authors suggest that 
multimedia is useful outwith the clinical trial setting, but not within it, and offer reasons as 
to why this may be the case.  They suggest that it could be because the informed consent 
process is already formalised through regulatory requirements, including the need for a 
written consent form, and that multimedia interventions may not add much to this already 
thorough disclosure process (Flory and Emmanuel 2004).  However, it must be noted that, 
as previously highlighted, they were limited by the terms used in their search strategy, as 
they did not include the term ‘knowledge’, and as a result may have missed relevant 
papers.   
 
Since this review, there have been several studies showing a benefit of AVPI in the 
clinical trial setting which will now be discussed, although it is acknowledged that further 
research in this area is necessary.  Only randomised studies were included in the Flory 
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and Emmanuel (2004) review, and so other relevant non-randomised studies will also be 
discussed below. 
 
In schizophrenia trials, a video was made to enhance the consent process, and 
knowledge was measured before and after viewing via an 80-item quiz (Wirshing et al. 
2005).  A highly structured educational video about the consent process was compared 
with a control video, which was about research generally and contained nothing about the 
consent process. The study sample included three groups: (a) patients with schizophrenia 
(n=83) who were being recruited for ongoing clinical trials (taken from 10 RCTs); (b) 
medical patients without self-reported psychiatric comorbidity; and (c) university 
undergraduates.  Wirshing et al. (2005) found that knowledge was increased by the highly 
structured video, and that video was an effective teaching tool across all populations. 
 
Joseph et al. (2006) evaluated a two-step education approach for patients potentially 
eligible for an HIV trial in Haiti.  Firstly, patients were shown a video based on the consent 
form.  The second session involved a one-to-one discussion with the social worker. Two 
hundred and fifty volunteers received the education.  Comprehension was assessed with 
16 true/false and 4 open-ended questions.  Volunteers who failed the evaluation received 
a repeat one-to-one education session.  Ninety percent of the sample (225/250) passed 
either the first or second evaluation, and were then considered eligible to enrol in the 
study.  This was an interesting study in that patients were not allowed to enrol in the study 
unless they met a certain standard in relation to understanding. It is difficult, however, to 
generalise the results as the sample was specific to HIV and came from a developing 
country where illiteracy is common.  It did not employ a randomised design, so it is not 
possible to gauge how effective the intervention was compared with other methods.  In 
addition, they used a new tool to assess understanding which would require further 
validation work. 
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Knowledge and adherence to trial requirements were assessed in a complex and 
demanding long-term trial for diabetes following the introduction on an education package 
consisting of written and audiovisual patient information as well as behavioural practice 
(Diabetes Control and Complications Trial Research Group 1989).  Results showed 
excellent knowledge scores following the intervention, and these were retained twelve 
months later. There was also good adherence to the trial.  Limitations include the fact that 
the study was not randomised and therefore could not compare approaches or 
consent/compliance rates. 
 
Another non-randomised study of note is the large-scale disease prevention study, the 
Women’s Health Initiative in the USA (McTiernan et al. 1995).  McTiernan et al. (1995) 
effectively used a multi-component informed consent process, similar to that in the 
diabetes study described above, as an ongoing informed consent process, updated as 
new information becomes available.  The aim is for 160, 000 women to be recruited over a 
period of 8-12 years at 40 clinical centres.  No details are currently available on the results 
of this study. 
 
Norris and Philips (1990) assessed patient understanding scores in relation to informed 
consent to clinical trials in two groups of patients in a duodenal ulcer study:  those who 
received a video and those who did not. Both groups received the standard written 
information. Patient understanding was assessed via a 10 question multiple-choice quiz, 
with the video group having substantially better understanding than the control group.  As 
a result of this, the authors strongly recommend using video as part of the informed 
consent process to clinical trials, as do Agre et al. (2003), who found that computer and 
video improved comprehension over written information alone for later phase clinical trials.   
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4.6.2 Cancer clinical trials 
Cancer education materials, including clinical trial consent forms, have been shown 
consistently to have readability levels exceeding patients’ abilities (Grossman et al. 1994; 
Cooley at al. 1995).  Their value in preparing patients for clinical trials must therefore be 
questioned.  A potential solution to this is ‘easy-to-read’ written material, which would not 
have the same level of detail as one written at a higher level. It may not therefore resolve 
a knowledge gap (Chelf et al. 2001).  It has been suggested by Chelf et al. (2001), 
following a review of the literature on cancer patient education, that because spoken 
vocabulary is at a much higher level than written vocabulary, audiovisual approaches may 
be a better solution.  Cancer patients often overestimate their prognosis with standard 
therapy and this may inhibit accrual to randomised controlled trials where standard 
therapies are the alternative, should they choose not to participate in the trial (Sheldon et 
al. 1993).  Sheldon et al. (1993) suggest that trial-specific AVPI, with general background 
information, could be given prior to the consultation to enable the doctor to focus on more 
sensitive subjects such as prognosis with standard therapy. 
 
AVPI has not been widely used to improve consent in the cancer setting, although it has 
potential value, as has been discussed in relation to the general clinical trial literature and 
within other areas of health care.  Three recent studies have shown benefits in the cancer 
trial setting in relation to the consent process itself (Curbow et al. 2004; Hitchcock-Bryan 
et al. 2007; Strevel et al. 2007). 
 
In phase I cancer trials, an educational DVD was compared with a placebo DVD (Strevel 
et al. 2007).  The educational DVD increased patient knowledge and satisfaction 
regarding participation.  The knowledge test was carried out with patients, but physicians 
also gave their perceptions of patient knowledge.  Although knowledge was increased as 
a result of the DVD, there was no difference in consent rates.  Fifty-five percent of patients 
felt that the DVD helped them to decide about participation.  This was a small scale study 
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(n=49) and limited to a very specific group of patients, for whom the main aim of the trial is 
to determine the toxicity rather than the efficacy of the drug/treatment.  Hence, these are 
patients with a poor prognosis, and with limited (if any) options for standard treatments. 
 
Curbow et al. (2004) investigated the effect of video vignettes on clinical trial knowledge 
and beliefs using a pre-test post-test design.  As discussed in Chapter 2 (Section 2.6.1.1), 
they distinguish beliefs from the concept of attitudes, as being cognitive statements rather 
than affective or evaluative statements about clinical trials. Knowledge is defined as 
‘correct factual information’, and beliefs as an ‘attribute linked with an object’ where the 
object is clinical trials (Curbow et al. 2004). Curbow et al. (2004) involved 161 patients 
with breast cancer and 101 controls, and found that video vignettes were a powerful tool 
for increasing clinical trial knowledge, but not for improving clinical trial beliefs.  In their 
summary, they suggest that a more concerted attempt to change beliefs rather than just 
by increasing knowledge is important. They suggest that this could be done by providing 
patients with direct experience of someone who has taken part in a trial, or by focussing 
on patients’ positive emotional responses to being in a trial (Curbow et al. 2004). 
 
Hitchcock-Bryan et al. (2007) developed a video about clinical trials, and tested it in a 
randomised trial in relation to informed consent of patients in a cancer centre in the USA.  
They found no difference in objective and subjective assessment of understanding of 
those in the intervention group, as compared with the control group.  However, it was 
reported at the American Society of Clinical Oncology conference (ASCO 2007) that the 
lack of difference may be due to the fact that the clinical trials clinicians at the cancer 
centre already put a substantial emphasis on the oral part of the consent process, and 
spend significant time with patients as part of this process.  A limitation of the study was 
that pre and post testing was not carried out, and it is not known if the groups were 
comparable in terms of understanding at baseline prior to the intervention.  It must also be 
acknowledged that this was a small scale study (n=77).  Despite this, patients found the 
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video useful in terms of information and decision making, both to themselves and to their 
family and friends.  It view of this, the video is now used routinely as part of the informed 
consent process in the cancer centre that undertook the study. 
 
Llewellyn-Thomas et al. (1995) randomised 100 patients undergoing radiotherapy to 
receive information about a hypothetical trial, either by audiotape or interactive computer 
programme.  They found no difference in understanding or satisfaction between the 
groups, but found that the computer programme group reported a more positive attitude to 
trial entry. 
 
4.7 AVPI and recruitment to clinical trials 
4.7.1 Introduction  
Although video has been used to some extent during the informed consent process for 
clinical trials, the research is limited, particularly in relation to its effect on patient decisions 
about whether or not to take part.  Interventions to increase patient recruitment are of 
particular interest in the current health care climate. There is high political interest in 
increasing recruitment to cancer trials, and also reviews advocating further research in 
this area, particularly in relation to AVPI (McLaughlin et al. 2002; McDaid et al. 2006). 
 
4.7.2 Evaluation of studies aimed at increasing recruitment to clinical trials 
There have been a small number of studies specifically focussing on AVPI as a tool to 
increase clinical trial recruitment, both in the general health care setting and specifically in 
cancer trials. 
 
4.7.2.1 Generally 
In health care generally, two studies of interest were found.  In Canada, Weston et al. 
(1997) investigated the effect of a patient information video in a perinatal trial in which 90 
women were randomised to written information versus written information plus video. 
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They were asked to complete a questionnaire immediately after entry and 2-4 weeks later. 
Knowledge, feelings about how worthwhile they thought the study was, and willingness to 
participate in the trial (should they become eligible) were assessed.  When initially asked, 
more women who watched the video thought they would consent to the study.  There was 
no difference initially in knowledge, but the video group retained more knowledge 2-4 
weeks later.  Weston et al. (1997) concluded that a patient information video combined 
with an information sheet may result in greater participation in a research trial.  However, 
the study showed ‘interest in participation’, but not how that translated into actual 
recruitment rates.  The authors acknowledge that it was not possible for them to 
determine whether it translated into improved recruitment for this trial.  In addition, the 
participants in the study were all highly educated. 
 
In HIV vaccine trials, Fureman et al. (1997) investigated the benefits of video used as a 
supplement to written information for 186 injection drug users, and assessed ‘willingness 
to participate’ in the trial.  Results suggest that written information should be combined 
with oral or visual materials to help people retain information.  They found that willingness 
to participate was not associated with knowledge but was associated with ‘trust in the 
government’ in relation to safety of the vaccines.  Limitations to the study were that the 
participants were in a hypothetical decision situation and were already enrolled in a study.  
 
4.7.2.2 Cancer setting 
Generally, there is no strong evidence for interventions that increase cancer patients’ 
recruitment to trials (McDaid et al. 2006), and it is an area where further research is much 
needed.  There is even less research specific to audiovisual interventions as a tool to 
increase recruitment in the cancer trial setting.  These studies will now be discussed. 
 
Du et al. (2008) conducted a randomised trial to investigate the effect of an educational 
video on clinical trials enrolment for patients with lung cancer.  Patients (n=145) were 
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randomised to receive either the National Cancer Institute video, ‘Cancer Clinical Trials:  
An Introduction for Patients and Their Families’ (viewed before their first clinic 
appointment), or standard care (the clinic appointment).  The primary endpoint was 
patients’ self-assessed likelihood to enroll in a clinical trial, which was measured on a 
scale of 1-5. Actual enrolment rates were also recorded. Patients were surveyed via a 
one-page questionnaire which claimed to assess knowledge and attitudes towards trial 
participation. This was completed at baseline (prior to the intervention) and follow up (two 
weeks later).  In addition to the one question assessing likelihood of enrolment, the 
questionnaire contained a total of 15 questions in 3 subscales which assessed 1) patients’ 
altruism, 2) perceived personal benefits and 3) perceived negative aspects related to 
participation in clinical trials.  The sample included patients who were potentially eligible 
for one of a wide range of clinical trials running at the centre, which included therapeutic 
and non therapeutic clinical trials, such as, educational, behavioural, chemoprevention 
and tissue collection trials. More than a quarter of the sample was African American (Du 
et al. 2008).  Results showed that for patients assigned to the video intervention, 
enrolment rates were higher for therapeutic trials (17.5% v 11.1%) and for all trials 
combined (25.4% v 15.9%).  However, this was not statistically significant. The 
intervention had a statistically significant impact on patients’ attitudes towards clinical trial 
participation and the likelihood to enrol score was significantly associated with actual trial 
enrolment. For all three subscales on the knowledge/attitudes questionnaire, there were 
no differences between study arms at baseline or follow up and no difference in the 
change scores for the subscales by study arm. 
 
There were several important limitations of this study, most of which have been noted by 
the authors. The small sample size meant that there was insufficient statistical power to 
detect a difference of less than 20% (Du et al. 2008).  Analysis comparing enrolment to 
therapeutic trials between the study arms was not restricted to eligible patients, since data 
concerning eligibility status was not collected at this time point. This means that ineligible 
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patients were also included, which does not give an accurate picture of enrolment. The 
three knowledge/attitude subscales correlated poorly with patients’ trial enrolment.  From 
the information reported in the paper it is not clear to what extent the questionnaire 
measured knowledge and attitudes, since subject areas only are given and not the 
questions within each section. Attempts to contact the author, to clarify, were 
unsuccessful.  It would appear from the subject areas that the focus was on attitudes 
rather than knowledge.  In order to assess the effect of the intervention on knowledge, the 
tool would need to be more specific to the content of the video, in order to be sensitive to 
changes as a result of the intervention.   
 
Work presented at the American Society of Clinical Oncology conference (ASCO 2003) 
showed an increase in consent rates by using audiovisual patient information in early 
phase drug trials.  Daugherty et al. (2003) studied the effect of a CD-ROM educational 
intervention for advanced cancer patients enrolling in phase I–II trials. They developed an 
interactive CD-ROM with touch screen monitor, which contained phase I-II trial information 
and videos of patients and oncologists talking about early phase trials.  Potentially eligible 
patients (n=199) were randomised to either view the CD-ROM or receive a written 
information leaflet.  After consulting with their clinician, patients were interviewed about 
their understanding.  CD-ROM users reported that it changed the way they made a 
decision to enter a trial (28%, compared with 12% of patients receiving the written 
information), and in some cases changed the decision itself (20% v’s 5%).  Daugherty et 
al. (2003) did a subset analysis and found that 71% of those who completed the CD-ROM 
subsequently enrolled in a trial compared with 58% who received the written information.  
Although this was a very specific patient population – advanced cancer, and a unique trial 
setting (phase I-II), the same issues of vulnerable cancer patients and complex trial 
information exist for patients in randomised cancer clinical trials. 
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In another small cancer phase I trial, already referred to in Section 4.6.2, an educational 
DVD was compared with a placebo DVD (Strevel et al. 2007).  No difference was found in 
consent rates to the trial, despite the finding that 55% reported that the DVD influenced 
their decision making about participation. 
 
In an attempt to improve accrual to a difficult clinical trial comparing very different 
treatment arms (radical prostatectomy with brachytherapy), a multidisciplinary patient 
information session (MDS) was established (Wallace et al. 2006).  The MDS involved a 
talk by a cancer patient who took part in an RCT, an information video, and discussion 
with a urologist and oncologist about the trial and both proposed treatments. Recruitment 
was increased from 0 out of 27 patients to 34 out of 263 patients.  Patient understanding 
was also increased following introduction of the MDS.  This led to the conclusion that men 
who understand their treatment options and trial rationale, as presented jointly by 
specialists from competing treatment modalities, may be better equipped to make an 
informed decision, and are more likely to consent to random assignment (Wallace et al. 
2006).  The value of this approach appears to be in the combination of methods in the 
MDS rather than just the video itself. 
 
4.7.3 Why AVPI might be of value in increasing cancer clinical trial recruitment rates 
The potential value of video in increasing clinical trial recruitment rates is not a new 
finding, despite the fact that the actual value is at present unknown.  The use of video, 
among other things, was identified as potentially helpful in explaining clinical trials to 
patients when investigating ways to improve enrolment to cancer clinical trials in 1991.  
Fisher et al. (1991) identified the major obstacles to patient enrolment by community 
oncologists, and identified potential aids to overcome them.  Primary obstacles were (1) 
time demands on oncologists and staff, and (2) explaining clinical trials to patients.  They 
planned to implement the potential aids identified, which included video, and to study their 
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impact on patient accrual.  Although this was reported in 1991, there does not appear to 
have been any follow-up work from the authors since then. 
 
AVPI, particularly video, has been shown to increase uptake of cancer screening, 
although it is acknowledged that the majority of studies included video as part of a wider 
education intervention.  Within the health promotion literature, an effect on decision 
making in terms of an increase in compliance and also behaviour change was shown in 
randomised clinical trials where patients receive an informational video or CD-ROM.   
 
As argued in Chapter 3, patient understanding appears to be the key component of 
informed consent, in terms of understanding that you are being asked to take part in a trial 
and understanding what, as the content of the information disclosure about the trial. It is 
known that misconceptions and poor understanding about clinical trials are common and 
that this is a contributor to patient refusal to clinical trials, and hence low clinical trial 
recruitment rates.  Although there is not the evidence, it has been suggested that patients 
who have a better understanding of clinical trials have more favourable attitudes towards 
randomised trials, and are more willing to consider participation in a clinical trial (Ellis et al. 
2001).  It would therefore appear that by improving understanding, patients would be more 
likely to consent to a clinical trial. 
 
Within the cancer trial setting, AVPI has been shown to improve informed consent by 
increasing patient knowledge and understanding, although it is acknowledged that there is 
a lack of research in this area.  This is despite AVPI being an established way of 
delivering patient information in other areas of health care, with clear benefits in relation to 
knowledge and understanding (without increasing anxiety), improving compliance, uptake 
of screening, and also in assisting patients with decision making. Since it is known that 
AVPI can improve patient understanding of information, and in some cases influence 
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decisions, it would appear that it has the potential to increase clinical trial recruitment 
rates.   
 
4.8 Limitations of previous work 
There are two substantial limitations with previous work testing AVPI.  Video is often used 
as part of a wider educational intervention involving other methods, such as written 
information, one-to-one discussion, counselling, charts and checklists. It is therefore 
difficult to say how much of an effect was due to the video itself and how much was due to 
the other aspects on the intervention.  This was an issue in a substantial number of 
studies.  In addition, as already discussed, knowledge or understanding was the main 
outcome measure for determining effectiveness of AVPI in much of the research.  There 
were substantial challenges in assessing this, since a variety of different tools were used, 
at a variety of different time points relative to the intervention, and with a lack of clarity of 
the terms knowledge, understanding and comprehension. 
 
4.9 Summary of Part III - AVPI 
Within the health care setting, AVPI has been shown to be an effective tool for increasing 
knowledge and understanding (without increasing anxiety), and patient satisfaction in 
relation to information received.  It appears to influence behaviour in health promotion, 
screening, management of side-effects and adherence to treatments. In the cancer 
setting, AVPI is widely accepted as a useful patient education tool, but limited work has 
been done in relation to its effect on the informed consent process in cancer clinical trials.  
Even less evidence is available in terms of its effect on consent rates themselves, 
although this is an area of increasing interest from researchers. There is a paucity of 
research examining the association between knowledge/understanding of the research, 
anxiety, and willingness to participate in a randomised clinical trial (Ellis 2000), although 
the potential benefits of AVPI on consent rates have been highlighted. 
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Video and CD-ROM, as methods of delivering patient information, have been shown to be 
effective, feasible and acceptable to patients. With DVD technology also now widely 
available for patients, DVD provides another means of delivering the same information.  
For reasons of effectiveness, flexibility of viewing, patient acceptability and cost, video, 
DVD and CD-ROM were chosen as the intervention for this study.   
 
Major conclusions from the literature  
 
 Conclusion 1 
AVPI has been shown to be an effective and useful tool for patient education in a variety 
of health care settings including health promotion, screening, surgery, rehabilitation and 
cancer care.  It has been shown to increase knowledge and understanding, improve 
compliance, increase uptake of screening and to assist patients with decision making. 
 
Study implications 
• AVPI (video/DVD/CD-ROM) was chosen as the intervention for this study due to its 
effectiveness in increasing knowledge and understanding and because it appears to 
be a widely available and acceptable medium for patients. 
 
 Conclusion 2 
AVPI has been shown to be an effective tool for increasing knowledge and understanding 
without increasing anxiety, and in some cases reducing anxiety. 
 
Study implications 
• Patient anxiety as well as knowledge/understanding was assessed at baseline and  
post intervention. 
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 Conclusion 3 
Further research is needed to evaluate AVPI in terms of improving the consent process in 
clinical trials and also in terms of its effect on consent rates.  The few studies that have 
been done in this area suggest that by increasing understanding, AVPI can improve the 
process and also increase recruitment rates. 
 
Study implications 
• The aim of the AVPI was to increase understanding as a means to increasing 
recruitment rates via a reduction in patient refusal. 
• The literature was used to determine optimal ways to develop the AVPI to achieve this 
aim (e.g. patient involvement, summaries on screen, medical consultants involved in 
the production). 
 
 Conclusion 4 
Tailored AVPI appears to be more effective than generic AVPI 
 
Study implications 
• Some degree of tailoring was incorporated into the AVPI which was developed specific 
to tumour type and localised geographically. 
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4.10 Summary of the literature review: Parts I-III (Chapters 2-4) 
The need to increase recruitment to cancer clinical trials has been highlighted, along with 
the need to do this in an ethical manner when supporting patients to make an informed 
choice about whether or not to participate in a trial.  Patients are asked to consider 
complex terminology at a very difficult, anxious time in their lives, soon after being given a 
diagnosis of cancer or news about recurrence.  The evidence from the three parts of the 
literature review, suggests that audiovisual patient information to improve patient 
understanding is a potential way of both increasing recruitment and improving the 
informed consent process. AVPI has been shown to be an effective and acceptable 
medium for information giving in the cancer care setting.  It was decided to focus on 
randomised trials because these trials involve the largest number of patients in cancer 
clinical trials, and also because of the problems associated with patients’ understanding of 
the term ‘randomisation’, and the substantial misconceptions discussed in the literature 
(e.g. Sutherland et al. 1990; Corbett et al. 1996; Featherstone and Donovan 2002). There 
is much potential for improvement in patient understanding in this area, which could lead 
to a more informed decision and higher numbers of patients being recruited to clinical 
trials. Key points from the full literature review are summarised briefly in Table 4.3. 
 
 
 
 
 
 
 
 
 
 
 
 145 
Table 4.3.  Key points from the literature review 
Key Points 
 
 
1. Further research is much needed to determine effective interventions to increase 
recruitment to cancer clinical trials. Research involving interventions targeted at the 
informed consent process to increase clinical trial participation should not be 
considered independently of the quality of the informed consent process, due to the 
dangers of coercion. 
 
 
2. Patient refusal is the most common reason for potentially eligible patients not 
participating in cancer trials, with issues around patient understanding (especially of 
randomisation) and informed consent widely identified as factors negatively affecting 
recruitment and contributing to patient refusal rates. It would appear, therefore, that by 
increasing patient understanding about the research, refusal rates can be reduced. 
 
 
3. Informed consent can be viewed as an autonomous choice, and as a consequence 
requires patient understanding as the key component, along with voluntariness and 
competence. 
 
 
4. AVPI (particularly video) has been shown to increase knowledge/understanding 
without increasing anxiety. It has also been shown to assist patients with decision 
making. AVPI therefore has the potential to reduce clinical trial refusal rates (and so 
increase recruitment) in an ethical manner, by improving patient understanding of the 
information they are being asked to consider, prior to decision making about clinical 
trial participation. 
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4.11 Aims of the study 
The aims of the study were: 
1) to determine the effect of an audiovisual patient information intervention on 
a) refusal rates to randomised cancer trials  
b) knowledge and anxiety   
2) to investigate patients’ perceptions of the AVPI 
3) to investigate reasons for accepting and declining clinical trial participation.  
 
4.12 Hypotheses 
4.12.1 Hypothesis 
The addition of a patient information video/DVD/CD-ROM, to supplement written 
information in the informed consent process for patients considering participation in 
cancer clinical trials, will increase knowledge/understanding and reduce rates of patient 
refusal without increasing anxiety. 
 
4.12.2 Null hypotheses 
1) There will be no difference in knowledge/understanding between the two groups  - a) 
patients receiving the audiovisual information in addition to written information and b) 
those that receive written information only.  
2) There will be no difference in clinical trial refusal rates between the two groups.  
3) There will be no difference in anxiety between the two groups. 
 
 
 
 
 147 
CHAPTER FIVE:  METHODS 
 
5.1   Introduction 
This chapter will describe and discuss the methodology employed to meet the aims of the 
study, taking into account the clinical context and information from the literature.  Study 
design and coordination will be discussed first, followed by sampling, recruitment and 
randomisation.  The measures and process for data collection will then be addressed, and 
finally ethical considerations, timescales and funding.   
 
5.2 Study design  
5.2.1 Design 
The study design was experimental in the form of a randomised controlled trial (RCT) 
(Robson 2002, p116).  This two group RCT aimed to compare patients who received the 
video/DVD/CD-ROM (intervention) with patients who did not (control).   
 
An RCT was considered the design of choice for this study because it provided an 
experimental setting to determine if the intervention (AVPI) is effective, with the best 
chance of controlling for confounding variables. Randomisation is designed to maximise 
the likelihood that if a variable is likely to affect the outcome (known and unknown), it will 
be equally distributed between the groups – in this case, in both (a) the written information 
group and (b) the AVPI + written information group.   
 
The standard reasons discussed by Shadish et al. (2002) where random assignment is 
not feasible or desirable were considered in relation to this study:  if information is needed 
rapidly; when much high quality prior information already exists; where the independent 
variable cannot be manipulated (e.g. age); and ethical reasons (e.g. cannot assign a 
patient to an event that can cause harm, e.g. cigarette smoking).  None of these reasons 
were applicable in this study. 
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Further justification for the study design came from the comprehensive guidance 
developed by the Federal Judicial Centre (1981) (in Shadish et al. 2002, p277).  They 
stated that prior to conducting an RCT, it is important to justify that: 
“.. the present conditions need improvement, that the proposed improvement is of unclear 
value, that only an experiment could provide the necessary data to clarify the question, 
that the results of the experiment would be used to change the practice or policy,  and that 
the rights of individuals would be protected in the experiment”.    
All of these points were applicable to the AVPI study where clinical trial recruitment rates 
and the informed consent process needed to be improved.  Although the AVPI 
intervention was considered to be potentially useful in this situation, the effect was 
unclear, due to lack of research evidence. 
 
The practical challenges of an RCT as discussed by Shadish et al. (2002) and Robson 
(2002), which included recruiting large numbers of suitable and willing patients, attrition, 
and compliance with the intervention, were not anticipated to be a problem in this study. 
 
5.2.2 Threats to validity 
“ A validity typology can greatly aid design….” (Shadish et al. 2002, pp38-39). Validity was 
an important consideration in this study and it is acknowledged that “validity is not the 
property of a method, but is a characteristic of knowledge claims, …in this case claims 
about causal knowledge” (Shadish et al. 2002, p54).  Random assignment of patients to 
study arms was carried out to reduce the threat to internal validity by eliminating selection 
bias (Shadish et al. 2002, p56).  In an attempt to prevent reactivity to the experimental 
situation, the hypotheses were not discussed with participants.  However, to meet ethical 
requirements, patients were informed that the study was looking at ways of improving 
information and making it easier for patients to decide whether or not to take part in 
research trials. They were told that the aim of the study was to see if information in 
video/CD-ROM/DVD format improves peoples’ knowledge about clinical trials, and if it 
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makes any difference to their decision about whether or not to take part in a clinical trial.  
Due to the nature of the intervention, blinding was not possible (Shadish et al. 2002, p78).   
However, the randomisation process was handled by administrative staff in the Clinical 
Trials Unit.  Clinical staff involved in recruiting patients to the study, were therefore not 
involved in the randomisation process and had no way of knowing which patient the 
intervention would be assigned to.   
 
5.2.3  Context of study 
The study can be viewed as a ‘sub study’ of the cancer clinical trial as it is nested inside 
the cancer trial. To avoid confusion with the clinical trial being considered by the patient, 
throughout the thesis, and as already noted in Chapter 1, this study is referred to as the 
‘audiovisual patient information study’ (AVPI study) or ‘study’.   
 
5.2.4 Intervention 
For ease of reading, the control arm is described first since the intervention arm involves 
standard practice as described in the control arm, in addition to the intervention itself. 
 
5.2.4.1 Control arm 
The control arm of the study (also referred to as the no-intervention arm) involved current 
standard practice in The Beatson West of Scotland Cancer Centre for discussing clinical 
trials with patients. Patients see either a registrar or consultant from the tumour site team, 
who discusses the trial and administers a trial-specific information sheet and consent form 
(visit 1). An appointment is then made for them to return to the clinic the following week.  
At this visit (visit 2), they see a clinician from the same team to decide on treatment and 
whether or not this will be part of a clinical trial.   
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5.2.4.2  Intervention arm 
The intervention consisted of an audiovisual patient information tool (AVPI) which 
addressed both generic and cancer site-specific clinical trial information, with a particular 
focus on randomisation.  It aimed to complement the written information sheet received by 
the patient about a specific trial, and was administered in addition to standard practice, as 
described above.   
 
The AVPI was developed by clinical and technical staff within the acute division of NHS 
Greater Glasgow and Clyde, via a multi-professional team.  Three different versions were 
made (lung, breast and colorectal cancer) with the same core content.  Patients were 
given the AVPI to watch at home:  there were three different formats (video, CD-ROM, 
DVD) to allow for patient preference and availability of equipment at home.  The process 
of developing the AVPI is described in detail in Chapter 6. 
 
5.2.5 Primary endpoint 
The primary study endpoint was the percentage of patients who declined participation in 
the clinical trial that was offered to them. Based on the literature, as discussed in Chapter 
2, it was assumed that 40% of patients refuse participation in cancer clinical trials. Given 
that assumption, the power calculation indicated that, and in order to have an 80% chance 
of detecting a 20% difference at the 5% significance level (two-sided), a total of 164 
patients were required (Machin et al. 1997, p45-table 3.1).  This number would then detect 
a reduction in refusal rate from 40%-20%.  This sample size also provides approximately 
80% power to detect a moderate standardised difference of 0.45 between continuous 
variables such as knowledge and anxiety scores.  
 
5.3 Co-ordination of the study 
The study was planned, initiated and led by the Cancer Consultant Nurse (CCN) for NHS 
Greater Glasgow and Clyde as Principle Investigator, with the support of a Research 
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Practitioner (RP) for patient recruitment and data collection. During periods of absence of 
the RP, the CCN exercised the responsibility for recruitment and data collection. A multi-
professional steering group (also known as the study team: Appendix 5.1) was set up to 
oversee and steer the project throughout its duration, and was chaired by the CCN.  The 
steering group consisted of the Professor of Medical Oncology, Research Practitioner, two 
patients who had previously participated in a randomised clinical trial, and the lead 
medical consultants and nurses for breast, lung and colorectal cancer at The Beatson 
West of Scotland Cancer Centre.  The lead for clinical psychology was involved – mainly 
by email, owing to staff shortages within clinical psychology. 
 
5.4 Sample 
Sampling was carried out at The Beatson West of Scotland Cancer Centre during January 
2005 until August 2006. 
Patients were eligible for the study if they: 
• had a diagnosis of colorectal, breast or lung cancer; 
• were clinically eligible for entry into a cancer treatment trial randomised against 
control/standard treatment, or best supportive care, running at the cancer centre; 
• had access to a video recorder, CD-ROM or DVD playing facilities; 
• could understand English. 
 
It is recognised that optimal practice would require the development of information in 
appropriate languages, in addition to English.  However, due to issues of cost and 
feasibility, it was decided in this study to use English only.  It was anticipated that, if the 
intervention proved to be a useful resource, translation would be considered for any future 
work. 
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All clinical trials for breast, lung and colorectal cancer which involved randomisation 
against control/standard treatment, or best supportive care, running at the cancer centre 
during the recruitment period, were identified for inclusion in the study (Appendix 5.2).  
 
5.5 Raising awareness 
Following identification of the clinical trials to be included, there was discussion with the 
tumour site-specific teams involved in the recruitment process for those trials.  These 
discussions involved registrars and consultants, clinical nurse specialists (CNSs) and data 
managers; they were carried out on a one-to-one basis for those directly involved in the 
consent process, and also as a group at team meetings. Nurses in the relevant wards 
were given both written and verbal information about the study at their regular ward 
meetings.  The aim of discussions was to ensure high awareness of the project and also 
to enlist support in the recruitment process.  Information about the study was made 
available through the intranet on The Beaston West of Scotland Cancer Centre website 
(which included the option to view the AVPI), and via the internet where study information 
could be viewed externally on the website.  
 
5.6   Patient recruitment  
5.6.1 Timeframe and targets 
The timescale for recruitment was estimated at 12-18 months based on numbers of 
patients entering randomised clinical trials in the six months prior to the commencement of 
the AVPI study.  It was recognised that recruitment would be dependent on the numbers 
of randomised trials open at the cancer centre, and that this would fluctuate due to the 
nature of multicentre clinical trials, with some trials inevitably opening or closing earlier or 
later than initially anticipated. A graph of recruitment targets based on an 18 month 
timeframe was produced, with a target of 9.1 patients per month to meet the overall target 
of 164 patients by June 2006.  Every month, recruitment rates were mapped against the 
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target.  Cumulative monthly recruitment targets for the duration of the study are shown in 
Figure 5.1 along with the actual numbers of patients recruited.   
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Figure 5.1. Monthly recruitment targets 
 
The overall target of 164 patients was reached by June 2006 but as the graph shows, 
recruitment continued until August 2006 to take into account the 9 patients that were 
replaced, as discussed in Section 5.6.4.   
 
There were a number of patients who had been entered into randomised clinical trials but 
had not been considered for the AVPI study because the RP was unaware of them.   
These patients were referred to as ‘missed’ patients.  In addition, to mapping the number 
of patients recruited to the study against the target figure, the data manager collated a 
monthly list of these missed patients.  Every month, the RP and the CCN reviewed 
recruitment figures, and the list of missed patients, to determine ways of preventing similar 
patients being missed in the future.  The majority of patients considering participation in a 
cancer clinical trial are routinely seen in the out-patient clinic, although some patients do 
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take part in this discussion in the ward.  In this study, it was anticipated that patients would 
come from both areas. The recruitment review process showed that, overall, 
approximately 75% of potential patients were identified for the AVPI study (337/450), with 
the majority of those missed, receiving care in ward areas.   Action that was taken as a 
result of identifying missed patients was additional education to ward areas, and with 
clinicians, to increase awareness of the study and of the process for referral of potential 
patients.  
 
Clinically eligible patients who were missed for the AVPI study, and who were not entered 
into a clinical trial (usually because of patient refusal), would be difficult to identify.  It is 
recognised that the process adopted for reviewing missed patients would not identify this 
group of patients, which was anticipated to be relatively small in number because of the 
active recruitment strategies employed in this study. Taking into account the reported 
clinical trial refusal rates from the literature, numbers of patients consenting to a clinical 
trial that were being missed in the AVPI study, and also the fact that monthly recruitment 
rates to the AVPI study were acceptable, no further action was taken to try and identify 
this group.  
 
5.6.2 Recruitment process 
Potential participants for the AVPI study were identified by the researcher from weekly 
clinic lists, discussion with clinicians, and by attending clinics and reviewing patient case-
notes. Clinicians, CNSs and data managers were given contact details for the RP/CCN 
and encouraged to phone if they had a potential AVPI study patient.  Weekly contact with 
clinicians was made to maintain the intensity and profile of the study and to optimise 
awareness of potential new patients.  
 
Patients were approached for the study by their clinician, at the same consultation visit to 
discuss the clinical trial.  Patients were not approached if subsequent clinic appointments 
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(including the visit to discuss their decision about entry into the clinical trial) were 
expected to be arranged outwith the cancer centre.  This was mainly for practical reasons 
since, due to the commitments of the study at the cancer centre, it would not have been 
possible for the RP or the CCN to attend outlying clinics.  It was considered important to 
limit the number of people involved in administering the questionnaires, in order to reduce 
variation and maintain consistency in approach.  For this reason, nurses in the outlying 
hospitals were not approached or asked to see patients for the purposes of this study.  
 
If the patient was willing to have further discussion about the AVPI study, the clinician or 
RP/CCN checked that they had access to video, DVD or CD-ROM playing facilities, and a 
follow up discussion was undertaken by the RP/CCN. An information sheet (Appendix 
5.3), and consent form (Appendix 5.4) for the AVPI study, which were developed 
according to requirements of the West Research Ethics Committee in relation to format 
and content, were given as a separate pack from the clinical trial information sheet and 
consent form.   
   
5.6.3 Screening 
In order to achieve the target number of patients for the study, 450 patients were 
potentially eligible from case-notes and clinical trial entry sheets: of these, 113 were 
identified retrospectively as having been missed/not referred for the AVPI study; 98 were 
not approached (85 because they were known to be receiving care outwith the cancer 
centre, and 13 mainly because they were considered too upset to be approached - see 
Section 5.6.3.2); 56 patients refused the AVPI study; and 3 patients were excluded as a 
result of the eligibility criteria (see Section 5.6.3.1).  It was not possible to approach 7 
patients who had consented to their cancer clinical trial at the same medical consultation 
that they received information about the trial.  This was an unexpected situation since 
standard ethical practice for the consent process in clinical trials, which is supported by 
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the cancer centre, is to allow at least 24-48 hours after patients receive the information 
before they make the decision about whether or not to participate in the clinical trial.  
 
As already mentioned in the previous section, a large number of the missed patients were 
inpatients.  Despite the additional education and awareness-raising sessions for ward 
staff, the majority of potentially eligible ward patients were still not identified and referred 
for the AVPI study.  It is difficult to know why this is the case but it could have been 
because the ward staff were busy with higher priorities related to patient care.  It is 
recognised that the presence of the RP or CCN in the ward may have helped to identify 
potential patients.  This was not undertaken because larger volumes of potential study 
patients were attending the clinics and it was considered that time was better spent 
focussing on recruitment from these areas. 
 
5.6.3.1 Exclusions  
Three patients were excluded from the study: two because they did not have access to 
video, DVD or CR-Rom playing facilities, and so they did not meet the eligibility criteria; 
and the other because she was deaf and unable to lip-read.  
 
5.6.3.2 Patients not approached for the AVPI study: 
In addition to the patients that were seen outwith the cancer centre (n=85), there were a 
small number of patients (n=13) who were not approached for the study for other reasons.  
This decision was made by the clinician, specialist nurse or the RP/CCN, primarily 
because of the patient’s degree of distress as a result of being given bad news, or 
uncontrolled symptoms from their disease as shown in Table 5.1. 
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Table 5.1. Patients not approached for the AVPI study 
 
 
Reasons that clinically eligible patients were not approached 
for the AVPI study 
 
 
Number of patients 
Receiving care/treatment discussions outwith cancer centre 85 
Considered by the clinician, CNS or RP/CCN to be too 
distraught to be approached.  
9 
Known to RP 1 
Cross for having to wait so long to be seen (breast clinic) so 
left before AVPI discussion  
1 
Needed immediate symptom control (pain) 1 
Needed an urgent investigation 1 
 
Total 
 
98 
 
 
5.6.4 Consent 
Written and verbal information about the study was given as previously described in 
Section 5.6.2. The decision was taken not to enforce the usual minimum period of 48 
hours between receiving information about a study and consenting, as it was considered 
important for the time to treatment not to be delayed.  If this time period (or longer) was 
introduced, taking into account practical implications, either the patient would be asked to 
attend for an additional visit to discuss the AVPI study, or the discussion with the clinician 
about their clinical trial would be delayed by at least one week.  Both these outcomes 
were considered by the steering group to be ethically unacceptable for patients with 
cancer waiting for treatment, and this was supported by the Ethics Committee. 
 
There was no pressure or expectation that the patient would consent to the study at the 
initial visit; however, the option was available should they wish to make the decision that 
day.  It was anticipated that some patients would choose this option to potentially give 
them more time to view the AVPI.  
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If the patient decided that day to take part in the AVPI study, he/she was randomised 
while at the clinic. If the intervention arm was drawn, a choice of video, DVD or CD-ROM 
was offered, and it was received that day to take home. If patients wished more time to 
consider whether or not to take part in the AVPI study, they were given the information 
sheet to take home with them, and a time was arranged for the RP/CCN to phone, to 
further discuss the study. If the patient then decided to participate, the RP/CCN checked 
the randomisation status, phoned the patient back with the result, and if they drew the 
intervention arm, posted out the video, DVD or CD-ROM as chosen by the patient.  All 
patients received the standard written information about the clinical trial in which they 
were considering participation. Patients who did not draw the intervention arm were 
reassured that their information needs would continue to be met by their clinical team.  
The clinical psychologist agreed to be available for staff and patient support should any 
issues arise, but this proved not to be necessary and was not accessed by either group.  If 
patients chose not to take part in the AVPI study, whether or not this was accompanied by 
the decision to accept or refuse the clinical trial, they were not approached again for this 
study. 
 
The initial target of 164 patients was reached within the anticipated timeframe; however, a 
further 9 patients were recruited to replace those who were identified at their second study 
visit as having become ineligible for the clinical trial, thus making their decision about trial 
entry hypothetical.  Hypothetical situations are not always representative of the real life 
experience and previous research has shown that patients can act differently when 
making personal decisions (Cassileth et al. 1982; Trauth et al. 2000) 
 
5.6.5 Refusal to the AVPI study 
Of the patients approached for the AVPI study (n=232), 56 refused to take part (24%). A 
large proportion of those who refused the AVPI study did not go on to enter the clinical 
trial (73%). Therefore, of those who refused the AVPI study, 27% (n=15) did go on to take 
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part in the clinical trial offered to them.  In general, a 24% refusal rate is fairly low, 
however one has to acknowledge that there may be a recruitment bias because the 
majority of refusers (73%) also refused the clinical trial.   If patients gave a reason for their 
decision not to take part in the AVPI study, this is shown in Table 5.2. 
 
Table 5.2. Reasons for AVPI study refusal 
Reason given by patient for refusing AVPI study 
 
 
Number of patients 
 
I have too much to think about/take in 13 
I don’t want any further information 8 
I have already made my decision 7 
I don't want the control arm 3 
I’m too upset 3 
I don't want the extra hassle 2 
I don't like questionnaires 1 
I feel squeamish at the thought 1 
I can't decide whether to have treatment at all 1 
No reason given 17 
 
Total 56 
 
 
5.6.6 Recruitment challenges  
There were a number of challenges recruiting to this study.  One of the main issues was 
that recruitment depended on the type of trials that were open at the cancer centre.  
Important factors included the nature of the treatments within the trial compared to ‘off 
study’ treatment options, where patients had treatment preferences.  This was particularly 
difficult when study arms were very different, for example, a standard chemotherapy 
regime being compared against a new type of drug treatment.  Another factor was the 
eligibility criteria for the clinical trial, which was particularly challenging if this was very 
restrictive, for example, excluding patients with co-existing medical conditions or 
symptoms that would be potentially exacerbated by the treatments in the trial.  In addition, 
there was only one opportunity to approach the patient, which was immediately after their 
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consultation with the clinician about treatment options, so the RP/CCN had to be present 
for this time.  This was potentially: (a) the patient’s first visit to the cancer centre; (b) when 
they were told the extent/nature of their disease for the first time; and (c) when they were 
told about disease progression.  As a result of this, patients were often very anxious and 
upset and not always receptive to further information. 
 
There were also substantial practical challenges recruiting patients from 15 medical 
consultants and their teams, with clinics often running concurrently, as well as the 
challenges associated with discussing the study in a busy out-patient setting.   
 
5.6.7 Recruitment summary  
Despite the challenges, a total of 173 patients, (target number plus those replaced), were 
recruited to the study over a period of 20 months, from January 2005 to August 2006.  A 
summary of recruitment is shown in Figure 5.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Recruitment summary 
232 Approached 
450 Patients identified for 
AVPI study 
173 Consented 
71% 
56 Refused 
24% 
3 Excluded 
1% 
98 Not approached  
 
113 Missed/not referred 
7 Consent for trial the 
same day 
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5.7 Patient randomisation 
Attention will now be focussed on the 173 patients who consented to take part in the AVPI 
study.  Following consent, patients were randomised to intervention or no intervention 
(1:1) by the data manager in the Cancer Research UK Clinical Trials Unit (CTU), from the 
information completed by the RP/CCN on the Registration Form (Appendix 5.5).  Figure 
5.3 shows the patient pathway through randomisation.   
 
Stratification was used to increase the statistical power of the study and to promote 
statistical conclusion validity (Shadish et al. 2002, pp45-46). 'Minimisation' is a method of 
adaptive stratified randomisation which is used in clinical trials, as described by Pocock 
and Simon (1975). Connolly and Low (2000) advise that socio-demographic and 
socioeconomic factors are considered in the planning stages of a trial, however, due to 
the inconsistencies in the literature across studies as discussed in Chapter 2, it is 
acknowledged that this needs to be on an individual trial basis taking into account the 
clinical context.  In light of this, the age and sex of the patient, in addition to the tumour 
type and trial were agreed as factors for stratification. The study was stratified for 
individual trial, tumour type, age and sex using the minimisation method, which was 
implemented in the CTU’s Oracle database.   
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Figure 5.3. Patient pathway through randomisation 
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5.8    Data collection 
Patients were seen on two occasions for the purposes of this study. These visits were part 
of patients’ general medical care, as they were attending the hospital anyway on these 
days.  These are known as ‘Visit 1’ (explanation of the clinical trial) and ‘Visit 2’ (return 
visit, usually 1 week later, to discuss decision).   Data was collected at both time points via 
structured questionnaires.  
 
A quantitative approach to data collection was employed in this study for two main 
reasons. 
(a) The primary endpoint was concerned with determining a causal relationship (between 
patient understanding and clinical trial refusal rates).  This could not be addressed using 
qualitative data. 
(b) For the other study objectives, there is already substantial evidence in the literature, 
particularly in relation to knowledge and anxiety.  It was considered that by using 
questionnaires to determine knowledge, anxiety, and factors affecting the clinical trial 
decision, this would enhance the evidence already available within the specific context of 
this study.  Knowledge would not be easily assessed in a qualitative setting and there are 
already well established tools available for assessing anxiety and for assessing factors 
affecting the clinical trial decision, which were used in this study. 
 
5.8.1 Measures/instruments 
In addition to the log sheet which contained mainly demographic data, three different 
questionnaires were used, as per Table 5.3, to measure understanding (referred to as the 
knowledge questionnaire), anxiety and factors affecting decision making.  These tools will 
now be described.  
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5.8.1.1 Log sheet  
Demographic data on all patients who were approached for the AVPI study was collected 
by the RP/CCN and entered into a log sheet (Appendix 5.6). Data collected was: code for 
potential clinical trial; patient name; diagnosis; stage of cancer; date of birth; referring 
consultant; clinician describing trial to patient at visit 1 and at visit 2; and whether or not 
the patient was then entered into the clinical trial.  Information about the patient’s gender 
was collected on the Registration Form (Appendix 5.5). Deprivation status was 
determined according to deprivation categories measured by the Carstairs scores for 
Scottish postcode sectors (Carstairs and Morris 1991) using data from the 2001 census 
(McLoone 2004).  Patients’ post code details were available from the knowledge 
questionnaire. 
 
5.8.1.2 Knowledge questionnaire (Questionnaire: Patient Understanding of Research)  
This is a new questionnaire developed for the purposes of this study to assess patient 
understanding of research, with a particular focus on randomisation, as there is currently 
no appropriate validated tool available.  The questionnaire was developed from the 
literature, and with patient and professional consultation. It was then tested with patients 
and nurses, and as a consequence small changes were made prior to usage in the main 
study.  The final questionnaire that patients completed at baseline (visit 1) and at visit 2 is 
shown in Appendix 5.8. The development and testing of the questionnaire is described 
and discussed in detail in Chapter 7. 
 
5.8.1.3 Assessment of anxiety (STAI-S) 
There are several well established tools available to assess patient anxiety.  In order to 
select an appropriate measure for this study, the literature was reviewed to determine 
which instruments were most commonly used within the clinical trial setting.  Sesti and 
Arbor (2000) reviewed the Medline and Health and Psychosocial Instruments databases 
from 1966 and 1985 respectively, and found that the measures most commonly used in 
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medication clinical trials were the Hamilton Anxiety Rating Scale (HAM-A), the Covi 
Anxiety Scale, the Hospital Anxiety and Depression Scale (HADS) and the State-Trait 
Anxiety Inventory (STAI).  The first two are clinician-rated, and were therefore excluded as 
potential instruments for this study, as it was considered important to assess anxiety from 
a patient perspective.  
 
The HADS is a 14 item self-report questionnaire which contains 7 items measuring 
depression and 7 measuring anxiety. It has been used as part of quality of life 
assessments in clinical trials, and is popular in the cancer setting in randomised trials of 
two or more treatments, where a wider psychological assessment than just anxiety is 
warranted.  The HADS is often used with physical symptom questionnaires, such as the 
Rotterdam Symptom Checklist, or quality of life questionnaires, such as the EORTC QLQ-
30. 
 
The Spielberger State-Trait Anxiety Inventory (STAI) is a self-report measure, which is 
concerned fully with anxiety and distinguishes between state anxiety (how one feels at the 
moment) and trait anxiety (how one generally feels).  The vast majority of studies on 
informed consent, and also clinical trial recruitment interventions which investigate 
anxiety, have used the STAI, allowing comparisons to be made across studies.  In 
addition to being used in many clinical trial settings, the STAI has been used in studies 
aimed at increasing knowledge, including those using video (e.g. Agre et al. 1994; Luck et 
al. 1999).   
 
The STAI is composed of two scales: 20 items measuring situational or state anxiety 
(STAI-S) and 20 items for trait anxiety (STAI-T).  ‘State’ anxiety refers to situational 
feelings such as apprehension, tension, nervousness and worry, whereas ‘trait’ refers to 
general feelings of anxiety-proneness (Sesti and Arbour 2000).  State anxiety refers to a 
palpable reaction or process taking place at a given time and level of intensity 
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(Spielberger 1983).  The STAI-S has been widely used to assess the level of state anxiety 
induced by stressful experimental procedures and also real life stressors such as surgery, 
job interviews and exams (Spielberger 1983). 
 
The STAI was the measure chosen to assess anxiety in this study, because the tool is 
well established and validated within the clinical trial setting, it has been widely used in 
informed consent and clinical trial recruitment studies, and also because it focuses solely 
on anxiety, with the particular advantage of being able to focus on state anxiety. 
 
The use of the STAI-S scale without STAI-T can be justified in this study, as the trait 
anxiety levels of the two study groups would be expected to be similar since the study is 
randomised. In addition, all patients with cancer will experience anxiety to some degree 
but the study is assessing the difference (if any) in anxiety as a result of the intervention 
+/- its effect on understanding. Anxiety was therefore assessed at the same time as 
understanding (at baseline and at visit 2) and decision making (visit 2), to investigate 
whether the AVPI had any effect on anxiety levels. 
 
The STAI-S consists of 20 items that evaluate how respondents feel ‘right now, at this 
moment’.  Individuals respond to each item on a 4 point Likert scale, indicating the 
frequency with which each strategy is used. The average time to complete it is minimal at 
6-10 minutes. Sample questions from the scale are shown in Appendix 5.9.  Permission 
was obtained from the publishers (Mind Garden), and questionnaires were purchased for 
use in this study.  
 
Scoring was carried out according to guidance in the manual (Spielberger 1983).  Each 
STAI item is given a weighted score of 1-4.  A rating of 4 indicates the presence of a high 
level of anxiety for 10 of the STAI-S items and the absence of anxiety for the other 10 
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items. Scores are then added together for all 20 items with overall scores varying from a 
minimum of 20 to a maximum of 80. 
 
5.8.1.4 Clinical Trial Decision Questionnaire 
The Clinical Trial Decision Questionnaire (CTDQ) is a two-page self-report form to assess 
patients’ reasons for accepting or refusing participation in the trial, perceptions of the 
consent process, and value of the AVPI (Appendix 5.10).  Patients completed this at visit 
2 only, after making their decision about whether or not to take part in the clinical trial that 
was offered to them.  Reasons for accepting or declining the trial were the main focus of 
this questionnaire.  
 
The CTDQ was designed specifically for this study, but includes the questionnaire used by 
Jenkins and Fallowfield (2000) to assess reasons for accepting and declining a trial (with 
kind permission from Dr V Jenkins). Jenkins and Fallowfield (2000) report in their paper, 
that the questionnaire was a similar design to that used by Penman et al. (1984). Jenkins 
and Fallowfield’s questionnaire was piloted on fifty patients with cancer who had agreed to 
take part in clinical trials, prior to the revised version being used in their study (Jenkins 
and Fallowfield 2000).  In the CTDQ, questions about the consent process and usefulness 
of the AVPI were derived from the literature and consultation with a panel of experts – 
clinicians and clinical trials nurses – to ensure content validity. 
 
5.8.2 Process 
An overview of the process involving the two patient visits and administration of data 
collection tools, is shown in the schedule of events table: Table 5.3. 
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Table 5.3.  Schedule of events 
 
 
VISIT 1 –  Hospital visit for initial discussion of clinical trial 
 
Discussion with potential participants for the AVPI study to determine eligibility. 
Information given about the study. 
 
Patients asked to consider the study and if desired, given further verbal information by the 
RP/CCN. 
 
1) Patient said ‘no’ 
Those who chose not to 
take part in the AVPI 
study +/- the clinical trial 
were not approached 
again. 
2) Patient unsure 
Those who wished more time to 
consider whether or not to take part 
in the AVPI study were given the 
information sheet home and a time 
arranged for the RP/CCN to phone 
them.  If they then decided to 
participate, the RP/CCN checked 
the randomisation allocation, and 
phoned back the patient with the 
result.  
 
Action was then as for ‘patient said 
yes’.  
 
3) Patient said ‘yes’ 
a)  Patients randomised to 
receive the intervention were 
asked whether they would 
prefer the video, DVD, or 
CD-ROM format. Where 
possible, they received it 
prior to leaving the hospital. 
 
b) Patients randomised to 
‘control’ were reassured that 
their information needs would 
continue to be met by the 
clinical team. 
Demographic details entered into log (Appendix 5.6). 
 
Letter sent to GP (Appendix 5.7). 
 
Patients given questionnaires to complete: 
• Knowledge questionnaire (Questionnaire: Patient Understanding of Research) 
             (Appendix 5.8) 
• STAI-S questionnaire  (Appendix 5.9) 
 
 
VISIT 2 – Decision making visit for treatment/clinical trial   
 
All patients were given questionnaires to be to be completed after their medical consultation 
and posted back to the RP/CCN: 
• Knowledge questionnaire 
• STAI-S questionnaire  
• Clinical Trial Decision Questionnaire (Appendix 5.10) 
 
Patient recruitment status (to clinical trial) was entered into a log.  
 
Record of returned questionnaires was kept (Appendix 5.11). 
 
Following questionnaire return, sheet of ‘correct answers’ to the knowledge questionnaire was 
given/sent to patients (Appendix 5.12). 
 
 
Data was collected from patient case-notes and from questionnaires.  Questionnaires 
were considered less intrusive than interviews when asking about sensitive areas such as 
reasons for acceptance and refusal. Although not assessed in this study, it is 
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acknowledged that there would be variation in the approaches of individual clinicians 
during the patient consultation in relation to factors such as the quality of the interaction 
and presentation of verbal information about the trial (Albrecht et al. 2003). However, the 
written information provided routinely, would be consistent.   
 
It was also acknowledged that there could be variation across patients for factors such as 
previous education, age, preference for method of information (e.g. AVPI v’s written). In 
anticipation of this, the randomised study design was chosen to minimise effects of any 
unanticipated confounding variables.  Other variables included were patient demographic 
details, previous education and research experience.   
 
Patients agreeing to take part in the AVPI study were allocated a study identification (ID) 
number which was then used in all subsequent trial documentation.  
 
5.8.3 Data entry 
Data from the registration form, log sheets and the patient questionnaires were entered 
into the Oracle database and SPSS (version 15, running on Windows XP). The data was 
entered by an experienced data manager and then checked by a clerical officer via 
comparison with the original data collection forms, as per the standard procedure within 
the clinical trials department.  All data fields were numbered according to a predetermined 
coding system. Once the details from the registration form were entered, the patient’s 
unique study number and randomisation result were allocated, and a set of data entry 
forms for the patient was automatically generated, along with a diary highlighting 
forthcoming patient visits and data collection time points.  Security checks were built into 
the system, such as each page having a number of patient identifiers including the 
patient’s unique study number, treatment allocation, and their initials, as well as password 
protection for the users.  Features to enhance accuracy, in addition to the data checking, 
were drop-down menus giving options rather than free text (e.g. for the parent study that 
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the patient was considering), and the RP/CCN had to check and sign-off patient study 
forms, prior to the second data check, if this had not already been done prior to data entry. 
 
5.9  Analysis 
Analysis was carried out on the entered data as described below. 
 
5.9.1 Primary endpoint:  clinical trial refusal rates 
The main comparison between the study arms, in terms of the primary endpoint, was 
performed using logistic regression using all randomised patients.  An attempt was made 
to incorporate minimisation factors used at the time of randomisation into the logistic 
regression, but the high degree of confounding between gender, tumour type and study 
meant that, of these, only age and gender could be used.  The odds ratio was derived 
from the logistic regression and the p-value for the comparison derived by the likelihood 
ratio method.  The association between baseline patient characteristics and study entry 
was also assessed in the context of a logistic regression model. 
 
5.9.2 Knowledge/understanding 
The change in knowledge score from baseline was compared between the two groups 
using the Mann-Whitney U test (the knowledge score is the number of correctly answered 
questions expressed as a percentage mark). The statistical significance of within-patient 
changes in knowledge score in each group was assessed using the Wilcoxon signed-rank 
sum test.  An assessment of the prognostic value of various baseline characteristics for 
change in knowledge score was assessed in the context of a linear model incorporating 
the study arm; the dependence of the prognostic value on the study arm was assessed by 
incorporating the appropriate interaction term. Multiple imputation (Rubin 1987) was 
applied to assess the robustness of the results of these analyses to missing data. 
Bootstrap methods were used to estimate the difference in median changes and 
associated 95% confidence intervals. 
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The association between baseline characteristics and baseline knowledge levels was 
assessed using the Mann-Whitney U test (2 categories), Kruskal-Wallis test (>2 
categories) or, for age, Spearman’s rank correlation. 
 
5.9.3 Anxiety 
A parallel analysis to that described for the knowledge score was conducted for the 
anxiety score.   
 
5.9.4 Reasons for accepting and declining clinical trial participation 
Reasons for accepting and declining clinical trial participation were tabulated, and the Chi-
square test used to compare the frequency of each reason in the two groups. Patients’ 
perceptions of the consent process were tabulated and the Chi-square test used to 
compare the frequency of each reason in the two groups. 
 
5.9.5 Patients’ perceptions of usefulness of the AVPI 
Descriptive statistics were employed, using frequencies to determine patients’ perceptions 
of usefulness of the AVPI. 
 
5.10 Ethical considerations 
5.10.1 Protocol approval 
Prior to initiation of the study, the protocol was submitted to the West Research Ethics 
Committee, the Research and Development Department within NHS Greater Glasgow 
and Clyde, and the Department of Nursing and Midwifery Research Ethics Committee at 
the University of Stirling. Following review by the West Research Ethics Committee, the 
patient information sheet required small amendments to the wording, in addition to 
changes to the knowledge questionnaire, to simplify the wording.  When this was 
undertaken, the protocol received full ethics approval. Minor changes were required as a 
result of review by the University ethics committee: they included clarification of the 
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recruitment process and simplification of the flow diagram showing the randomisation 
process. 
 
The protocol was also submitted to, and approved by, in-house (The Beatson West of 
Scotland Cancer Centre) research committees – specifically, the Internal Trials Advisory 
Board (ITAB) and the Clinical Trials Executive Committee (CTEC).   
 
The study was conducted within the Research Governance Framework of NHS Greater 
Glasgow and Clyde, and was run according to internationally agreed Good Clinical 
Practice Guidelines (ICH 1996). The Declaration of Helsinki was followed where relevant 
(World Medical Association 1964, 2004). 
 
5.10.2 Patient information and support 
Patients considering cancer clinical trials are potentially very vulnerable, and there was 
the possibility that, as a result of completing a questionnaire on decision making about the 
trial, more questions would arise, and patients would need additional support.  Provision 
of additional support was made available from their own medical clinician, and also from 
the Clinical Psychologist. The AVPI study information sheet advised patients to contact 
their own clinician, should they have any issues.  In addition, the potential for issues was 
highlighted to clinicians and CNSs who were vigilant in assessing the need for additional 
support, although in reality this proved not to be required.  The patient’s GP was also 
informed about the study (See Appendix 5.7). 
 
The AVPI written information sheet and consent form contained the essential elements for 
informed consent, as required by the ICH Good Clinical Practice (GCP) guidelines (ICH, 
1996).  Contact numbers were given for the Cancer Consultant Nurse and the Research 
Practitioner, and the patient was advised that their GP would be informed. 
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5.10.3 Questionnaires 
Patients were given each questionnaire only once at each time point.  Questionnaires 
were kept short and user-friendly to minimise the burden on the patient.  Although the 
patient was given three questionnaires at the same time point, it was anticipated that they 
should take no longer than 15-20 minutes, in total, to complete.  After completing the 
knowledge questionnaire at visit 2, all patients received a copy of the ‘correct’ answers in 
an attempt to correct any misconceptions that still existed. 
 
5.10.4 Confidentiality 
Confidentiality was respected at all times throughout the study, with adherence to the 
Data Protection Act (Department of Health 1998) and compliance with the NHS Scotland 
Code of Practice on Protecting Patient Confidentiality (Scottish Executive 2003). 
 
The only information that contained patients’ names was the demographic log sheet. This 
was considered necessary to ensure that the correct patients were followed up at visit 2.  
This log was kept in a locked drawer in the CCN’s office. All other study information, 
including returned questionnaires, was kept in a separate locked cupboard. Patients were 
informed in the written information sheet that demographic details would be collected. The 
information sheet also included reassurances about anonymity and confidentiality. 
 
Patients were allocated a Study Identification (ID) number. This was used on all 
questionnaires, and made it possible to link them to the demographic data, which was 
entered into the computer without the patient’s name or hospital number. Electronic 
information was password-protected.  The computer in the CCN’s office, to which no-one 
else has access, was used, in addition to a computer in the RP’s office and in the Clinical 
Trials Unit.  These offices were locked when vacant. Following completion of the study, 
the data was stored and destroyed in accordance with Standard Operating Procedures in 
the Clinical Trials Unit, specifically No 002, Filing and Archiving of Clinical Documentation.  
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5.11 Timescales  
A work plan with approximate timescales was drawn up as shown in Table 5.4 as a guide 
for the steering group and this was adhered to throughout the duration of the study 
 
Table 5.4.  Study work plan  
Extended literature review 3 months 
Development of questionnaires 2 months 
Ethics submission 4 months 
Develop and test video 4 months 
Pilot study of knowledge questionnaire 6 months 
Training for Research Practitioner 2 weeks 
Informing staff about study 1 month 
Data collection  12 -18 months 
Analysis 4 - 6 months 
 
 
5.12 Costs and funding 
5.12.1 Costs 
Approximate costs were calculated for the project and these are shown in Table 5.5.  The 
majority of costs were associated with developing, filming and producing the intervention. 
 
Table 5.5. Costs 
Item Cost (£) 
Consumable costs such as paper, envelopes and ink  met by department 
Time required by Research Practitioner for data collection, and Clinical 
Trials Unit input in relation to randomisation  
met by department 
(a) Returning of consent forms (prepaid envelope - estimated as 
necessary for half of study population, n=82) 82 x £0.28   
(b) Sending out video/DVD/CD-ROMs (estimated as necessary for a 
quarter of study population, n=41) 41 x £0.69 (packaging) + 41 x 
£1.15  (postage)  
(c) Returning questionnaires (all patients) 164 x £0.28 
22.96 
 
75.44 
 
 
45.92 
Videos/DVD’s/CD-ROMs. Filming and production costs (includes 
Medical Illustration, actor and music license)  
5,400.00  
Data management 499.72 
Permission rights for STAI 200.00  
 
Total Costs 
 
£6,244.04  
 
5.12.2 Funding 
Full funding for the study was secured, with £6,044 from the Chief Scientist Office as a 
Cancer Programme Support Grant, and £200 from The Beatson West of Scotland Cancer 
Centre Fund to cover permission rights for the STAI questionnaire. 
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CHAPTER SIX:  DEVELOPING THE INTERVENTION 
 
6.1   Introduction 
The aim of this chapter is to discuss the development of the study intervention, which was 
audiovisual patient information (AVPI), in the form of a video, DVD and CD-ROM. The 
purpose of the AVPI was to inform patients about randomised controlled trials, as a 
supplement to their trial-specific written information sheet.   
 
6.2 Background 
Audiovisual patient information is known to be an effective way of informing patients about 
treatment, as discussed in Chapter 4.  Nurses are key providers of patient information in 
many areas of clinical care, and are becoming more and more involved in developing it 
(Strachan 2004).  They have a crucial role in ensuring that the information is accurate, 
appropriate to the patient and useful.  However, most nurses have never been taught how 
to develop patient education materials, and there is limited research evidence in the 
literature, which focuses on the materials-development process.  What is available tends 
to focus on speciality-specific written information and on assessing readability (Griffen et 
al. 2003).   Less attention, however, has been given to developing other formats such as 
the audiovisual route.   
 
In relation to AVPI, most articles briefly discuss the development of the video as part of an 
intervention study designed to assess the effectiveness of the AVPI, often in terms of 
increasing knowledge.  Minimal attention is given to the process of development itself, and 
to the quality of the resultant production.  An exception to this is the work by Carey et al. 
(2007), who adopted a systematic approach to the development of audiovisual materials 
for oncology patients.  They examined literature relating to the preparation of patients for 
potentially threatening medical procedures, psychological theory, the theory of innovation 
diffusion, and patient information. From this, they identified four key principles as being 
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important: stakeholder consultation; provision of information to prepare patients for the 
procedure; evidence-based content, and promotion of patient confidence. They then used 
this to develop an audiovisual resource to prepare patients for chemotherapy treatment.   
 
Steinke (2002) also describe the development process, in this case for a videotape 
intervention for sexual counselling after myocardial infarction. This paper provides useful 
practical guidance, and highlights the importance of patient involvement throughout the 
process. Production challenges are described in another publication, and include issues 
such as copyright, intellectual property and establishing content validity of the video-script 
(Steinke 2001).  
 
In cancer education, Meade (1996) reviewed the literature and describes a systematic 
process for producing videotapes for cancer education and research.  This work highlights 
practical aspects such as budget considerations, script development, narration and 
location, as well as the importance of involving members of the target audience 
throughout the development process, which in the AVPI study would be patients eligible 
for randomised cancer clinical trials. 
 
Several authors/organisations have produced generic guidance for developing patient 
information, mainly focussing on written approaches: for example, the Scottish Executive 
Guidelines for writing patient information (2001c), local hospital policies, and the step-by-
step guide for producing patient information literature written by North et al. (1996), all of 
which provide useful practical advice. The Macmillan Information Materials Guide 
(Macmillan Cancer Relief 2003), although focussing predominantly on written materials, 
does offer some support for nurses in developing other formats, advising on issues such 
as structuring the production and copyright.  
 
 177 
Developing audiovisual patient information is still a relatively new role for nurses and, 
although the literature was used where relevant in this study, a lot of the process which 
will now be discussed was dependent on clinical and technical expertise of the staff 
involved. 
 
6.3 Development of the AVPI 
Development of the AVPI involved staff and patients working together to achieve the 
overall aim of ensuring that the end-product was user-friendly and fit for purpose – to 
inform patients about randomised controlled trials, as a supplement to their trial-specific 
written information sheet.  There were many components of the development process 
which will be discussed under the headings of: content; logistics and organisational 
issues; patient involvement; ethics; finance; script; filming; editing and copyright. 
 
6.3.1 Content of the AVPI 
Although it was considered important to deal generally with the concept of clinical trials in 
the AVPI, and focussing particularly on randomisation, in order to meet the aims of the 
study, it was also considered important for patients to identify personally with the content.  
Three separate AVPI productions for the three cancer types involved in the study – lung, 
breast and colorectal – were produced. Most of the core content was identical, but each 
version was also tailored to the individual cancer type.  In view of increasing availability of 
DVD and computer technologies to the general public, the production was made available 
in both DVD and CD-ROM format, in addition to video, to allow patient choice depending 
on preference and availability of technology at home.  Although AVPI could potentially 
also be made available to patients as web-based information via the internet, this 
approach was not pursued, in light of the common complaints reported with this 
technology, such as the inability to open video clips and the length of time needed to load 
each page (Cumbo et al. 2002). In addition, many patients do not have access to 
Broadband technology which would be a necessary requirement.  
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6.3.2 Logistics and organisational issues 
The steering group set up for the purpose of the study (as described in Chapter 5, Section 
5.3) was responsible for overseeing the development of the AVPI.  The steering group 
provided the stakeholder consultation aspect discussed by Carey et al. (2007).  Expertise 
was also sought, where appropriate, from the lung, breast and colorectal cancer lead 
medical consultants and specialist nurses, a radiographer-counsellor, and clinical trials 
unit personnel.  Ethical advice was sought from the Professor of Clinical Oncology, who 
previously chaired the Local Research Ethics Committee.  In addition, guidance was 
directly sought from two patients who had previously participated in a randomised cancer 
trial; they commented on various drafts of the scripts, as did members of the steering 
group.  As well as participating in the work of the steering group, the patients also 
contributed through separate meetings with the CCN and RP as described in Section 
6.3.3.  The steering group guided all aspects of developing the AVPI: for example, the 
decision to include a visual description of ‘randomisation’ by using images of flip charts 
showing medications, and also the decision to involve clinicians speaking in the 
production, in addition to the actress-presenter.  
 
There was also a dedicated operational project team with the specific task of developing 
the intervention.  This team dealt with logistics and numerous other related issues such 
as: ethics; finance; scriptwriting; filming; editing and intellectual property rights which will 
be discussed later in the chapter.   The operational project team consisted of three nurses 
undertaking the functions of (1) project lead, (2) script writer, (3) director and (4) co-
ordinator (Table 6.1), all of them working in conjunction with a professional actress and 
the hospital’s Medical Illustration Department. 
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Table 6.1.  Roles of nurses directly involved in developing the intervention 
Role in Project Person / Nursing role 
Project lead  Cancer Consultant Nurse 
Script writer Cancer Consultant Nurse and  
University Lecturer/Researcher 
Director University Lecturer/Researcher 
Coordinator Research Practitioner 
 
The director, who co-wrote the script with the project lead, was a colleague of the CCN 
who had extensive previous expertise and experience in both directing and script writing, 
within and outwith nursing.  The coordinator role was crucial for ensuring planning and 
organisation of operational issues pertaining to the project. 
 
As part of the general study timetable (Chapter 5, Table 5.4), four months was allocated to 
video development.  This consisted of two months for script development and two months 
for filming, editing and production.  
 
6.3.3 Patient involvement 
There are some good examples of work where patient involvement has greatly contributed 
to high quality patient information materials (Steinke 2002 (video); Chavez et al. 2004 
(video); Paul et al. 2004 (information booklet)).  From the beginning of this project there 
was a real commitment to have patients meaningfully involved in the planning and 
development of the AVPI.  It is acknowledged that selecting the most appropriate service 
users or patients is crucial to meaningful user involvement. There is, however, no 
definitive guidance currently available on the best way to do this (Symon and Clegg 2005).  
In the absence of such guidance, Clinical Nurse Specialists were asked to purposively 
select patient representatives according to the following criteria: 
• diagnosis of lung, breast or colorectal cancer – one patient from each of the 
cancer sites being addressed in the AVPI; 
• experience of taking part in a randomised cancer trial; 
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• willing to attend meetings to discuss the script and the AVPI production itself, also 
to comment on draft work outwith the meetings.  
 
The advice sheet ‘Top tips for effectively involving and recruiting patients and carers’ 
developed by the Picker Institute Europe and the NHS Modernisation Agency Clinical 
Governance Support Team was used as a guide for patient involvement (Picker Institute 
2008). Patients were asked to represent their cancer group in addition to personal 
interests, and effectively to act as key informants and expert advisors to the project.  It 
would have been preferable to have involved more than one patient from each cancer 
group, but this was not possible, as logistics and timescales necessitated a quick 
turnaround of script development and production. 
 
A preliminary meeting was arranged outwith the hospital setting, so that the project lead 
and coordinator could meet with the patients to discuss the project and elicit their thoughts 
on a very early draft of the script. Two of the three patients identified by the specialist 
nurses participated. The identified patient with breast cancer was keen to be involved, but 
in the event was unable to participate due to personal circumstances.   
 
Both of the patients involved had previously taken part in a randomised cancer trial, one 
for lung cancer, the other for colorectal cancer.  One was currently receiving treatment as 
part of a clinical trial.  One of the patients was involved in professional film production (this 
was initially unknown to the specialist nurse and the project team), and he had a wealth of 
experience which he was keen to share, in addition to what he could contribute from a 
patient perspective.  Over time, several drafts were discussed with the patients, which led 
to very useful changes in visual images and wording.  An example of this was the cutting 
of scenes showing treatments being prepared under sterile conditions in pharmacy labs, 
where staff wore gowns, masks and gloves.  These images were considered ‘scary’ and 
unnecessary by the patients. 
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6.3.4 Ethics 
6.3.4.1 Ethics review 
Since the AVPI was part of a research study, a full ethics submission had to be 
completed, as discussed in Chapter 5, Section 5.10. This included an outline of the 
subject areas to be covered in the AVPI, developed from the literature, Good Clinical 
Practice Guidelines for clinical trial information-giving, and expert opinion.  The study 
protocol made provision for a previous chairman of the ethics committee to review the 
draft script prior to filming, and to ensure that the content was objectively balanced. This 
review resulted in minor changes to some of the wording to the final script prior to filming. 
The Ethics Committee were happy with the outline presented to them and did not ask to 
review the full script or the final AVPI prior to it being used in the study. 
 
6.3.4.2 Consent 
Written consent for filming was obtained from all patients and staff participating in the 
production, whether they had speaking parts, or whether they were filmed as part of the 
foreground or background.  No staff refused to take part.  One patient and her family were 
reluctant to be filmed as part of a background scene, and subsequently were not 
consented, nor filmed. 
 
6.3.4.3 Protection of images 
The Medical Illustration Department were requested to return all images (both used and 
unused takes) to the project lead for safe, locked storage, and provided a written 
agreement that images had not, and would not, be used by them for any other purpose.  
This was primarily to ensure the protection of the images due to ethical requirements 
regarding consent, confidentiality and storage. It was also considered important to be able 
to certify that the images developed, obtained and co-ordinated for the purposes of the 
AVPI remained unique and were not then utilised by others in subsequent AVPIs or other 
health care materials.    
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6.3.5 Finance 
As discussed in Chapter 5 (Section 5.12), funding for the study was secured from the 
Chief Scientist Office as part of a Programme Support Grant.  The majority of funding was 
budgeted to cover the costs of developing the AVPI, including medical illustration costs, 
actress, props, and the music licence for the soundtrack. 
 
6.3.6 Script 
6.3.6.1 Content and writing 
The main function of the AVPI was to give people information to help them understand 
more about randomised cancer trials.  Patients would be receiving the AVPI at the same 
time as they received written information about the specific randomised trial that they were 
considering taking part in.   
 
The broad outline for the structure and content of the AVPI, as well as the detail for the full 
script, was developed from the following sources:  
• International Conference on Harmonisation (ICH) Good Clinical Practice 
Guidelines (ICH 1996);  
• Scottish Executive Guidelines for Patient Information (Scottish Executive 2001c); 
• patients/users; 
• existing written patient information about clinical trials; 
• the literature;  
• discussion with expert clinical trials nurses and clinicians.    
 
Areas covered in the AVPI include: how drugs/treatments are developed; importance of 
clinical trials; what randomised trials are and when they are carried out; criteria for taking 
part; benefits/disadvantages of taking part in a randomised trial; funding issues; 
voluntariness of decision and freedom to withdraw at any time.   
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Additional creative writing was used to demonstrate the difficult concept of randomisation, 
which is described by the actress-presenter using flip charts with pictures of bags of 
chemotherapy as a visual aid. Within the production, to try to assist with understanding of 
the randomisation concept, several examples are given of types of randomised trials, 
including a trial where one of the arms is ‘best supportive care’.  There are pictures of 
patients receiving treatment and a voiceover describing the main principles such as that of 
uncertainty about which treatment is best (equipoise) and also emphasising that the 
doctor does not decide which treatment the patient will get.   
 
At the end of the AVPI the presenter encourages patients to consider their decision 
carefully about whether or not to take part, reassuring them that whatever they decide, it 
will be fully supported by their clinical team.  She then refers them to their trial-specific 
information sheet for further information.   
 
Content validity of the final script was established by the steering group, project team and 
the lung, breast and colorectal cancer teams, who reviewed several drafts before the final 
version – draft 6 – was ready for use.  The final script used in filming is shown in Appendix 
6.1.  
 
The Macmillan Information Materials Guide for developing new patient information served 
as a production guide for the video, including basic principles of signposting to alert the 
patient to what will be covered, on-screen graphics to make it possible for patients to read 
while they listen, and summaries of important points (Macmillan Cancer Relief 2003). 
 
6.3.6.2 Presentation and delivery 
A personable and professional local actress, someone patients would identify with, was 
considered desirable to present the AVPI on behalf of the cancer centre. The preference 
was for someone who would be slightly familiar and recognisable, but not be so well 
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known as to detract from the content.  To minimise the potential effects of mismatch of 
race and gender (Lenert et al. 2000), a female white presenter was considered desirable.  
The majority of the study sample was anticipated to be white Caucasian and a large 
number would be female patients with breast cancer.  Age was also considered, in order 
to select a presenter who patients could relate to (Steinke 2002). Because the majority of 
patients were expected to be between 40 and 60 years of age, an actress of this age was 
chosen.  An actress colleague was initially contacted, who was interested but unable to 
commit to fixed filming sessions owing to other work commitments. Numerous agencies 
were then contacted with a brief, and various actresses were offered as potentially 
appropriate.  The actress who was contracted to present the AVPI was known to the 
director, and had previously worked with her on a separate project.  This further confirmed 
suitability. 
 
During early discussions, it was determined that using autocue would speed up the filming 
by reducing rehearsal time and, more importantly, facilitate accuracy of the content, which 
was essential given the nature of the project.  The Medical Illustration Department was 
able to arrange and operate this function.  In addition, the actress was given the script one 
week in advance of filming in order to familiarise herself with the terminology and general 
ambience of the piece.  
 
6.3.7 Filming 
6.3.7.1 Clinical setting 
Filming requirements were both internal and external, with the majority of internal filming 
carried out in the clinical setting.  Internal filming took two days, and external filming half a 
day, as originally planned, although schedules were very tight.  The clinical setting was 
chosen in preference to the studio, and filming was undertaken during working hours to 
ensure that the AVPI reflected the ‘real’ clinical environment, and to avoid a ‘staged’ 
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effect.  However, this did pose substantial organisational challenges, and required 
detailed preparation.  
 
Participating clinical departments were areas that the patients would be familiar with, and 
included the out-patient department and day case clinic area, clinical research department 
(out-patient and day care), patient reception area, radiotherapy department and 
pharmacy. The clinical research department was used for the majority of the formal 
presentation in the AVPI.  All of the areas are continually busy with patients, and filming 
was scheduled in advance to work around quieter times wherever possible. Early 
involvement of clinical departments in the planning stages facilitated access to the areas 
required for filming, and also encouraged staff themselves to participate in the production. 
 
6.3.7.2 Localising the production 
In keeping with the need to ensure relevance for the three patient groups, the AVPI was 
localised by utilising clinical areas for the internal filming and involving an actress with a 
local accent.   External filming reflected city landmarks leading to the cancer centre, which 
were used at the start of the production. These were all places that the patients would 
already be familiar with, hopefully making identification more likely.  Visual images were 
supported by the title music, which also reflected the local culture and would be familiar to 
the target audience.  The lung, breast and colorectal cancer medical clinicians presented 
a short section at the beginning and end of the relevant versions of the AVPI, to provide a 
spotlight on the individual cancer type, to help maintain a clinical focus, and to make it 
instantly identifiable.  Medical involvement at the beginning and end of the AVPI was used 
because patients view medical consultants as experts and authority figures, and the intent 
was to draw viewers to the credibility and importance of the content (Steinke 2002). 
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Separate photographs were taken of the lung, breast and colorectal cancer clinical teams, 
which were used on the back cover of the AVPI packaging.  This was included to help 
patients identify with the production, as they would recognise staff involved in their care. 
Getting the teams together for these photographs proved challenging, since clinicians 
were often at clinics outwith the department.  Consequently, it took four weeks to get the 
team photographs, and it was not possible to get the group together for one sitting.  As a 
result, it was necessary to take between two and six individual/group photographs for 
each team, and to merge them together on the back cover.  The cancer treatment centre 
and a nurse/patient information-giving scene set in the day ward of the cancer centre, 
were shown on the front cover. 
 
6.3.8 Editing 
Following discussion with the Medical Illustration Department, three days were planned for 
editing:  one day for Medical Illustration to sort and number the final takes of clips from the 
26 scenes, and to digitise them; two days for the nurses directing and producing to work 
with Medical Illustration to edit the production.  As advised by Steinke (2002) it was 
essential that the nurses were involved in the editing process with Medical Illustration. In 
practice, editing took one full day longer than the anticipated three days.  This time was 
needed to improve continuity and visual effects, and was a crucial part of the process. 
 
A draft copy of the production was reviewed by the project team on two occasions.  Small 
changes were made, and then a formal viewing session arranged with the steering group.  
This resulted in minor changes to visual effects and timing of sequences. 
 
6.3.9 Copyright/intellectual property rights 
The issue of copyright was particularly challenging owing to the number of 
stakeholders/experts involved, and also because the work was being undertaken as part 
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of a university course.  The AVPI was copyrighted to the CCN as project lead, and the 
hospital’s Research and Development Office were also involved, according to the NHS 
Greater Glasgow and Clyde Policy on Intellectual Property Rights. This included a 
meeting with Scottish Health Innovations Limited (SHIL) and the preparation of preliminary 
documentation that could be progressed, pending the results of the study and future plans 
for the AVPI. 
 
As stated previously, a local cover version of a well-known song was chosen as the title 
track for the video.  Since it was a cover version of a song that was written and originally 
recorded by a different artist, permission rights had to be sought from the two record 
companies involved.  The company and artists responsible for the cover version recording 
were very supportive of the use of the track for the purpose intended, and were keen to 
see all royalties waived.  However, the company representing the original writer in the 
USA would not support this and, following negotiations, an agreement was reached which 
included the payment of royalties and use of the track for 5 years, which was limited to the 
UK.  
 
6.4 Discussion 
The study intervention was successfully developed, but there were substantial challenges 
and opportunities during the process which will now be discussed. 
 
6.4.1 Challenges 
The main challenges were centred around the financial and technical constraints, scope of 
the project, and involving a new team with varying expertise to deliver to tight schedules.  
The financial constraints led to the decision to involve the hospital’s Medical Illustration 
Department; this then led to technical constraints, specifically around sound editing and 
restricted types of filming.  Whilst Medical Illustration did have experience in audiovisual 
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information production, this was mainly focussed on developing teaching videos with 
traditional formal scripting and presenting.  These projects were usually undertaken 
entirely by the Medical Illustration Department and were developed with minimal input 
from nursing and medical staff.  This project was on a relatively large scale and required a 
developmental approach to incorporate expertise from a variety of areas (patients, 
nursing, medical, scripting and filming). 
 
Filming was difficult in some clinical areas, mainly owing to busy patient environments, but 
also as a result of small spaces with restricted access, where it was sometimes difficult to 
find appropriate camera angles.  Scenes were filmed according to location rather than 
script order, which led to some compromises in editing to address issues of continuity.  
However, this did not affect the quality of the final production. 
 
 A particular challenge in relation to expertise was in trying to harness the skills and 
talents of the nurses involved, and supporting the development of non-traditional nursing 
roles such as script-writing and film direction, whilst at the same time collaborating with, 
and valuing, the contribution of other members of the production team.  The majority of 
the team did not know each other prior to working on the project, and had to develop very 
quickly as a team so that they could work together closely during the filming, in a fairly 
intense environment where good leadership was essential. 
 
The scope of the project, developing three different AVPIs with the same core content, 
resulted in substantial additional time being required by various members of the 
production and clinical teams in filming, and also in the editing phase. This proved to be 
more onerous than initially anticipated. Other challenges, which have already been 
discussed, were associated with ethics and issues of copyright. 
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6.4.2 Opportunities 
Although there were substantial challenges associated with the project, there were also 
important opportunities.  Effective team-working across multi-professional clinical teams 
and technical staff led to mutual respect and a better understanding of individual roles.  
The ability to use the team expertise effectively was invaluable. Collaborating with 
colleagues with diverse expertise was a positive finding of the process that was also 
reported by Meade (1996) in her work in developing AVPI. There was significant goodwill 
generated from both patients and staff, all of whom were enthusiastic and motivated about 
the work and keen to help in any way they could.  The process itself was fun and exciting, 
and provided important learning opportunities, leading to much discussion about various 
areas of patient care, such as informed consent and ethical issues.  As found by other 
AVPI projects (Meade 1996; Steinke 2001), organisation and preparation was key to the 
success of the project.  The process allowed expert clinical nurses to extend their roles 
and develop additional skills, which will ultimately be used for patient benefit. 
 
One of the most important opportunities was the contribution of patients.  This experience 
led the team to a fuller appreciation of the patient’s contribution. The experience also 
enabled a better understanding of how to involve patients meaningfully in future work.  It 
must be acknowledged, however, that patient numbers were small, and that it would have 
been useful to consider factors such as age, gender and cultural background as these 
variables may influence patient responses to the format and wording used in the 
production.  In addition, it would have been useful to have spent more time on identifying, 
recruiting and engaging appropriate patient representation. 
 
6.5 Conclusion  
As a result of the commitment and enthusiasm of the project team, the AVPI was 
developed as planned, within the allocated timescales, and was considered user-friendly 
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and fit for the purpose intended. Much was learned from the process of developing the 
intervention, which has implications for practice as discussed.  
